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5reast epithelial cells are prone to the development of cancer and radiation is known to be 
an inducer of cancer. However, irradiation of breast tissue is often used in a useful manner: 
mammography to detect breast cancer in an early stage or radiotherapy to eradicate breast 
cancer. 
In this thesis, we analyzed the cellular response to radiation in relationship to breast cancer screen-
ing and treatment. In a first part, we investigated the biological efficiencies of different radiation 
qualities in different cell types using different cellular endpoints. In a second part, the individual 
radiosensitivity was investigated with respect to different clinical endpoints such as normal tissue 
reactions to radiotherapy and susceptibility to radiation-induced carcinogenesis. 
High-LET (linear energy transfer) radiation is used increasingly in radiotherapy due to its high 
efficiency to induce DNA damage and to kill cancer cells compared to γ-radiation. Furthermore, 
travelers in space are continuously irradiated with high-LET radiation. Our results obtained with 
fast neutrons in human peripheral lymphocytes and MCF-10A cells are conform to literature re-
ports regarding the effects of high-LET radiation. While a lower number of radiation-induced 
DNA DSB (double strand break) was observed for neutron radiation compared to γ-rays until 
about 4h post-IR, foci repair was slower and more residual foci were present at later time points. 
Furthermore, neutrons seem to be more effective in inducing micronuclei and inhibiting cell pro-
liferation. These results are important in light of radioprotection in space and to assess the effects 
of radiotherapy on healthy and cancerous tissue. 
In mammography screening doses are low, but there is always the risk to induce DNA damage 
and this in a large group of asymptomatic women. Irradiation of human lymphocytes with 30kV 
X-rays resulted in a modest increase in the number of DNA DSB compared to γ-rays, but these 
DSB were more difficult to repair correctly by the cell and resulted in a more pronounced increase 
in micronuclei compared to γ-rays. Furthermore, in the 0 to 20 mGy dose-range a hypersensitive 
response for DSB induction was observed in mammary glandular epithelial cells present in re-
sected breast tissue, probably caused by the bystander effect. This hypersensitive response in the 
dose range representative for mammography screening, together with the findings obtained with 
chromosomal aberrations at higher doses might suggest that also in the 0-20mGy dose range more 
chromosomal aberrations than initially assumed by the linear no threshold (LNT) model will be 
induced. These findings may have important implications for risk assessment of mammography 
screening. 
Summary
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6Analysis of the relationship between cell cycle phase, LET and radiosensitivity using DSB repair 
deficient cell lines (MCF-10A cell lines with a knockdown in BRCA1, BRCA2 and Ku70) con-
firmed that non-homologous end joining (NHEJ) plays a role throughout the whole cell cycle, 
while homologous recombination (HR) only functions in late S and G2 phase of the cell cycle. 
Furthermore, the importance of HR in S or G2 phase rises as the complexity of the break increas-
es. This results in relative biological effectiveness (RBE) values for micronucleus (MN) induction 
which are much higher when cells are irradiated in G1 compared to the S and G2 phase of the cell 
cycle. 
The radiation response is influenced by the clinical radiosensitivity of the individual and the late 
toxic reaction of some women to radiotherapy limits the dose which can safely be administered. 
We attempted to identify breast-cancer patients who showed severe late toxic reactions to radi-
otherapy. In a matched case-control study using human lymphocytes, the in vitro clinical radio-
sensitivity of cases and controls was assessed with four different endpoints related to DNA DSB 
repair and apoptosis. The results suggest that a patient’s intrinsic radiosensitivity is involved in 
the development of late radiotoxic effects. As the biological mechanisms behind the different 
symptoms of late toxicity differ, it can be expected that not all clinical manifestations of late ra-
diotoxicity are linked to the same degree to intrinsic radiosensitivity with respect to DNA repair 
and apoptosis. Of the four radiosensitivity tests applied, the apoptosis assay seems to be most 
promising in the framework of predicting radiotoxic effects in individual patients. 
As BRCA1 and BRCA2 are important proteins in the DNA DSB repair pathways, mutations in 
the BRCA genes could lead to an increased susceptibility to radiation-induced carcinogenesis. The 
knockdown of BRCA1 and BRCA2 proteins in mammary epithelial cells of about 50%, a con-
dition which is representative for heterozygous mutation carriers, led to a significantly increased 
radiosensitivity based on MN formation and cell proliferation, which was most pronounced at low 
doses. The results imply that caution should be taken when administering ionizing radiation to 
heterozygous BRCA1 or BRCA2 mutation carriers.
7orstepitheelcellen kunnen ontwikkelen tot borstkanker en ioniserende straling is daarvoor 
een risicofactor. Bestraling van borstweefsel wordt echter ook vaak op een nuttige manier 
gebruikt, zoals bijvoorbeeld met mammografie om borstkanker in een vroeg stadium te 
ontdekken of radiotherapie om borstkanker te behandelen. 
In deze thesis hebben we de cellulaire respons op straling bestudeerd in relatie tot borstkanker 
screening en behandeling. In een eerste deel analyseerden we de biologische efficiëntie van ver-
schillende stralingskwaliteiten in verschillende celtypes met verschillende eindpunten. In een 
tweede deel werd de individuele stralingsgevoeligheid onderzocht in relatie tot verschillende kli-
nische eindpunten zoals de respons van het gezonde weefsel op radiotherapie en de gevoeligheid 
tot stralingsgeïnduceerde ontwikkeling van kanker. 
Hoge LET straling wordt meer en meer gebruikt in radiotherapie door zijn efficiëntie in het indu-
ceren van DNA schade en het doden van kankercellen in vergelijking met γ-stralen. Ook worden 
personen in de lucht- en ruimtevaart continue blootgesteld aan hoge LET (lineare energie transfer) 
straling. De resultaten die we verkregen met hoge LET straling in humane lymfocyten en MCF-
10A cellen zijn in overeenstemming met wat in de literatuur beschreven wordt voor hoge LET 
straling. Hoewel een lager aantal stralingsgeïnduceerde DNA DSB (dubbel streng breuken) geteld 
werd voor bestraling met neutronen in vergelijking met γ-stralen tot ongeveer 4 uur na bestraling, 
was het herstel van de DSB foci trager en waren er meer persistente foci op latere tijdspunten. 
Bovendien waren de neutronen efficiënter in het induceren van micronuclei en het inhiberen van 
cel-proliferatie. Deze resultaten zijn belangrijk in het kader van stralingsprotectie in de ruimte- en 
luchtvaart en om de effecten van radiotherapie op gezond en aberrant weefsel te kunnen inschat-
ten. 
In mammografie screening zijn de dosissen laag, maar er is altijd het risico om DNA schade te 
induceren, en dit bij een grote groep asymptomatische vrouwen. Bestraling van humane lymfo-
cyten met 30kV X-stralen had in een kleine stijging in het aantal DNA DSB tot gevolg in verge-
lijking met γ-stralen. Voor de cel is het echter moeilijk om deze DSB correct te herstellen en dit 
resulteerde in een uitgesproken stijging in het aantal micronuclei in vergelijking met γ-stralen. 
Bovendien werd in het dosisgebied 0 tot 20 mGy een hypersensitieve respons voor de inductie van 
DSB geobserveerd in borstepitheelcellen in gedisecteerd borstweefsel, vermoedelijk veroorzaakt 
door het bystander effect. Deze hypersensitieve respons in een dosisbereik dat representatief is 
voor mammografie screening in combinatie met onze bevindingen voor chromosomale aberraties 
bij hogere dosissen, suggereert dat ook in het dosisgebied 0 tot 20 mGy, meer chromosomale 
aberraties geïnduceerd zullen worden dan initieel aangenomen door het LNT (linear no theshold, 
lineair zonder drempel) model. Deze observaties kunnen belangrijke implicaties hebben voor de 
risico-inschatting bij mammografie screening. 
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8Analyse van het verband tussen cel-cyclus, LET en stralingsgevoeligheid in borstepitheel cellij-
nen die deficiënt zijn in DSB herstel-genen (MCF-10A cellen met een knockdown in BRCA1, 
BRCA2 en Ku70), bevestigde dat NHEJ (non-homologous end joining, niet homologe verbinding 
van de DNA-eindes) een rol speelt gedurende de volledige celcyclus en dat HR (homologous 
recombination, homologe recombinatie) enkel actief is in de late S en G2 fase van de celcyclus. 
Bovendien stijgt het belang van HR in S en G2 naarmate de complexiteit van de DSB stijgt. Dit 
resulteert in relatieve biologische efficiëntie (RBE) waarden voor micronucleus-inductie die veel 
hoger zijn wanneer de cellen bestraald worden in de G1 fase van de celcyclus in vergelijking met 
de S en G2 fase van de celcyclus. 
De stralingsrespons wordt beïnvloed door de klinische stralingsgevoeligheid van het individu 
en de late toxische reactie van sommige vrouwen op radiotherapie limiteert de dosis die maxi-
maal kan worden toegediend. We deden een poging om borstkankerpatiënten te identificeren die 
ernstige laat-toxische reacties vertoonden op radiotherapie. In een gepaarde case-controle studie 
waarbij gebruik werd gemaakt van humane lymfocyten, werd de in vitro klinische stralingsge-
voeligheid van cases en controles geëvalueerd met vier verschillende eindpunten die gerelateerd 
zijn aan DNA DSB herstel en apoptose. De resultaten suggereren dat de intrinsieke cellulaire stra-
lingsgevoeligheid van een patiënt betrokken is bij de ontwikkeling van late radiotoxische effecten. 
Gezien de biologische mechanismen achter de verschillende klinische symptomen verschillen, 
kan verwacht worden dat niet alle klinische manifestaties van late radiotoxiciteit in dezelfde mate 
gelinkt zijn aan de intrinsieke radiosensitiviteit gerelateerd met DNA herstel en apoptose. Van de 
vier testen die gebruikt werden lijkt de apoptose test de meest veelbelovende te zijn om radiotoxi-
sche effecten bij individuele patiënten te voorspellen. 
Gezien de belangrijke rol van BRCA1 en BRCA2 in de DNA DSB herstel pathway, kunnen 
BRCA1 en BRCA2-mutaties leiden tot een stijging in gevoeligheid van stralingsgeïnduceerde car-
cinogenese. De knockdown van BRCA1 en BRCA2 in borstepitheelcellen van ongeveer 50%, een 
situatie die representatief is voor heterozygote mutatiedragers, leidde tot een significant verhoog-
de stralingsgevoeligheid, gebaseerd op de vorming van micronuclei en cel-proliferatie en dit was 
meest uitgesproken voor lage dosissen. Deze resultaten impliceren dat voorzichtigheid geboden is 
bij het gebruik van straling bij BRCA1 en BRCA2 mutatiedragers. 
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1 Ionizing radiation
1.1 What is ionizing radiation
Ionizing radiation (IR) consists of electromagnetic waves and/or high energy particles with suf-
ficient energy to eject orbital electrons from atoms and molecules they traverse, thereby ionizing 
them. 
Neutrons, electrons, protons, α-particles and heavy charged ions are different types of particle 
radiation and can be described by the charge and mass of the particle. Electromagnetic IR has 
neither mass nor charge and consists of pure energy in the form of photons – wave like particles. 
X-rays and γ-rays are electromagnetic radiation. 
1.2 Damage by IR
Ionizing radiation deposits energy randomly while traversing matter, hereby causing ionizations 
of atoms and molecules. Direct effects of ionizations occur when radiation deposits part of its 
energy directly in critical biological target molecules, thereby ionizing a component of this criti-
cal target. The indirect effect of ionization occurs when the radiation ionizes a non-critical target 
and the radicals that are induced by these ionizations in turn subject the critical target to chemical 
attack (1, 2) (see figure 1.1)
The energy of the ionizing radiation will be deposited in the cell. Since about 80% of the cell con-
sists of water, indirect effects occur primarily through ionization of water molecules. This process 
is referred to as water radiolysis and leads to the formation of OH., e-aq, H. and H3O+. These ions 
and free radicals are extremely reactive, and especially the OH radical is believed to cause a lot of 
indirect damage to critical target molecules. The most critical target molecule in the cell, which can 
be damaged either by indirect or direct ionizations, is the DNA-molecule. There are different cate-
gories of radiation damage to the DNA, all of which have a different biological significance (1, 2). 
• Base damage: change or loss of a base. While mostly repaired properly, this can lead to muta-
tions in the bases-sequences which can have major consequences to the cell. 
• Sugar damage
• Crosslinks: intra- and interstrand DNA-DNA crosslinks and DNA-protein crosslinks. When not 
properly repaired, this kind of damage may be lethal to the cell. 
• DNA single-strand breaks (SSB): breaks in one chain of the DNA molecule. SSB can be effi-
ciently repaired by the cell, with little long-term consequences. 
• DNA double strand breaks (DSB): two SSB in opposite strands approximately 10 to 20 base-
pairs apart, causing a complete break of the DNA molecule. DNA DSB can be lethal to the cell. 
• Complex DNA damage sites: when the density of the ionizations increases (see further), different 
forms of DNA damage will be clustered in one damage site, which can be highly lethal to the cell. 
16
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FIGURE 1.1
Schematic representation of direct and indirect radiation-induced DNA lesions. Figure from (1).
1.3 LET
The interactions of radiation with matter are often described in terms of the linear energy transfer 
(LET). The LET of a particular type of radiation is the average energy deposited along the track 
of a particle or photon per unit distance and is expressed in keV/µm (kilo electronvolt/µm). This 
ionization density is dependent on several parameters, including the mass, charge and energy of 
the radiation. On this basis radiation is categorized into two types, low-LET radiation like X-rays, 
γ-rays and β-particles which have a low average ionization density, and high-LET radiation like 
neutrons, α-particles and heavy ions, which have a high ionization density (see figure 1.2) (2-4). 
An inverse relationship exists between the kinetic energy of radiation and the LET (table 1.1) (5). 
X-rays and γ-rays have no mass or charge, but through their interaction with the absorbing medi-
um they will eject electrons from atoms by the Photoelectric or Compton effect. These ejected fast 
electrons, with a low mass and a negative charge, will pass through matter constantly interacting 
electrostatically with other electrons and in the process lose energy. If the force of the electrostatic 
interaction is sufficient to remove the electron from its atom, further ionizations occur. As a result, 
the ionizations are sparse and distant from each other (4). The primary mode of damage to the cell 
of low-LET radiation will be via indirect ionizations.
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Due to its higher mass and/or charge, high-LET radiation has a greater probability to interact with 
the electrons and atomic nuclei from the absorbing medium. When a particle collides with a heavy 
nucleus, energy loss can be huge, producing a lot of ionizations in a very short distance (4). Direct 
ionizations of the DNA molecule are more likely to be caused by high-LET radiation. 
Both high and low-LET radiation qualities will induce DSB. Low-LET radiation will produce 
DSB at the track-ends of low-energy second electrons which will be spread evenly over the cell 
(see figure 1.2). High-LET radiation will induce DNA DSB along their entire track, but the DSB 
will be more clustered and as a result they are more complex in nature (see figure 1.2) (6-8). The 
dose-response curve for DSB induction for both low and high-LET radiation is linear (Y = c + αD) 
over several orders of magnitude (9, 10). 
FIGURE 1.2
Schematic representation of the ionizations patters of high and low-LET radiation. Figure from (1). 
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TABLE 1.1
LET values for different types of radiation. Adapted from (5, 11). 
When measuring mis- or unrepair of DSB in function of dose, e.g. a dose response curve based on 
chromosomal aberrations or cell survival, then the difference in ionization density between low 
and high-LET radiation is reflected in the shape of the dose response curve. Most dose response 
curves can be described by a linear quadratic function (Y = c + αD + βD2 for chromosomal ab-
errations or ln(S) = – αD – βD2 for cell survival). The linear component results from un- or mis-
repaired DSB induced by a single-track event, while the quadratic component arises from un- or 
misrepair of DSB induced by two track events. At low doses of low-LET radiation, the probability 
of two tracks traversing a target is low and only the linear component will contribute. As the dose 
increases, the probability of two-track events will also increase. However, as the LET of the radi-
ation increases, the importance of single track events increases as well, and the α-component will 
become more important. As a result, the curve will become close to linear or linear with increasing 
LET (figure 1.3) (4, 12). 
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1.4 Relative biological effect or RBE
Due to the differences in ionization densities between low and high-LET radiation, equal doses of 
radiations with different LET will cause a different biologic effect. The different effectiveness for 
inducing a particular biological endpoint by different radiation qualities is represented by the rel-
ative biological effect (RBE). The RBE is defined as the ratio of a dose of the reference radiation 
and the dose to the test radiation that produce the same biological response (1). In figure 1.3 the 
RBEA=Z/Y and the RBEB=Y/X. 
It is important to note that the RBE for a certain radiation quality is not constant, but varies de-
pending on several factors. In general, when using RBE values to compare the effectiveness of 
different radiation qualities, is it important to state precisely how a particular RBE measurement 
was obtained. As stated in the definition, the RBE is dependent on the dose, the endpoint and the 
reference radiation. Historically 200 kV X-rays were used as reference radiation, nowadays most-
ly 60Co γ-rays are used (4). An increase in RBE is noted for a decrease in dose (e.g. in figure 1.3 
FIGURE 1.3
Schematic representation of the dose response curve for chromosomal aberrations following high and low-LET radiation. Figure adapted 
from (4). 
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RBEA is smaller than RBEB), and changes in RBE are most prominent at low doses (13). End-
points that can be considered are e.g. cell survival, chromosomal aberrations and DNA damage 
induction. Furthermore RBE is influenced by the depth, dose rate, fractionation, cell type used, 
oxygenation, etc. (13). These factors can influence the level of biological damage differently fol-
lowing exposure to the reference radiation than to the test radiation and as a result influence the 
RBE of the test radiation. 
RBE increases with the LET of a radiation up to an optimum value of approximately 100 keV/µm. 
At higher LET values, the RBE decreases again due to overkill. A phenomenon where, due to the 
very high ionization densities, more energy is deposited than needed to kill a cell and the biolog-
ical effects of the radiation become inefficient (figure 1.4). While recent studies show that there 
are differences in RBE of different low-LET radiation qualities, for risk calculation all low-LET 
radiation qualities are considered equally efficient in inducing damage. (1, 14, 15). 
FIGURE 1.4
Dependence of RBE on LET and the phenomenon of overkill by very high-LET radiations. Figure adapted from (13).
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1.5 The oxygen enhancement ratio
The radiation damage caused by indirect ionizations of H2O is dependent on the presence of free 
oxygen, while this is of less importance for direct ionization. As a result, the cell’s oxygen status 
will greatly affect the response of cells exposed to low-LET radiation while the oxygen status 
of cells exposed to high-LET radiation has a limited effect (12). The oxygen enhancement ratio 
(OER) is used to compare the response of cells irradiated in the presence and in the absence of 
oxygen and is defined as the ratio between the irradiation doses required to produce a biological 
effect, in the absence and the presence of oxygen respectively (1). The OER of mammalian cells 
for cell killing ranges from 2.5 to 3 for photons and it decreases with increasing LET. Fast neutron 
beams exhibit OERs between 1.5 and 1.8, whereas the OER for more densely ionizing α-particles 
is close to 1 (11) (figure 1.5).
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FIGURE 1.5
Survival curves of human kidney cells irradiated under hypoxic and aerobic conditions with different qualities of radiation.
 : radiation under hypoxic conditions;  : radiation under aerobic conditions. Figure from (11).
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1.6 Dose deposition
The way the radiation beam deposits energy while traveling through mass, the dose distribution, 
is very different between charged and uncharged particles. With conventional X-rays and γ-rays, 
the dose absorbed by the tissue increases rapidly and then decreases exponentially with increas-
ing depth (figure 1.5). Heavy charged particles on the other hand, behave very differently. When 
a charged particle slows down, it loses energy more and more rapidly and reaches a maximum 
rate of energy loss, called the Bragg peak, just before the particle comes to rest (figure 1.6). The 
biological effect of such particle will change along with the dose deposition and the Bragg peak 
will coincide with the highest biological effect. A 195 MeV carbon beam will for example have 
an RBE of approximately 1.3 in the entrance or plateau region of the depth dose curve, which will 
rise to approximately 3 in the Bragg peak (16). Due to their mass, heavy charged particles scatter 
less and their trajectory will be relatively straight. As a consequence a highly precise dose local-
ization is achieved due to limited beam divergence (17). Remark that neutrons, while high-LET, 
are uncharged particles and their depth-dose characteristics are similar to those of high energy 
X-rays (12). Protons on the other hand, have a conventional RBE of 1.1 and are considered almost 
equal to photons, but will deposit most of their energy locally in a Bragg peak (18, 19).
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FIGURE 1.6
Depth-dose characteristics for different types of radiation. Figure from (20). 
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1.7 Absorbed dose, equivalent dose and effective dose
The quantity used to assess radiation exposure is absorbed dose, defined as the amount of energy 
deposited per unit mass. One joule of energy deposited in a kilogram of matter is referred to as 1 
gray (1Gy). While still popular in some countries, the rad is a deprecated unit of absorbed dose 
and 100 rad equals 1Gy. The absorbed dose does not describe the possible health effects caused 
by radiation, since it does not take into account the RBE of the radiation and the different radio-
sensitivities of tissues to radiation. 
The equivalent dose takes into account the different biological effects of various types and ener-
gies of radiation. HT is calculated by multiplying the mean absorbed dose deposited in the body or 
organ T with the radiation weighting factor WR, which is dependent on the type and energy of the 
radiation R (see figure 1.7). Examples of WR are given in table 1.2. 
The probability of radiation to induce cancer or genetic effects (stochastic health risks, see further) 
is dependent of the organ or tissue being irradiated. This is taken into account in the effective dose 
(E), which converts different radiation doses delivered to specific body parts into an equivalent 
uniform total body dose that entails the same risk for stochastic effects. The effective dose is the 
weighted sum of the tissue weighting factors (WT) with the tissue equivalent doses (see figure 
1.7). Examples of WT are given in table 1.3.
FIGURE 1.7
Overview of absorbed dose, equivalent dose and effective dose. Figure adapted from (21)
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Both the equivalent dose and the effective dose are expressed in Sievert (Sv). Remark that equiva-
lent dose and effective dose are for use in radiological protection and are not directly measurable. 
In this thesis, as for all experimental work, the absorbed dose (Gy) has been used as measure for 
radiation dose.
TABLE 1.2
Examples of radiation weighting factors W
R
. Table adapted from (14).
TABLE 1.2
Examples of radiation weighting factors W
R
. Table adapted from (14).
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1.8 Radiosensitivity
Radiosensitivity is a broad term and can be related to cells, tissues and individuals. It is a measure 
of the degree of response of the cells, tissues or individuals to radiation, with a large response 
indicating high sensitivity. See table 1.4 for an overview of the use of the term radiosensitivity at 
different levels (22). 
There is a link between the different levels of radiosensitivity. Some tissues are radiosensitive 
because their cell populations have a high propensity to undergo apoptosis, e.g. salivary glands. 
Other tissues are more radioresistant because of their structural organization, e.g. if a small part 
of the lung is destroyed by a high dose of radiation, lung function can be maintained by the re-
maining healthy tissue. Individuals also vary in radiosensitivity and this can be associated with 
cellular radiosensitivity and possibly genomic instability. At present, there is only fragmentary 
understanding of the relationships between the various measures of radiosensitivity (22). 
Since the term can be used on different levels, radiosensitivity should always be used in con-
junction with a well-defined endpoint. This end-point might be defined clinical, as in the case of 
normal tissue reactions to radiotherapy or in relationship to specific disease endpoints such as 
cancer. Alternatively, radiosensitivity can be related to cellular phenomena such as cell killing or 
the induction of chromosomal damage. 
1.9 Medical consequences of radiation
Radiation causes molecular changes and these changes can cause effects at cellular, tissue and 
organ level. At the individual level, ionizing radiation can cause disease and even death, but the 
link between the quality of the radiation, the type of exposure, the dose and its effects is not al-
ways clear and a lot of parameters play a role. Most evidence for the effects of ionizing radiation 
comes from epidemiological studies. The lifespan studies (LSS), following the whole-body radi-
ation exposure from the survivors of the atomic bombs in Japan is the most informative and has 
the most statistical power (e.g. (23-25)). Also data of cohorts of well-defined medically exposed 
individuals are available (e.g. (26-35)). 
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TABLE 1.4 
A summary of the main forms and assays of radiosensitivity in common use. Table adapted from (22). 
Whole	  organism	  
radiosensitivity
Is	  measured	  by	  assays	  such	  as	  LD50/30,	  which	  refers	  to	  the	  radiation	  dose	  required	  to	  kill	  
50%	  of	  a	  given	  population	  within	  30	  days	  of	  exposure
Normal	  tissue	  
radiosensitivity	  or	  
clinical	  
radiosensitivity
generally	  used	  in	  the	  context	  of	  the	  reaction/damage	  to	  non-­‐target	  tissues	  as	  a	  
consequence	  of	  radiotherapy	  for	  cancer	  and	  other	  conditions.	  They	  are	  asses	  by	  clinical	  
evaluation	  of	  tissue	  damage	  using	  a	  variety	  of	  scoring	  schemes.	  The	  main	  tissues	  of	  concern	  
include	  skin	  (burnin)	  lung	  and	  connective	  tissue	  (fibrosis).
Susceptibility	  to	  
radiation	  
carcinogenesis
refers	  to	  differences	  in	  susceptibility	  amongs	  individuals	  (or	  strain	  of	  mice)	  to	  radiation-­‐
induced	  cancer	  in	  specific	  tissues.	  It	  is	  measured	  in	  emidemiological	  (human)	  studies	  or	  
experimental	  animal	  carcinogenesis	  studies.	  Generally	  this	  is	  considered	  in	  terms	  of	  yield	  of	  
tumours	  (in	  a	  specific	  tissue)	  per	  unit	  absorbed	  dose.
Tissue	  
radiosensitivity	  (for	  
cancer)
refers	  to	  the	  difference	  in	  sensitivity	  of	  individual	  tissues	  in	  organisms	  to	  radiation-­‐
associated	  carcinogenesis.	  Most	  information	  for	  this	  comes	  from	  epidemiological	  studies	  
and	  is	  generally	  considered	  in	  terms	  of	  yield	  of	  tumours	  (in	  specific	  tissues)	  per	  unit	  
absorbed	  dose.	  Tissue	  radiosensitivity	  can	  also	  refer	  to	  differences	  in	  response	  to	  
radiotherapy	  of	  tissues	  in	  terms	  of	  their	  function	  or	  structure.	  
Cellular	  
radiosensitivity	  
referens	  to	  a	  wide	  range	  of	  phenomena	  measured	  at	  the	  cellular	  level	  where	  reponses	  to	  
radiation	  can	  vary	  between	  individuals	  or	  cell	  types.	  Endpoints	  can	  be	  cell	  killing,	  
chromosomal	  damage,	  damage/repair	  to	  DNA,	  cell	  cycle	  endpoints,	  apoptosis,	  etc.	  It	  is	  
measured	  in	  yield	  of	  the	  endpoint	  per	  unit	  absorbed	  dose	  or	  parameters	  derived	  from	  dose-­‐
response	  relationships.	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It is clear that ionizing radiation can induce cellular damage and as a consequence induce disease. 
The effects of ionizing radiation are categorized into two groups, tissue reactions, formerly known 
as deterministic effects (36), and stochastic effects (37). Stochastic effects are effects which occur 
by chance. The probability of occurring but not the severity is regarded as a function of dose with-
out threshold. Stochastic effects result from injury to a single cell, mostly a specific mutation in 
a single gene or mutations involving loss of DNA. If the damage is not correctly repaired the cell 
may die or alternatively the cell may survive with DNA mutations that affect cellular behavior. A 
small fraction of such mutations can contribute to the development of stochastic effects. Cancer 
and heritable effects are categorized as stochastic effects. The excess lifetime risk of mortality for 
solid cancers and leukemia are given in table 1.5. The risk of heritable diseases due to exposure 
is based on animal experiments and is estimated to be 0.54% per Gray (Gy) in the reproductive 
population (37-40). Tissue reactions, formerly termed deterministic or non-stochastic effects, are 
effects which only become apparent if a threshold dose is exceeded and the probability and se-
verity of the effect increases with increasing dose. The damage results from the collective injury 
of a substantial number of cells in the affected tissue. The threshold dose is effect-specific and 
depends on the individual sensitivity. Acute doses up to 0.5 Gy are believed to produce no tissue 
effects, although this is under discussion. Examples of tissue effects are cataracts, non-malignant 
skin damage and impaired fertility (36-38, 41). 
TABLE 1.5
Excess lifetime risk of mortality (averaged over both sexes). Data from (40). 
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Upwards from 100 mGy, there is a linear relationship between the dose received and the long term 
effect of the irradiation (17). The effects of low (<100 mGy) and very low doses (<10 mGy), are 
less clear. Available epidemiological data do not have sufficient power to assess the radiation risks 
of low and very low exposure levels (42). However, the inability to quantify these risks does not 
imply that the risk to the population is negligible. A very small risk, if applied to a large number 
of healthy individuals, can result in a significant health problem (42). 
In vitro studies investigating cellular and genetic effects show the consequences of low and very 
low doses of ionizing irradiation. After an exposure to just a few mGy, e.g. γH2AX foci can be 
demonstrated (10, 43, 44) or changes in transcription level of genes can be detected (45-47). Not 
only cell effects are present at doses as low as a few mGy, gene expression analysis demonstrated 
that different gene profiles were highlighted after low and high doses of X-rays in whole blood 
(48). 
However, how these effects translate into low-dose risks, and whether they have detrimental or 
beneficial effects, is still a matter of debate. 
There are different scenarios to extrapolate high dose risks to low doses. The linear no threshold 
(LNT) model is the golden standard in radiation protection and assumes a linear relationship 
between dose and risk from 0 Gy upwards (see figure 1.8 curve a). By using the LNT model, the 
assumption is made that no radiation dose, no matter how small, can be regarded as safe. The 
LNT model is based on data from epidemiological studies providing a linearly increasing radia-
tion-induced cancer risk from about 100 mGy to 2.5 Gy and extrapolates this linearity to the low 
and very low dose region. The argument for linear extrapolation considers radiation effects due to 
autonomous responses of individual cells (17). However, studies show that different mechanisms 
can play at low and high doses, which can cause us to either under- or overestimate the risks of 
low doses (42) (see figure 1.8 curves b-e). 
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FIGURE 1.8
Schematic representation of different possible extrapolations of measured radiation risks down to very low doses, all of which could, in the-
ory, be considered with higher-dose epidemiological data. curve a: LNT model; curve b: low-dose hypersensitivity; curve c: adaptive response; 
curve d: threshold hypothesis; curve e: hormesis. Figure from (42).
The observation that ionizing radiation can cause effects in un-irradiated “bystander” cells is 
called the bystander effect. These un-irradiated cells can be neighboring to the irradiated cells, but 
also be remote and do not even need to be present at the time of exposure. The bystander effect 
is predominant at very low doses, down to the mGy level, but stabilizes at higher doses because 
more cells are directly targeted by the radiation (42, 49, 50). It leads to a steep dose response at 
very low doses, which saturates at higher doses probably because all relevant cells that can be 
affected are already affected (51, 52) (See figure 1.6 curve b). 
The irradiated cells propagate signaling molecules to neighboring cells via gap-junction mediated 
intercellular communication and via the release of diffusible factors into the extracellular environ-
ment (53-57). Cyclooxygenase-2 (COX-2) seems a crucial modulator of the system (58).
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Interestingly, the gene sets which are upregulated after low dose irradiation are inflammatory and 
immune-related, whereas at high doses the main response is the activation of p53 signaling in-
ducing cell cycle arrest and apoptosis processes. The upregulated chemokines, cytokines, MAPK 
(mitogen-activated protein kinases) and NFκB (nuclear factor kappa-light-chain-enhancer of acti-
vated B cells) have been proven to play a central role in the bystander effect (48).
The bystander effect can cause low-dose hypersensitivity, which is characterized by a higher than 
expected biological effectiveness of the radiation at very low doses, while the cells start to exhibit 
a relative radioresistance at higher doses (59). 
Another possible mechanism for low-dose hypersensitivity is the need to pass a certain damage or 
stress-threshold before efficient repair will take place (60-62) (See figure 1.8 curve b).
While the bystander effect and low-dose hypersensitivity response cause an underestimation of 
the damage induced by low-dose radiation, other mechanisms could result in an overestimation 
of the induced damage. The threshold hypothesis implies that below a certain dose there are no 
radiation health effects (See figure 1.8 curve d). Studies on adaptive response or hormesis (see 
respectively figure 1.8 curve c and e) claim that irradiating cells with a low priming dose helps 
them to be “prepared” before being challenged with a higher dose. There are a number of differ-
ent mechanisms that are thought to be involved in inducing the adaptive response: anti-oxida-
tive stress response by antioxidant molecules, enhanced DNA repair detection and signaling or 
enhanced repair efficiency and activation of an immune defensive response (63). It is clear that 
the bystander effect can also be a mechanism for adaptive response. The adaptive, or protective 
response from the priming dose, can be over a few hours for anti-oxidative stress, up to a few days 
for DNA repair and up to several months for immune enhancement (64) (See figure 1.8 curve c).
Remark that mechanisms as bystander effect, threshold hypothesis, hypersensitivity and adaptive 
response are not mutually exclusive. Differences in radiation dose and quality, cell type and cel-
lular environment might trigger a different response to the radiation. 
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2 DNA DSB repair
2.1 DNA damage response
DNA is constantly damaged by endogenous and exogenous agents. DNA lesions can prevent 
genomic replication and transcription and if they are not repaired or misrepaired, they can lead to 
mutations or large-scale genome aberrations that may lead to cell malfunction or cell dead. Espe-
cially the DNA DSB is considered to be very cytotoxic because their correct repair is intrinsically 
more difficult than that of other types of DNA damage. Improperly repaired DSB often lead to 
large chromosomal rearrangements such as deletions, translocations and amplifications, which 
can lead to tumorigenesis if for example the deleted region encodes a tumor suppressor protein 
or if an amplified region encodes a protein with oncogenic potential (65). In order to maintain the 
genomic integrity of the DNA, cells have an elaborate system to counteract the genotoxic stress 
induced by ionizing radiation, known as the DNA damage response (DDR). 
In the DDR pathway the damage is initially detected by “sensor” molecules. The signal is then 
transferred to “transducer” proteins, that will amplify the signal and recruit “effector” proteins 
to the damaged site. Subsequently the attracted effector proteins induce cell cycle arrest, DNA 
damage repair or apoptosis (65) (see figure 2.1). 
FIGURE 2.1
General organization of the DNA damage response pathway. Figure from (65). 
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The main sensor protein is always an important member of the PIK3 (phosphatidylinositol-4,5-bi-
sphosphate 3-kinase) kinase family, DNA PKcs (DNA-dependent protein kinase catalytic subu-
nit), ATM (ataxia telangiectasia mutated) or ATR (ATM- and RAD3-related). However, which of 
these proteins will actually initiate the DDR, is dependent on the origin of the DSB. 
There remains controversy about the proteins that initially sense the DNA DSB induced by irradi-
ation and start the signaling cascade. The Mre11/Rad50/Nbs1 (MRN) complex has been ascribed 
a critical role in detecting the break and recruiting ATM via the C-terminus of Nbs1 (66-68). The 
ATM kinase is considered a key protein in the DSB response and activation by autophosphoryl-
ation at Ser1981 of the kinase results in dissociation of the latent ATM dimers into active mono-
mers (69). Activated ATM monomers have a very strong kinase activity and have been shown to 
phosphorylate hundreds of monomers, including proteins involved in checkpoint activation and 
DNA-repair (see figure 2.2) (70, 71). 
FIGURE 2.2
The initial phases of DSB repair. Figure from (70).
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A critical target of ATM in the DDR is the phosphorylation of the C-terminus of the histone 
variant H2AX (γH2AX). Phosphorylated γH2AX creates a binding site for the BRCT (BRCA1 
C-terminal) domain of MDC1 (Mediator of DNA damage checkpoint1). Positioning of MDC1 at 
the DSB creates a binding γH2AX place for additional DSB-repair proteins, including the MRN-
ATM complex. This amplifies the signal, binding of MRN-ATM to MDC1 will phosphorylate 
more H2AX, creating more binding sites for MDC1 (72-74). 30 Minutes after induction of the 
break, a plateau is reached with a γH2AX domain that extends for hundreds of kilobases along the 
chromatin around the DSB (70) (see top figure 2.2). γH2AX serves as a docking site for media-
tor proteins, such as 53BP1 (53 binding protein 1), NBS1 (Nijmegen breakage syndrome 1) and 
BRCA1 (breast cancer early onset1), which will be phosphorylated by ATM and will transduce the 
signal to downstream effectors (70) (see bottom figure 2.2). 
2.2 Cell cycle checkpoint arrest
To ensure fidelity of DNA replication and chromosome segregation, cell cycle checkpoint arrest 
ensures the activation of surveillance mechanisms to prevent progression through the cell cycle 
until critical processes involved in DNA repair have been completed. In response to the initiation 
of the DDR, proteins involved in the control of the cell cycle checkpoints will also be activated 
to temporarily stop the transition of the cell through the cell cycle to allow time for repair and to 
ensure that genetic errors are not transmitted to subsequent generations (75, 76). 
The cell cycle has several checkpoints, namely the G1/S, intra-S-phase, G2/M and mitotic check-
points. Checkpoint activation is based on the inhibition of cyclin-dependent kinase (cyclin-Cdk) 
complexes, which regulate all progression through the cell cycle (see figure 2.3).
FIGURE 2.3
Control of the cell cycle by cyclins and Cdks and their regulation by cell cycle checkpoints. Figure from (77). 
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The G1/S checkpoint is induced when DNA damage is detected to prevent replication of DNA of 
cells that were in G1 at the time of DNA damage to progress into S-phase. The checkpoint is me-
diated by two distinct signal transduction pathways, the Chk1/Chk2-Cdc25A-Cdk2 pathway and 
a second pathway centered around p53 (Chk1/Chk2-p53-p21). As a result, the G1-cycline-Cdk 
complexes, including cyclin-Cdk2 complexes, are inactive, preventing phosphorylation of the 
retinoblastoma (Rb) protein. This causes the E2F transcription factor, which is important for the 
regulation of many genes initiating DNA replication, to remain inactive (see figure 2.4) (77-79). 
The intra-S-phase checkpoint is activated to prevent replication of damaged DNA. Downregula-
tion of CDC25A subsequently causes inactivation of the S-phase-promoting Cdk2-cyclingE and 
prevents loading of Cdc45 on replication origins, hence inhibiting DNA synthesis (79). 
The G2/M checkpoint prevents the cells from entering mitosis and transducing DNA damage to 
daughter cells. This checkpoint is subject to the Chk1/Chk2-Cdc25c-Cdk1 pathway. The arrest is 
achieved through continued phosphorylation of Cdk1-cyclinB1 kinase, preventing the cell to enter 
mitosis (see figure 2.4) (77, 79). 
FIGURE 2.4
Overview of the G1/S and G2/M checkpoint regulation pathways following ATM/ATR activation. Figure from (77).
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The mitotic or spindle activation checkpoint (SAC) prevents the onset of anaphase until all chro-
mosomes are properly attached to the spindle and ensures that chromosome segregation is correct. 
Downregulation of CDC20 prevents the activation of the polyubiquitylation activities of the an-
aphase promoting complex (APC), thereby arresting the cell in metaphase (80). 
2.3 DNA DSB repair pathways 
DSB are primarily repaired by one of two pathways, non-homologous end joining (NHEJ) or 
homologous recombination (HR), irrespective of their cause (81). Furthermore a number of back-
up pathways exist which can be used under certain conditions or when repair via NHEJ or HR is 
not possible. 
2.3.1 Non-homologous end joining (NHEJ) (see figure 2.5)
Non-homologous end joining is the main DSB repair pathway in mammalian cells and can be used 
in all phases of the cell cycle (82-84). NHEJ is based on the direct ligation of the two termini of the 
broken DNA molecule. Ionizing radiation will often induce DSB with nonligatable single strand-
ed ends. For DNA ligation by NHEJ, blunt ends are needed and processing of the single stranded 
DNA overhangs is in general required prior to ligation. This processing can however result in loss 
of nucleotides, making this pathway potentially error-prone. DSB repair via the NHEJ pathway 
takes a few hours to complete. 
DNA repair by NHEJ is mainly regulated by actions of DNA-PK and the Ku70/Ku80 heterodimer. 
Ku is available in abundance and binds with high affinity to DNA termini in a sequence-independ-
ent manner. Immediately after induction of a break, Ku will bind to both ends of the broken DNA 
molecule (85-87). Its binding tethers and protects the DNA termini. Binding of Ku to the DNA 
recruits the catalytic subunit of DNA PKcs to the DSB site, leading to the formation of the DNA 
PK holoenzyme (88). DNA PKcs is activated by phosphorylation, mainly via autophosphorylation 
and potentially by other kinases such as ATM and ATR. The binding of DNA PKcs with both Ku 
and the DNA termini, enhances greatly its kinase activity, and is thought to be a necessary step in 
NHEJ repair (89). The activated DNA PKcs facilitates then the recruitment of other repair factors 
to the DSB site, such as Artemis, the XRCC4/DNA ligase 4 complex and XRCC4-like factor and 
will expose the termini to the recruited nucleases and polymerases. 
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Processing of the single-strand overhang to obtain the blunt ends needed for ligation can occur in 
two ways. The overhang can be resected, which can be done by nucleases such as Artemis (90, 
91), Exo1 (exonuclease 1) (81, 92) and WRN (werner syndrome) (81, 93) or a complementary 
strand can be synthesized using the overhang as template which is done by DNA polymerase µ 
and λ (71, 94, 95). 
Subsequently, DNA ligase IV, XRCC4 and XLF (XRCC4-like factor) ligate the broken DNA 
termini to complete repair. XRCC4 has no known enzymatic activity, but will act as a scaffolding 
protein through which it stabilizes and stimulates the ligase activity of DNA ligase IV (96, 97). 
XLF is recruited to the break by Ku and stabilized by interactions with the ligase IV/XRCC4 com-
plex. The protein seems to stimulate ligation of non-compatible DNA ends, thereby preventing 
nucleotide loss during NHEJ (81, 82, 90). 
2.3.2 Homologous recombination (HR) (see figure 2.5)
DNA repair by HR uses the undamaged sister chromatid to repair the DSB and is therefore less 
prone to errors. Consequently HR only plays a role in S and G2 phase of the cell cycle. 
The HR pathway is initiated by 5’-end resection at the DSB terminus resulting in 3’ single strand-
ed DNA (98, 99). This is facilitated by the endonuclease activity of Mre11 (part of the MRN-com-
plex) and is regulated by CtBP-interacting protein (CtIP) in a ATM and BRCA1 dependent man-
ner (100). Following the formation of long tails of 3’ ssDNA, hSSB1 molecules are initially bound 
to it and then displaced by replication protein A (RPA) to the sites of the DSB (101, 102). The 
RAD52/BRCA2/RAD51/RAD54 complex is then recruited to the ssDNA by a BRCA1/PALB2 
(partner and localizer of BRCA2 (breast cancer early onset2)) complex. This facilitates the re-
placement of RPA by RAD51, thus stabilizing the filament and catalyzing the invasion (103). To 
facilitate invasion into the sister chromatid strand, the two chromatids are tethered together by 
structural maintenance of chromosomes (SMC) proteins 1, 3, 5 and 6 (104). The filaments will 
search for and invade the homologous template which leads to the formation of a heteroduplex 
or hybrid DNA referred to as the D-loop (displacement loop) structure. Second end capture of 
the break by the D-loop results in two four-stranded branched DNA-structures, called Holliday 
junctions (105). These Holliday junctions are able to undergo branch migration whereby DNA 
polymerase δ (DNA pol δ) carries out DNA synthesis to restore the missing sequence information 
using the intact duplex DNA template. Once DNA replication is complete, the Holliday junction 
is resolved by DNA resolvases through a complex process that remains unclear (106). The entire 
process takes several hours to complete. 
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FIGURE 2.5
The two main DNA DSB pathways. HR is represented schematically on the left and NHEJ on the right. Figure adapted from (81). 
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2.3.3 Alternative DNA DSB repair pathways
Next to NHEJ and HR there are some alternative DNA DSB repair pathways: B-NHEJ, also 
named alt-NHEJ, Microhomology Mediated End Joining (MMEJ) and Single Strand Annealing 
(SSA). All three have certain commonalities, but there are also differences between them and it 
is unclear in how much they are different pathways or variations of a single pathway. B-NHEJ, 
MMEJ and SSA play an important role as backup pathway for NHEJ in DSB repair in G1 and 
early S-phase cells. They have slower kinetics than NHEJ, are less faithful than NHEJ and are 
marked by larger deletions and translocations (107). 
These pathways operate independent of the core NHEJ proteins: DNA-PKcs, Ku and Lig4 in 
complex with XRCC4. Different from NHEJ, these pathways depend on end-resection, initiated 
by MRN and CtIP (108). POL4, LIG3 are found to be required for MMEJ, while PARP (poly-ADP 
ribose polymerase) and LIG1 seem to be required for B-NHEJ (see figure 2.6). 
For B-NHEJ no homology is needed, while MMEJ relies on homologies of only a few nucleotides 
and SSA on homologous sequences ranging from 10bp to several kilobases (109). 
FIGURE 2.6
Comparison between classical NHEJ and alt-NHEJ or B-NHEJ. Figure from (110). 
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2.4 Determinants of DSB repair pathway choice
Pathway choice is an interplay between different factors such as: phase of the cell cycle, the pres-
ence of the sister chromatid, cell type, chromatin complexity and the complexity of the damage 
induced (81). 
2.4.1 Cell cycle phase
Irrespective of the cell cycle, NHEJ is the main DNA DSB repair pathway in most mammalian 
cells and HR plays a relatively minor role (111). While NHEJ is the main pathway throughout the 
cell cycle, there is competition with HR and with the alternative pathways. A sister chromatid, 
which is needed for HR, will only be available in late S and G2 phase of the cell cycle and as 
such, HR is only available then. B-NHEJ, MMEJ and SSA require no or very small homologies 
and can be used throughout all phases. Since the different pathways have a different accuracy, the 
availability and use of a repair-pathway throughout the cell cycle, influences the radiosensitivity 
of the cell (see figure 2.7). 
2.4.2 Complexity of the damage
High-LET radiation, with its dense ionization pattern, will produce more clustered damage and 
hence complex damaged sites (112-114). These complex damage sites are known to have a slower 
rate of repair compared to the DSB induced by low-LET radiation (113). Radiation-induced DSB 
repair is biphasic with a fast component, repairing damage within 2h and a slow component with 
a half-life of 2-10h (115-117). In mammalian cells, studies have shown that, even though HR has 
the capacity to function in G2 phase, NHEJ also represents the major DSB repair pathway in G2 
(118) and this seems to be the fast component of DSB repair (119, 120). Complex DSB are mainly 
repaired by the slow component of the DDR (121, 122). CtIP, activated by ATM, is indispensable 
for the repair of these complex DSB with slow kinetics, both in G1 and G2 phase (17). Thus DSB 
resection is crucial for repair of complex DNA damage in all cell cycle stages and there seems 
to be a direct correlation between DSB complexity and the degree of resection. The increased 
requirement for processing of DNA ends observed for complex DSB, forces the pathway choice 
towards resection-dependent repair pathways. In G2 this pathway is represented by HR and the 
importance of HR increases as the LET of the radiation increases (118, 123). Evidence for sub-
stantial resection in the G1-phase and lack of HR in this cell cycle stage suggests that MMEJ is 
a major repair pathway choice for complex DSB in G1-phase, especially for the subset of lesions 
repaired with slow kinetics. The fact that rejoined DSB arising from ion-induced clustered DNA 
damage are often characterized by deletions and flanking microhomologies support this notion 
(124, 125). However, other studies show a dependency on ATM and Artemis, pointing to B-NHEJ 
(118). 
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2.4.3 Chromatin complexity
Another important factor that influences the pathway choice is the complex organization of the 
chromatin. The chromatin structure and nucleosome organization will have a significant influence 
on the efficient detection and repair of DSB. The DSB-repair machinery must be able to (1) detect 
DNA damage in different chromatin structures, (2) remodel the local chromatin architecture to 
provide access to the site of damage, (3) reorganize the nucleosome-DNA template for processing 
and repair of the damage and (4) restore the local chromatin organization after repair has been 
completed (70, 126, 127). Recent studies consistently show that the dense packing of nucleosomes 
and the presence of specific heterochomatin-binding complexes are a significant barrier to repair 
DSB located in the heterochromatin (70, 128-131). Repair of DSB is significantly slower in het-
erochromatic regions (121, 132). In response to DSB, the induction of KRAB-associated protein 
1 (KAP-1), which functions to maintain the heterochromatin, is phosphorylated by ATM, promot-
ing a general relaxation of the chromatin structure (70). This relaxation of the chromatin will be 
followed by HR-mediated DSB repair in G2. In G1 and early S-phase, repair by NHEJ is most 
common after relaxation of the chromatin, however complex breaks in heterochromatin during G1 
will be repaired by one of the back-up pathways (133). 
2.4.4 Choice of the repair pathway (see figure 2.8)
Following radiation-induced DNA DSB formation, there is competition for binding to the lesion 
by the Ku/DNA-PK and MRN complex. DNA-PK binds rapidly to all DSB, either because Ku has 
strong DSB-binding capacity or because it is highly abundant. This will initiate NHEJ, which will 
make a first attempt to repair the DSB. If rapid rejoining by NHEJ cannot ensue (109) either due 
to the DNA lesion or chromatin complexity, then DSB repair occurs in an end resection-dependent 
manner, for which CtIP is indispensable (125). In G2 phase this pathway is HR, while in G1 this 
is probably MMEJ. If resection cannot ensue, then NHEJ makes a further attempt to repair the 
DSB and, indeed, can function efficiently. The switch from NHEJ to HR seems to be promoted by 
BRCA1, which repositions 53BP1 to promote resection (134, 135). 
However, resection or possibly a later stage in the progression to HR commits to HR and pre-
cludes the possibility of returning to NHEJ usage (121). When HR cannot progress beyond the 
resection step due to loss of BRCA2, then NHEJ cannot rejoin the DSB. This suggests that exces-
sive resection due to loss of BRCA2 precludes the ability to utilize NHEJ (121).
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2.5 Apoptosis, necrosis, mitotic catastrophe and senescence
In order to prevent transfer of the defective genetic material, cells may activate cell death or senes-
cence, which is an irreversible arrest of cell proliferation, instead of DNA DSB repair pathways. 
The most important cell death pathways following irradiation are apoptosis, necrosis and mitotic 
catastrophe. 
FIGURE 2.8
Decision tree for DNA DSB repair pathway choice. Figure from (109). 
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2.5.1 Apoptosis
Apoptosis, or programmed cell dead, represents a regulated suicidal process, that results in the 
rapid destruction and removal of the cell. Apoptosis is an important process during development 
and aging and as a homeostatic mechanism to maintain cell populations in tissues. Apoptosis also 
occurs as a defense mechanism such as in immune reactions or when cells are damaged by e.g. 
radiation or toxic agents. A wide variety of stimuli and conditions, both physiological and patho-
logical, can trigger apoptosis, however whether or not they actually lead to apoptosis is cell type 
dependent (136). 
Apoptotic cells are characterized by morphological changes like plasma membrane blebbing, 
chromatin condensation, reduction of cellular volume and finally fragmentation of the cell and 
nucleus into membrane-enclosed structures, known as apoptotic bodies (137). 
The two most important apoptotic-pathways are an extrinsic and an intrinsic pathway, both of 
which can be regulated at multiple levels and can be activated by radiation (see figure 2.9) (136). 
Both the intrinsic and extrinsic pathway are characterized by the sequential activation of specific 
proteases known as caspases (cysteine-dependent, aspartate-specific peptidases) (138). The intrin-
sic pathway, also called the mitochondrial pathway, is activated more often in response to radia-
tion-induced damage. It is typically initiated by DNA damage, which will lead to activation of p53 
and then p21 (139, 140). In response, the balance of pro- and anti-apoptotic proteins is changed, 
leading to the mitochondrial outer membrane permeabilization (MOPS) which disrupts the mi-
tochondrial function. MOPS releases several potentially lethal proteins from the intermembrane 
space into the cytoplasm such as e.g. cytochrome c. Cytochrome c will activate and bind with 
subsequently APAF1 (apoptotic protease activating factor 1) and ATP/dATP ((deoxy)adenosine 
triphosphate). This conformation, called the apoptosome, will mediate the activation of caspase-9 
(138, 141). To activate the extrinsic pathway or death receptor pathway, death-signals from the 
surrounding environment bind the death-receptors on the membrane, which causes the activation 
of caspase 8. Both caspase-9 and caspase-8 will go on to activate the cascade of executioner 
caspases: caspase-3, -6 and -7 via mitochondria dependent and independent mechanisms. This 
will eventually lead to the formation of apoptotic bodies (138, 141-144). 
Induction of apoptosis following radiation can also occur independently of caspases and is then 
activated by the apoptosis-inducing-factor (AIF). AIF is expressed and compartmentalized into 
the mitochondria in physiological conditions. After a cellular injury, such as radiation-induced 
damage, AIF is cleaved and translocated to the nucleus where it interacts with DNA and causes a 
caspase-independent chromatin condensation and large scale DNA fragmentation (145). 
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2.5.2 Necrosis
Necrosis has long be regarded as an accidental form of cell death, however more recent evidence 
shows that some forms of necrosis actively involve defined signaling pathways that contribute to 
the cell’s death. Necrosis can be induced by exposure to various physico-chemical stressors such 
as ionizing radiation, oxidative stress and calcium overload. Necrosis can be induced very fast, 
when cells receive a very high dose of ionizing radiation or it can occur delayed following mitotic 
catastrophe (see further) (146). 
FIGURE 2.9
Overview of the most important pathways radiation-induced apoptotic pathways. Figure from (144).
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Necrotic cells are characterized by swelling of the cell and the organelles, formation of intracel-
lular vacuoles and plasma membrane rupture. Unlike apoptosis there is no fragmentation of the 
DNA. Eventually cell lysis will occur and the intracellular content is spilled, which may induce 
inflammation (147). 
Depending on the initiation-mechanism, different forms of necrosis can be described. TNF (tumor 
necrosis factor) is the best studied initiator of necrosis, but also pathogens, physico-chemical 
stress and release of inducers by other necrotic cells may induce necrosis. Most necrotic pathways 
are dependent on RIPK1 (receptor-interacting protein kinase) and RIPK3 for regulation. Necro-
sis mostly happens independently of caspases, although some necrotic-like cell-death pathways 
which involve caspases have been described. Furthermore, caspase-8 seems to negatively regulate 
TNF-initiated necrosis (147, 148).
2.5.3 Mitotic catastrophe
Mitotic catastrophe is a term used for cell death that occurs during or as a result of an aberrant 
mitosis. It has been controversial if mitotic catastrophe should be considered a type of cell death 
or rather an abnormal mitosis leading to cell death executed by apoptosis or necrosis. Consistent 
for all cell deaths following mitotic catastrophe is that they are delayed, occurring 2 to 6 days 
following radiation (144, 149, 150). 
The two most important mechanisms for induction of mitotic catastrophe is a deficient G2/M 
checkpoint and hyperamplification of centrosomes, both of which are linked to p53 inactivation 
(150, 151). As a result, the cell will enter mitosis prematurely where it will be stopped in its 
progression by the mitotic checkpoint. This delay, which occurs often after radiation, results in 
caspase activation and subsequent mitochondrial damage and eventually leads to delayed apopto-
sis in metaphase. However, often cells adapt to the mitotic checkpoint and exit the arrest but fail 
cytokinesis. These polyploid cells can survive for days and may even proceed to another round 
of cell division, acquiring an increasing amount of chromosomal aberrations. In the end these 
polyploid cells will die either by delayed apoptosis, delayed necrosis or induced senescence (144, 
149, 152). 
2.5.4 Senescence
Senescence is a state of permanent cell cycle arrest, and as such senescence prevents the prolif-
eration of cells that are at risk for tumorigenic transformation. Senescent cells do not divide but 
remain metabolically active. Replicative senescence is induced by the ageing of the cell, while 
stress-induced premature senescence can be induced by different stressors like radiation, osmotic 
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and mechanical stress, heat shock, genotoxic drugs etc. (153-155). However both types are closely 
related (see figure 2.10). 
Cells in both replicative and stress-induced senescence exhibit the same morphological and mo-
lecular markers: enlarged and flattened morphology, β-galactosidase activity, an activated DDR 
and cell cycle arrest machinery (p53, p16, p21) and a senescence-associated secretory phenotype 
(156, 157). 
Induction of a cell into senescence is initiated by activation of ATM. Activated ATM will lead to 
upregulation of the important downstream target p53, which in turn will trigger the transcription 
of p21. p21 acts to inhibit cyclin-dependent kinase 2 (CDK2) and blocks functional CDK2/cy-
clinE complexes, inhibiting the progression of cells from G1 to S-phase of the cell (158-160). The 
ATM-p53-p21 pathway is active 2 to 4 hours after irradiation (161). Another pathway leading to 
senescence goes via the p16 protein. Hyperactivation of the oncogenic Ras pathway, upregulates 
p16. Increased p16 levels inhibit cyclin-dependent kinases 4 and 6 (CDK4 and 6), which are as-
sociated with the progression of G1 cells into S-phase (162-164). The p16 pathway is slower and 
induction of p16 is observed from 5 days after exposure (165, 166). 
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FIGURE 2.9
Major pathways of replicative and stress-induced senescence. Figure adapted from (155)
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3 Radiotherapy
Radiotherapy, together with surgery and/or chemotherapy remains one of the cornerstones of can-
cer treatment. More than half of all cancer-patients are estimated to receive radiotherapy. Radio-
therapy aims to long-term control of the tumor or has a palliative role. 
3.1 Techniques used in radiotherapy
The two main methods used in radiotherapy are external beam radiation therapy or teletherapy, in 
which a beam of radiation is directed to the target tissue from outside the body, and brachytherapy, 
a technique where radioactive sources, such as 192Ir or small 60Co sources, are placed in a body 
cavity or placed directly in the tissue. For some tumors, such as cancer of the uterine cervix and 
the prostate, teletherapy and brachytherapy often are used sequentially or even concomitantly 
(167). 
External beam radiation therapy can be delivered with several types of treatment modalities. Lin-
ear accelerators producing megavoltage X-rays are today’s standard for radiotherapy. 60Co γ-ray 
sources are mostly used in less developed countries, since they are not so dependent on power and 
infrastructure and have an exceptionally stable beam output. X-ray machines producing between 
50 and 300kVp are used to treat superficial lesions. An increasing number of radiation therapy 
centers operate cyclotrons or synchrotrons that accelerate beams of protons or heavier charged 
particles to treat slowly growing, large hypoxic tumors (167). 
Radiotherapy often starts with an imaging modality, CT (computed tomography) or MRI (magnet-
ic resonance imaging) often in combination with PET (positron emission tomography) or SPECT 
(single-photon emission computed tomography) to define the volume of the tumor and the clinical 
target volume in relationship to the organs at risk. These images together with information about 
the tumor, lead to the treatment planning (167). Important in the treatment planning is sparing the 
healthy tissue, the organs at risk in particular, while giving a lethal dose to the clinical target vol-
ume. In conventional radiotherapy, the dose given to the healthy tissue is the real limiting factor. 
However an increase of 10% in dose deposited in the tumor typically gives an increased probabil-
ity of about 20% of local control of the tumor itself (see figure 3.1) (168). 
To deposit those large doses in the tumor while sparing the healthy tissue, different techniques 
are possible. High energy photon beams are more penetrating than traditional 50-300 kVp energy 
X-ray beams and have a skin sparing effect. More advanced techniques apply irregular fields us-
ing multileaf collimators. These intensity modulation radiation therapy (IMRT) techniques make 
use of 6 to 10 entrance ports and the intensity of the non-coplanar beams is varied across the ir-
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radiation field by means of variable multileaf collimators that are computer controlled (see figure 
3.2) (20, 169). Brachytherapy can provide better conservation of healthy tissue since the radiation 
source is placed within or adjacent to the target tissue and the radiation usually does not have to 
traverse healthy tissue to reach the target tissue (167). A better dose-deposition to the clinical 
target volume can be achieved by the use of charged particles. The Bragg peak assures a very 
precise dose deposition and by modulating the energy of the particles a spread out Bragg peak 
will be made to cover the complete volume of clinical interest and spare the surrounding tissue 
and organs (17). 
FIGURE 3.1
The probability of tumor control and deleterious effects in the healthy tissue, depends largely on the dose to which both tumor cells and 
healthy tissue are exposed. Figure from (168). 
3.2 Biological fundamentals of radiotherapy
The total prescribed dose in radiotherapy is typically in the range of 40 to 60 Gy, administered in 
different fractions. The first radiation oncologists realized that giving a smaller daily dose over 
a period of weeks also resulted in good tumor control with less severe side effects compared to 
single high-dose treatments (170). 
Loss of reproductive ability of the tumor cells caused by DNA DSB is the primary way by which 
radiation kills cells. Any cell that is incapable of reproducing is by definition considered dead, 
although it may still be metabolically active for some time. The response of tumors to radiation 
has therefore been largely characterized in terms of factors that influence the ability of radiation 
to damage DNA and affect a population of cells in tumors to recover from such damage. In 1975 
Withers described the 4 R’s, factors that are critical in determining the net effect of radiation ther-
apy on tumors (171). In 1987 a fifth R was added (12, 170, 172, 173):
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FIGURE 3.2
Dose deposition plan for radiotherapy for a total breast radiation, with at the top a transversal view and at the bottom a sagittal view. The 
pictures on the left show the dose deposition for conventional radiotherapy using wedges for a better dose homogeneity, the pictures on 
the right show the dose-deposition for IMRT. The better homogeneity of the dose-deposition using IMRT can immediately be noted. Pictures 
courtesy of Hurmans C. from the Catharina Hospital in Eindhoven, The Netherlands. 
• Repair. During a few hours after exposure repair of sublethal cellular damage will occur and 
cells will recover. This is very important for the healthy tissue surrounding the tumor and hap-
pens in the time between the fractions. 
• Repopulation of tumor cells after radiation. During the 4 to 6 weeks course of radiotherapy, 
tumor cells that survive the initial fractions may proliferate and thus increase the number of 
cells which must be killed. This is of course disadvantageous and is an argument against frac-
tionation. 
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- Repopulation of tumor cells after radiation. During the 4 to 6 rse of radiotherapy, 
tumor cells that survive the initial fractions may proliferate and thus increase the number of 
cells which must be killed. This is of course disadvantageous and is an argument against 
fractionation.  
- Redistribution of cells within the cell cycle: The cellular sensitivity to radiation is strongly 
influenced by the position in the cell cycle, with cells in S-phase being the most resistant and 
cells in late G2 and M the most sensitive (174). Cells in stationary phase also tend to be more 
radioresistant than cells in active proliferation. The cycling cells that survive the first few 
fractions, are statistically more likely to be caught later in a sensitive phase and so be killed by 
a subsequent dose, a process termed cell-cycle resensitization.  
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• Redistribution of cells within the cell cycle: The cellular sensitivity to radiation is strongly 
influenced by the position in the cell cycle, with cells in S-phase being the most resistant and 
cells in late G2 and M the most sensitive (174). Cells in stationary phase also tend to be more 
radioresistant than cells in active proliferation. The cycling cells that survive the first few frac-
tions, are statistically more likely to be caught later in a sensitive phase and so be killed by a 
subsequent dose, a process termed cell-cycle resensitization. 
• Reoxygenation of surviving cells. In a tumor, the hypoxic cells will selectively survive the 
first dose fractions. Thereafter, when their oxygen supply improves, their radiosensitivity will 
increase. While the process of reoxygenation is not completely understood, different factors 
seem to play a role. 
• Blood flow through vessels that where temporarily closed have recirculation again 
• In damaged cells respiration will be reduced which increases oxygen diffusion distance
•  Cell death leads to tumor shrinkage and a reduction in intercapillary distances, thus allow-
ing oxygen to reach hypoxic cells. 
• Radiosensitivity (intrinsic). There are big differences in radiosensitivity between different cell 
types, whether they are healthy or tumor cells. 
Modern radiotherapy protocols are based on manipulating these effects so as to maximize tumor 
cell kill while avoiding normal tissue toxicities, particularly those arising in late-responding tis-
sues. Treatments generally involve multiple fractions spaced over a period of time. In between the 
fractions, the healthy tissue will recover from the sublethal damage, while the tumor cells will be 
sensitized to the damaging effects of later fractions due to reoxygenation and redistribution of the 
cells over the cell cycle. 
Currently the trend in radiotherapy is to use less fractions of a higher dose (hypofractionation). 
The precise dose-deposition in modern radiotherapy techniques safeguards the healthy tissue, 
while delivering a markedly higher and more lethal dose to the target volume. This effect seems to 
be enhanced by the vascular injury sustained by the endothelial cells supplying the cancer tissue 
with oxygen and nutrients and immunological and bystander effects (18, 172, 175, 176). Further-
more, hypofractionation offers advantages for the patient as well as economic advantages (18). 
Certain tumors are radioresistant to photons and protons, these are mainly slowly growing tumors 
for which phenomena as reoxygenation and redistribution are not an important radiosensitizing 
mechanism. For these tumors, high-LET types of radiation can be advantageous. There are huge 
differences in intrinsic radiosensitivity between cell types, and these differences are more pro-
nounced for low-LET than high-LET radiation types. If tumor cells are more resistant to X-rays 
than the critical normal cells, high-LET radiation might reduce this difference in radiosensitivity 
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and thus sensitizes the tumor cell population relative to normal tissue. The high RBE of high-
LET radiation qualities induces more complex damage, which will be harder to repair by the 
cells. The differences in radiosensitivity due to cell-cycle position are considerably reduced with 
high-LET radiation. Furthermore, as human tumors are generally characterized by the presence 
of hypoxic cell fractions, the role of oxygen in the radiation response of cells may have important 
implications towards the use of radiotherapy in cancer treatment. Direct ionizations, common for 
high-LET radiation types, are less sensitive to hypoxic conditions than indirect ionizations (see 
figure 1.4). Therefore, tumor sites in which hypoxia is a problem, for example some head and 
neck tumors and prostate cancer, might benefit from high-LET radiotherapy (11, 12, 18, 177-179). 
3.3 Toxic effects following radiotherapy
While the dose-deposition in radiotherapy is hugely improved, the healthy tissue still receives a 
dose, mainly in the entrance and exit channels of the radiation beams, but also where malignant 
structures invaded the healthy tissue or normal tissues like blood vessels within the tumor. The 
DNA damage in these tissues can induce early and late toxic effects and lead to systemic disease 
and cancer (see figure 3.3) (180). 
Early or acute toxic effects of radiotherapy occur during or shortly after the radiotherapy and are 
usually found in tissues with a high proliferative activity. Most acute symptoms, like dermatitis, 
mucositis and hair loss are the result of radiation-induced DNA damage which causes the cell to 
lose its ability to proliferate and leads to cell depletion (181). Other acute responses, such as ery-
thema of the skin and increased intracranial pressure in the central nervous system are the effect of 
an inflammatory response (181). Healing of the inflammation, which is usually complete, is based 
on proliferation of surviving tissue stem cells within the irradiated volume or migration of stem 
cells from unirradiated tissue (12, 182). 
Late or chronic toxic effects manifest themselves in approximately 5% of the patients, after a 
latent time of 6 months to many years and are, with a few exceptions, irreversible and progres-
sive (184, 185). Chronic tissue damage is a dose-limiting factor in the treatment of some tumor 
types and as an increasing number of people are cancer survivors and life expectancy rises, the 
prevention or reduction of late side effects has become an important issue (186). Late toxic ef-
fects present themselves in tissues with a slow turnover. Late toxic effects are an orchestrated, 
active biological response induced by the early release of cytokines and has the features of wound 
healing (181, 187). This response is mediated by various cell types, including inflammatory, stro-
mal, endothelial and parenchymal cells actively responding through the release or activation of 
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FIGURE 3.3
Overview of the adverse effects of radiotherapy. Figure from (183). 
downstream cytokines and growth factors. The main pathogenic effects occur in the parenchyma 
of the organs, in the connective tissue and vascular endothelial cells (181). The immune system 
regularly contributes to the chronic reactions. Chronic toxic effects include e.g. radiation-induced 
fibrosis, atrophy, vascular damage, neural damage and a range of endocrine and growth-related 
effects (12, 182, 183). The development of a second primary cancer is also considered a late effect 
of radiotherapy, with a latency period of 5 years for leukemia and up to 10 years for solid tumors 
(188, 189). Other factors such as lifestyle (smoking, diet), immune function, hormonal status, 
genetic variation and concomitant therapy-related elements (e.g. chemotherapy), will also play 
a role in the development of a second primary cancer. However, the relative risk of developing a 
second cancer that is associated with specific treatments generally exceeds the risk that is associ-
ated with lifestyle factors, including those that might have contributed to the development of the 
first cancer (188). 
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4 Breast cancer
4.1 Incidence and mortality (all numbers taken from Globocan (190))
4.1.1 Cancer in general
Cancer is a major illness worldwide. Incidence rates per year worldwide are about 205 and 165 
per 100.000 individuals for men and women respectively. There are big differences in incidence 
across the word, with male incidence rates ranging from 79 per 100.000 in Western Africa to 
365 per 100.000 in Australia and New-Zealand, where the high rates of prostate cancer are a 
significant driver. Female incidence rates have less variation, ranging from 103 per 100.000 in 
South-Central Asia to 295 per 100.000 in Northern America. There is less regional variability in 
mortality, with the highest mortality for men in Central and Eastern Europe (173 per 100.000) 
and the lowest in Western Africa (69 per 100.000). For women the highest mortality rates are in 
Eastern Africa (111 per 100.000) while the lowest rates are in Central America an South-Central 
Asia (72 and 65 per 100.000) (see figure 4.1). 
FIGURE 4.1
Overview of cancer incidence and mortality rates throughout the world in 2012. (Figure from (190)). 
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Worldwide the most prevalent cancer in men is lung cancer (34 per 100.000), closely followed 
by prostate cancer (30 per 100.000). However, in more developed regions prostate cancer has the 
highest incidence. The cancer with the highest mortality in men is lung cancer (30 per 100.000). 
In women breast cancer has the highest incidence rate (43 per 100.000), followed by colorectal, 
cervix and lung cancer (all three 14 per 100.000). Breast cancer has the highest mortality rate in 
women (13 per 100.000) worldwide, closely followed by lung cancer (11 per 100.000). Again 
there are big differences worldwide, however breast, lung, cervix and colorectal cancer are the 
four cancers with the highest incidence around the world and breast cancer and lung cancer have 
the highest mortality rates (see figure 4.2).
FIGURE 4.2
Incidence and mortality rates of the most prevalent cancers in men (left) and women (right) in 2012. (figure from (190))
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4.1.2 Breast cancer
Breast cancer is by far the most common cancer among women, with an estimated 1.67 million 
new cancer cases diagnosed in 2012. About 25% of all cancers diagnosed in 2012 in women were 
breast cancers. In more developed regions, incidence rates are highest and range between 85 and 
95 per 100.000. In less developed regions the incidence rates are lower and range around 27 per 
100.000. Since the late 1980s and early 1990s in developed countries an increase in incidence of 
breast cancer is observed (191-193). 
Over the past 25 years, breast cancer mortality has decreased in North America and several Euro-
pean countries. The more favorable survival of breast cancer in the high-incidence well developed 
regions of the world, causes the range in mortality rate to be lower across the world, with rates 
ranging from 6 in Eastern Asia to 20 per 100.000 in Western Africa. The differences in incidence 
and mortality across the world lead to a survival of about 80% in more developed regions and 40% 
in less developed regions (191-193).
FIGURE 4.3
Incidence and mortality rates of breast cancer throughout the world in 2012. Figure from (190). 
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4.2 Breast cancer risk factors
4.2.1Hormones
Exposure to estrogen increases the breast cancer risk, therefore any factor that increases the expo-
sure to these hormones is a potential risk factor. 
Reproductive factors associated with increased exposure to endogenous estrogens produced by 
the ovaries, such as early menarche, late menopause, low parity and late age at first birth are rec-
ognized breast cancer risk factors (194-196). Similarly, women exposed to exogenous estrogen, 
for example through menopausal hormone therapy or oral contraceptives are often at increased 
risk. New guidelines pointing to the danger of menopausal hormone therapy and the of hormone 
levels in oral contraceptives led to a decrease in use of exogenous estrogen (197-201). 
4.2.2 Lifestyle factors
Lifestyle factors are associated with breast cancer. There is an estimated 10% increased risk per 
unit of alcohol consumed per day (202) (1 unit equals 10g or 12.5 ml of pure alcohol). Overweight 
is also associated with breast cancer, but only in postmenopausal women, with a gain of 5kg/m² 
in body mass index resulting in an 8% increase in risk (202). On the contrary, excess weight is 
associated with a decrease in risk in premenopausal women. These associations can be explained 
by hormonal factors: alcohol consumption and postmenopausal obesity are related to higher cir-
culating estrogen levels (203). 
Notice that the geographical pattern seen in breast cancer incidence and mortality can largely be 
explained by reproductive and hormonal factors influencing incidence and by the accessibility to 
early detection and treatment influencing both incidence related to over-diagnosis and mortality.
 
4.2.3 Breast density
Breast density reflects the proportion of fibroglandular tissue in the breast as opposed to nondense 
fatty tissue. High breast density has been shown to be an independent risk factor for increased 
breast cancer risk and benign breast disease. Comparison of the lowest and the highest breast 
densities, shows a 4-fold increase in breast cancer risk for the highest breast densities (204-208). 
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4.2.4 Radiation
Breast exposure to ionizing radiation is associated with an increased risk of breast cancer. Di-
rect evidence comes from studies investigating cancer incidence in the atomic bomb survivors 
of Hiroshima and Nagasaki and from follow-up studies of patients treated with radiotherapy for 
hematological malignancies or patients who were intensively monitored by X-ray fluoroscopy e.g. 
for scoliosis or tuberculosis (23-25, 207, 209-214). 
These studies have also shown that some factors described as risk factors for developing breast 
cancer, also seem to enhance the radiation-induced breast cancer risk: age at irradiation and at-
tained age, age of menarche or the time of first pregnancy, nulliparity, obesity, family history of 
breast cancer, benign breast disease and genetic factors (215-219). However, most of these factors 
should be interpreted cautiously as they modify the radiation risk only marginally and repro-
duction of the results seems challenging (219, 220). Carriers of genetic mutations, like BRCA1, 
BRCA2 or ATM, are suspected to have a higher risk for radiation-induced breast cancer. The 
evidence for enhanced risk is strongest for ATM, but results are still inconclusive (219, 221-223). 
Age at exposure and attained age seem to have the highest modifying effect on radiation-induced 
breast-cancer risk. Compared to exposure of young adults (30-40 years) the risk in children ap-
pears to be three fold in the atomic bomb lifespan population (23-25). After exposure at young 
age the risk continues to be elevated throughout the remainder of a woman’s life, with the largest 
excess rates occurring at ages similar to those at which breast cancers are seen in absence of expo-
sure (224). Also dose-time information of the exposure (total dose, dose rate, fractionation, dose 
per fraction) and radiation quality can modify the risk. 
4.2.5 Genetic background
The strongest risk factor for breast cancer development is family history. Up to 15% of the pa-
tients diagnosed with invasive breast cancer have at least one first-degree female relative with the 
disease (225). Individual risk increases with increasing number of relatives affected by breast or 
ovarian cancer and with decreasing age at which it was diagnosed (225). Twin studies estimate 
that around 27% of breast cancers are caused by hereditary factors (226, 227). However, only 5 
to 10% of breast cancers have a strong inherited component with only 5% being due to high pen-
etrance genes transmitted in an autosomal dominant fashion (228-231). The two most important 
high penetrance genes are BRCA1 and BRCA2 (Breast Cancer susceptibility gene 1 and Breast 
Cancer susceptibility gene 2). Additional high penetrant genes are PTEN, TP53, CDH1 and STK11 
but they are very rare (232, 233). Furthermore, moderate penetrance genes like ATM, CHEK2, 
BRIP1 and PALB2 (234-237) and low penetrance genes (238) have been identified (see figure 4.4). 
BRCA1 was the first high penetrance gene to be discovered in 1990 (228). Pathogenic mutations in 
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FIGURE 4.4
Proportion of the familial component of breast cancer caused by known genes and low-risk alleles. Figure from (239). 
BRCA1 confer a lifetime risk of breast cancer between 60% and 85%, with increased relative risks 
at younger ages. Type and position of the mutation, genetic modifiers and environmental effects 
explain the interindividual differences (240, 241). Furthermore, BRCA1 mutation carriers have an 
increased risk of ovarian cancer between 40 and 60% (242-247) and may have an increased risk 
of pancreatic malignancy (248). BRCA1 mutation carriers are affected by breast or ovarian cancer 
at substantially younger age and have a breast cancer risk of approximately 3% by the age of 30 
(244). 
BRCA1 is a large gene with 24 exons located on 17q2.1 and codes for a 220 kiloDalton (kDa) 
protein. Mutations are found throughout the coding sequence of the gene, with the majority being 
frameshift mutations resulting in truncated proteins (249). A few founder mutations have been 
identified, the best known are in the Ashkenazi Jewish population, with 1.2% of the individuals 
carrying one of the two BRCA1-founder mutations (250, 251).
BRCA1 has diverse roles in multiple DNA repair pathways and in checkpoint regulation. It in-
teracts with tumor suppressors, DNA repair proteins and cell cycle regulators through its various 
functional domains (252, 253). BRCA1 is directly involved in the very early stages of the HR 
DNA repair pathway where it binds to the DSB through its association with the abraxas-RAP80 
complex. In a next step, it is involved in CtIP-mediated 5’ resection of the DSB through its inter-
action with CtIP and the MRN complex. BRCA1 also interacts with PALB2 and BRCA2, which 
in turn will attract RAD51 to the DSB (254-257) (see figure 4.5). The role of BRCA1 in NHEJ and 
single strand annealing (SSA) is less clear and still under discussion. It is proposed that BRCA1 
removes the NHEJ proteins from the DBS to regulate the choice between HR and NHEJ. BRCA1 
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activates G1/S, S-phase and G2/M checkpoints through complexation with BARD1 (258). The 
G1/S checkpoint activation goes via phosphorylation of BRCA1 by ATM or ATR and subsequent 
phosphorylation of p53. The exact mechanism of the BRCA1-BARD1 control of the S-phase and 
G2/M checkpoint is still not well understood (259-261). 
BRCA2, discovered in 1994 (262), is a second high penetrance gene and pathogenic mutations 
confer a lifetime breast cancer risk between 40 to 85% (243-247, 263-265). There is more var-
iability of risk associated with mutation in BRCA2, suggesting that the gene is more modifiable 
than BRCA1 (239). The risk of ovarian cancer in BRCA2 mutation carriers is between 20 and 
30% (242-244, 263). Furthermore, women with a pathogenic mutation have an increased risk of 
cholangiocarcinoma, melanoma, pancreatic and gastric cancers (266). Male carriers of BRCA2 
have a lifetime risk of prostate cancer of 14-20% along with a 10% lifetime risk of male breast 
cancer (267). 
FIGURE 4.5
Overview of the most important functions of BRCA1 and BRCA2 in de DDR pathway. Figure from (268). 
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BRCA2 is a very large gene with 27 exons, located on 13q12.3 and coding for a 380kDa protein. 
Mutations occur throughout the gene, as with BRCA1 the majority being frameshifts. Again a 
founder mutation in the Ashkenazi Jewish population has been found, with 15% of the population 
carrying the mutation (250, 251). Homozygous mutations in BRCA2 have been shown to cause 
Fanconi Anaemia (FANCD1) (269), an autosomal recessive disorder, which is characterized by 
progressive bone marrow failure, congenital developmental abnormalities and early onset of acute 
myelogenous leukemia and squamous cell carcinomas of head and neck region (270).
BRCA2 also plays an important function in DSB repair, although the role of BRCA2 is less broad 
compared to BRCA1. BRCA2 is recruited to the DSB through interaction via the BRCA1-PALB2 
complex and has its main function in facilitating HR through recruitment of RAD51 to the DSB. 
It is crucial in HR as it regulates both the strand invasion and the appropriate stabilization/disas-
sembly of the oligomerized Rad51 (271, 272) (see figure 4.5). 
4.3 Detection and screening of breast cancer (see table 4.1)
Detection and treatment of breast cancer in an early stage gives a better prognosis, a better quality 
of life and a reduction in mortality (273, 274).
Mammography (see figure 4.6 (a)) is the most common detection method for breast cancer. With 
low energy X-rays, generally 28kVp, the breast tissue is imaged. In standard practice, a cranio-
caudal and a mediolateral oblique projections are taken, resulting in breast glandular doses of typ-
ically 3-5 mGy per two-view mammography (42, 275-277). The images are analyzed for masses, 
asymmetries, distortions and micro-calcifications and are compared with previous mammogra-
phies for changes which are potentially suspicious. Lesions smaller than 1 cm and not yet palpable 
can be found with mammography. In many countries, breast cancer screening programs based 
on periodic mammography exist for women aged between 50 (or 40) and 70 (or 75) years (278). 
These screening programs have shown to reduce breast cancer mortality (279). However, there are 
Introduction
4 Breast cancer
61
some limitations to mammography. The sensitivity of mammography is highly variable, ranging 
from 90% in women with fatty breast parenchyma to 36% in women with dense breasts (280, 
281). This can result in false positive screening results and 1.5 to 7% of the women participating 
in European screening programs are called back for further imaging work-up such as supplemen-
tary mammographic views or ultrasound. Of the recalled women, about 20% will receive a biopsy 
(274, 282-284). Furthermore there is also the concern about the use of ionizing radiation and 
associated breast dose, which always implies a risk for radiation-induced breast cancer. Although 
the dose is small, this cannot be neglected in view of the large population size and the repetitive 
character involved in this type of asymptomatic screening. 
The evolution from film-mammography to full field digital mammography already lowered the 
dose by approximately 22% (276) and further dose reduction can be expected with technological 
advancements like photon counting (285, 286). Digital breast tomosynthesis is another technical 
advancement of mammography, where the combination of different mammographic images taken 
from different angles are combined into a 3D image. Tomosynthesis is designed to overcome 
the problems of overlapping tissue, and has a higher specificity. However, sensitivity for micro-
calcifications is slightly reduced and the dose received is approximately 50% higher than for a 
conventional mammogram (287, 288). 
 
Ultrasound (see figure 4.6 (c)) is widely available, inexpensive, requires no contrast injection, 
does not use ionizing radiation and is well tolerated by patients. Hand-held scanning is evolving 
in two-dimensional automated whole breast ultrasound systems, which aim to standardize the 
screening examination and produce a consistently high quality examination. Ultrasound in breast 
cancer screening is sensitive but has a low specificity and is mostly used as an adjunct for mam-
mography or MRI when mammography alone does not give a decisive answer e.g. in patients with 
high breast density (289, 290). 
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FIGURE 4.6
(a) Mammogram showing an malignant breast tumor. (b) MRI of the breasts. An invasive ductal breast carcinoma is seen in the left breast. 
(c) Ultrasound of the breast with a mass suspicious for malignancy. 
Magnetic Resonance Imaging (MRI) (see figure 4.6 (b)) has superior sensitivity to mammography 
and ultrasound in the detection of invasive cancer, however it is often criticized for decreased 
specificity. The sensitivity of MRI can be further increased by the use of contrast MRI, which 
gives an image of the blood flow. MRI is recommended as an adjunct to mammography in selected 
patients at high risk for developing breast cancer e.g. patients with a BRCA1 or BRCA2 mutation 
and is also used for evaluating inconclusive mammograms and ultrasounds images and evaluating 
the response on chemotherapy (291, 292). 
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4.4 Pathology
The breasts mammary glands are highly modified apocrine sweat gland. At puberty the female 
breasts develop under the influence of estrogen and progesterone secreted by the pituitary gland 
and ovaries. During the first pregnancy, a significant increase in mammary glands is noted, mainly 
under the influence of estrogen and progesterone, but also prolactin, growth hormone, insulin 
and adrenal hormones have an influence. After the first pregnancy, the mammary glands are fully 
developed. Until the menopause, the breasts undergo cyclical changes in activity which is con-
trolled by the hormones of the ovarian cycle. After menopause, the breasts, like the other female 
reproductive tissues, undergo progressive atrophy and involution (293). 
TABLE 4.1
Strengths and limitations of breast imaging modalities. 
AWBUS: automated whole breast ultrasound system
MRI: magnetic resonance imaging
Table adapted from (288). 
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FIGURE 4.7
Normal breast tissue with a terminal duct giving rise to a lobule consisting of multiple acini. Terminal duct together with the lobule form a 
terminal duct lobular unit (TDLU). The terminal duct lobular unit is surrounded by dense collagenous connective tissue (pink) and fat (white). 
Picture from (293). 
Breast tissue consists mainly of adipose and fibroglandular tissue. The fibroglandular tissue of a 
breast consists of 15 to 25 independent glandular units called breast lobes. The lobes are separated 
from each other by moderately dense collagenous septa and are embedded in adipose tissue. Each 
lobe is drained by a single large duct, the lactiferous duct, which forms a dilatation called the lac-
tiferous sinus just before opening on the surface of the nipple. Within each lobe of the breast, the 
main duct branches repeatedly to form a number of terminal ducts, each of which leads to a lob-
ule consisting of multiple acini. Each terminal duct and its associated lobule is called a terminal 
duct-lobular unit. Each terminal duct-lobular unit is surrounded by dense collagenous connective 
tissue and fat (293) (see figure 4.7). 
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Breast cancer is a heterogeneous disease. Carcinoma in situ of the breast is a pre-cancerous or 
non-invasive cancerous lesion of the breast and it rarely produces symptoms. Ductal carcinoma in 
situ (DCIS) is usually detected through screening mammography, while lobular carcinoma in situ 
is not associated with calcification and is typically an accidental finding in a biopsy performed 
for another reason (294, 295). DCIS is a non-obligate precursor of invasive breast cancer, and up 
to 40% of these lesions progress to invasive disease if untreated. Currently it is not possible to 
predict accurately which DCIS are more likely to progress to invasive carcinoma (296). 
Invasive ductal carcinoma (IDC) is by far the most common type of breast cancer, representing 
80% of the invasive breast cancer cases, followed by invasive lobular carcinoma (ILC), account-
ing for 10% of the breast cancers (297, 298). Apart from the different etiology, IDC and ILC are 
marked by other differences. Patients with ILC are generally 3 years older, and diagnosed in a 
more advanced stage with tumors which are generally progesterone and estrogen receptor nega-
tive (299). ILC seems to be more strongly associated with exposure to female hormones than IDC 
and as a result it’s incidence has varied more than that of IDC depending on environmental and 
lifestyle factors such as menopausal hormone therapy (300). Genetically, IDC is overrepresented 
by patients carrying mutations in BRCA1 and TP53 (297, 301), while ILC is associated with a 
mutation in CDH1, the diffuse gastric cancer susceptibility gene (300, 302).
Breast tumors are classified according to the histological appearance of the cancer cells. As cancer 
progresses, the cancer cells lose their differentiation and this is used to grade breast cancer. Three 
parameters are used to grade breast cancers: mitotic activity, tubule/gland formation and nuclear 
pleomorphism. Well differentiated cells (low grade) have a better prognosis than poorly differen-
tiated cells (high grade) (303). 
TNM-staging is also applied on breast tumors and is based on the size of the tumor (T), whether 
or not the tumor has spread to the lymph nodes (N) and whether the tumor has metastasized (M). 
Larger tumor size, nodal spread and metastasis have a higher stage number and a worse prognosis. 
DCIS and LCIS have a stage 0, while stage 4 cancers are metastatic cancers (303, 304). 
4.5 Breast cancer treatment
Treatment of breast cancer generally starts with the surgical removal of the tumor and surrounding 
tissue. Depending of the size of the tumor, a small part (breast conserving surgery) or the whole 
breast (mammectomy) can be removed. During the surgery one or more lymph nodes are sampled 
by sentinel lymph node biopsy to check for invasion of breast cancer cells to the regional lymph 
nodes. 
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Radiotherapy is often given after surgery to the region of the tumor bed and the regional lymph 
nodes (adjuvant radiotherapy). The irradiated volume can be the whole breast or part of the breast 
surrounding the tumor volume. The majority of breast cancer recurrences occur near the primary 
tumor site (305-308) and partial breast irradiation has the advantage that it minimizes the dose to 
the healthy tissue, reducing late effects and it spares the adjacent organs including heart, lungs and 
ribs (309, 310). IMRT is standard practice, although a good dose-distribution can also be obtained 
with high energy X-rays in tangential fields and with techniques as irradiation in prone position. 
Hypofractionated irradiation schemes are now standard, of which the two most important ones are 
42.5 Gy in 16 fractions (Canadian Trial) and 39Gy in 13 fractions (START A), possibly followed 
by a boost to the tumor site of 10 or 16 Gy (311, 312).
Brachytherapy is also used for the treatment of breast cancer. Dose deposition is good, with almost 
complete sparing of the surrounding tissue. However, with interstitial brachytherapy, fat necro-
sis and scarring can occur due to the invasive nature of the procedure, while with intercavitary 
brachytherapy dose homogeneity is difficult when the surgical cavity is irregular and superficial 
cavities can lead to higher skin doses and increased toxicity. With 192Ir a dose of 34Gy is given in 
two daily fractions for a period of 5 days.
The role of radiotherapy in decreasing the risk of recurrence and breast cancer death is well estab-
lished (313-315). Adjuvant radiotherapy given after breast conserving surgery halves the rate of 
recurrence in the long term and reduces breast cancer related death by one-sixth (316). Additional 
nodal irradiation in women with node positive breast cancer further reduces the risk of recurrence 
and increases the overall survival (317). 
Adverse side-effects of radiotherapy in breast cancer patients are well described. During or shortly 
after the course of breast cancer radiotherapy a large portion of the patients will experience radi-
ation dermatitis to a certain degree, leading to poor cosmetic outcomes (318-320). The pathology 
of late normal tissue reactions in breast cancer patients comprises processes such as pigmentation 
changes, atrophy, fibrosis and vascular damage (181). Factors associated with an increased risk of 
late toxic side effects in breast cancer patients can be separated in two general categories. First, 
radiation therapy related risk factors including the total dose and additional boost, the irradiat-
ed volume, the fractionation regimen and the total treatment time (321, 322). Secondly, patient 
and therapy-related factors may influence the risk and severity of late normal tissue toxicity af-
ter breast cancer treatment. Especially breast size increases the risk, but also age, concomitant 
chemotherapy or hormonal treatment, trauma or surgery in the irradiated site, co-morbidities in-
volving impaired vascularity such as diabetes and hypertension (181, 320, 323).
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The induction of second primary cancers (SPC) by radiotherapy for breast cancer treatment is 
dependent on the same factors as the general late toxic effects. The most common sites of SPC are 
breast, bone, ovary, lung, thyroid and leukemia (324). Also the development of radiation-induced 
heart disease has been described after breast cancer irradiation (325). Proton therapy can effi-
ciently spare the heart during the treatment of left-side breast-cancer (326), whereas with X-rays, 
a large fraction of the heart is generally exposed. Breast cancer is therefore becoming a major 
application of protontherapy (18, 327-329)
Adjuvant chemotherapy or hormone therapy can be given before or after surgery and in combina-
tion with radiotherapy. Which adjuvant therapy will be used is highly dependent on the receptor 
status of the tumor. Tumors can express receptors for estrogen (ER+), progesterone (PR+) and 
human epidermal growth factor 2 (HER2+), which can be used for treatment purposes. ER+ and 
PR+ tumors require estrogen to continue growing, and can be treated(330) by hormone blocking 
therapy, like tamoxifen, which block the receptors or e.g. aromatase inhibitors which block the 
production of estrogen (331). Trastuzumab, an anti-HER2 monoclonal antibody is used against 
HER2+ tumors. Trastuzumab will block the HER2-receptors and prevent growth factors to bind 
to the receptors and stimulate the cells (332). Triple negative tumors, which have the worst prog-
nosis, are treated with chemotherapy, which destroys fast-growing and/or fast-replicating cells 
and may cause serious side effects. Often a combination of multiple chemotherapeutic agents 
are used, depending on different factors such as the stage of the tumor and the health and age of 
the patient. A standard chemotherapy regimen can e.g. be cytoxan, methotrexate and fluorouracil 
given 4-weekly for 6 cycles (330).
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5  Assays to measure  
the effect of radiation
Radiation-induced damage can be measured in different ways. Depending on the technique used, 
the initial DNA damage, the repair kinetics or the cellular outcome can be determined. Throughout 
this thesis, a number of tests were used: the γH2AX foci assay, the micronucleus assay, the apop-
tosis assay and the crystal violet cell proliferation assay. 
5.1 The γH2AX foci assay
The quantification of DNA DSB induction and repair was done in the past with pulsed field gel 
electrophoresis (PFGE). 
More recently the quantification of γH2AX-foci as a measure for the number of DNA DSB has 
come into focus (333). The phosphorylation of the histone variant H2AX at the site of the DSB 
(see chapter 2.1 and figure 5.1), leads to the formation of γH2AX foci around the break and a 
quantitative one on one relation between foci and the number of radiation-induced DSB has been 
found for low-LET radiation, in particular γ-radiation for doses under 1Gy (334). Within minutes 
after irradiation these foci can be visualized with immunostaining and a maximum is reached 15 
to 30 min after exposure (335-338). 
The γH2AX foci assay allows to detect very low doses of a few mGy (10). Furthermore, by ana-
lyzing the number of foci at different time-intervals after irradiation, the kinetics of disappearance 
of the foci and as such the repair of the breaks can be followed. Persistence of repair foci at 24h, 
48h or even longer after irradiation can be used as a measure of the repair capacity of the cell. Also 
foci of other proteins involved in the DDR, such as ATM and 53BP1 show a close correlation to 
DSB induction and repair and can be visualized with immunostaining (69, 339). To enhance to 
reliability of the foci-technique and exclude background-foci, a double staining can be done for 
two DSB-foci proteins, such as γH2AX and 53BP1 to assess how they co-localize (see figure 5.2) 
(340). 
γH2AX foci induction will follow a linear dose-response curve, higher doses can however lead to 
saturation and can cause a flattening of the curve. 
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FIGURE 5.1
Schematic overview of the γH2AX and other repair foci- assay. Ionizing radiation causes a DSB, which triggers the activation of the DNA 
damage response. The cascade of events results in the phosphorylation of histone variant H2AX in the region around the break (see section 
2.1 DNA damage response for more details). γH2AX, but also e.g. ATM and 53BP1, can be visualized with immunostaining. Figure adapted 
from (341).
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FIGURE 5.2
Repair foci staining. Picture a shows a γH2AX staining in the nuclei of irradiated lymphocytes. Picture b depicts a γH2AX and 53BP1 double 
staining. Picture c shows the same cell stained with a γH2AX and 53BP1 double staining, the pictures are taken in different fluorescent chan-
nels. c1 shows the γH2AX staining in the TRITC channel, c2 shows the 53BP1 in the FITC channel. Remark the colocalization of both proteins. 
Figures from our lab. 
5.2 The micronucleus assay
By means of cytogenetic analysis, chromosomal aberrations, which are the result of un- or mis-
repaired DSB, are scored. Chromosomal aberrations are good biomarkers to assess radiation 
exposure and radiosensitivity. Examples of cytogenetic techniques used in radiobiology are the 
dicentric assay, chromosome painting to score stable translocations and the MN assay (cytokine-
sis-block micronucleus assay). 
The MN assay, which is used in this thesis, is based on the analysis of small extranuclear bodies 
which contain mainly acentric chromosome fragments in binucleated cells. In short, in this assay 
cells are irradiated and after irradiation cytochalasin B is added to the cell cultures to inhibit cel-
lular division. Mitosis will proceed, but the radiation-induced acentric chromosome fragments, 
resulting from un- or misrepaired DSB, will not be included in the daughter cells, as the fragments 
lack a centromere and cannot attach to the spindle fibers. After mitosis a nuclear envelope will 
form around the new nuclei and around the fragments, which are then called micronuclei (342-
344) (figure 5.3 and 5.4). 
(a) (b) (c1)
(c2)
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FIGURE 5.3
Schematic overview of the MN assay. Irradiation of the cell will induce chromosomal damage. Both the acentric fragment and the lagging 
chromosome will lead to the formation of a MN. Cytochalasin B is added to inhibit cellular division. Figure adapted from (343). 
FIGURE 5.4
MN assay on lymphocytes. In picture (a) the cells and MN are stained with DAPI (4’,6-diamidino-2-Phenylindole; a nuclear stain). In picture (b), 
a FISH pan-centromere staining is additionally performed. One MN is centromere-negative and contains an acentric fragment (MN top left), 
the other two MN have a positive centromere-signal implying they contain whole chromosomes. Figure from our lab.
Radiation-induced MN contain mostly acentric fragment. However, MN can also arise spontane-
ously and those MN mostly contain whole chromosomes. A high interindividual variation in the 
number of spontaneous MN will make the assay less sensitive in the low dose range, resulting 
in a detection limit of approximately 0.2 Gy. A Fluorescent in situ hybridization (FISH) pancen-
tromere staining can be used to distinguish to a large extent between the radiation-induced and the 
spontaneous MN (345, 346) and makes the assay more sensitive by lowering the detection limit 
to 0.05-0.1 Gy (figure 5.4).
Cytochalasin B
	  
(a
) 
(b
) 
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The MN assay can be done on all cell types that can be stimulated to divide and irradiated cul-
tures will normally contain a mixture of cells in all phases of the cell cycle. Human peripheral 
blood lymphocytes are often used in the MN-assay for biological dosimetry or in patient studies. 
Lymphocytes are resting cells in G0 phase of the cell cycle. If the lymphocytes are not stimulated 
to divide before irradiation but only afterwards, all cells will be irradiated while in G0, which 
is called the G0 MN assay. In the G2 MN assay, lymphocytes will be first stimulated to divide 
before they are irradiated and a short incubation time is used after the irradiation. This causes an 
enrichment of binucleated cells which were irradiated in the G2 phase of the cell cycle (347). The 
G2 MN +caf assay is an adaptation to the G2 MN assay, where caffeine is added to the irradiated 
cultures. Caffeine abrogates the G2/M checkpoint (68, 69) and the use of caffeine on G2-cells will 
allow heavily damaged and yet unrepaired cells, which would otherwise be blocked at the G2/M 
checkpoint, to progress through mitosis. This allows us to analyze differences in individual repair 
efficiency independent from differences in individual cell cycle control (70, 71).
The induction of chromosomal aberration typically leads to a dose-response curve which is lin-
ear-quadratic in shape and which is defined by an α-component (the linear component) and a 
β-component (the quadratic component). 
In this thesis, ellipses have been constructed to analyze inherent differences in radiosensitivity at 
the 95% confidence level. The ellipses represent the set of α and β-values that demarcate a 95% 
confidence interval and are based on the average values and variances. They delimit the covari-
ance between the cellular dose-response parameters which represent the inherent radiosensitivity 
(α), as well as the capacity to accumulate damage (β). When two ellipses don’t overlap, they indi-
cate a significant difference in radiosensitivity at the 95% level (see figure 5.5) (348). 
A dose-wise comparison is possible to assess differences in radiosensitivity or in efficiency of 
radiation-qualities. However, in this thesis, the area under the curve (AUC) was also calculated to 
assess differences in radiosensitivity based on the whole dose-response curve. 
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FIGURE 5.5
Example of two the 95% confidence ellipses based on MN dose response curves of two different donors. The ellipses don’t overlap, suggesting 
that the donors are inherently different in radiosensitivity. Figure from our lab.
5.3 Apoptosis assay
Apoptosis or programmed cell death is one of the major cell death pathways activated by IR. Ap-
optosis will be the result of the DNA damage response when the damage to the DNA is too severe 
to be repaired. A number of assays can be used to detect apoptosis, such as FLICA staining based 
on caspase activity (349), TUNEL assay based on detection of DNA fragmentation, Annexin V 
staining and detection of changes in mitochondrial membrane potential (350, 351). 
In this thesis, apoptotic cells were detected with flow cytometry using an Annexin V and 7-ami-
noactinomycin D (7-AAD) staining. Phosphatidylserine is predominantly located on the cytosolic 
side of the plasma membrane. One of the first steps in apoptotic cells is the flipflop of phosphati-
dylserine from the inner side of the membrane to the extracellular side. Annexin V will bind to the 
extracellular phosphatidylserine and will allow the detection of the early apoptotic cells. 7-AAD 
is a viability dye, which will be excluded from viable cells during the first phases of apoptosis. 
In a later stage, loss of membrane integrity will lead to the uptake of 7-AAD and allow for the 
detection of late apoptotic cells (352).
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5.4 Crystal violet cell survival assay
As a consequence of radiation a cell can lose its ability to proliferate, which is known as reproduc-
tive failure. The standard assay to determine reproductive failure is the colony formation assay. 
This assay is based on the ability of individual cells to divide and form macroscopically visible 
colonies after a few divisions (2, 13). 
In this thesis the crystal violet cell survival assay was used. This assay is not based on colony 
formation but on cell proliferation, and as such is suitable for cells that do not form well-defined 
colonies (e.g. the MCF-10A cells used in this thesis) (353). In the crystal violet proliferation assay, 
cells are irradiated and seeded in a low concentration. Cells are incubated for 5 to 10 days, during 
which time those cells which are still capable of proliferation will divide. After this period, the 
cells will be fixed and stained with crystal violet. Crystal violet, a basic dye, will bind with cellular 
components. After washing and bringing the dye in solution again, optic density of the extracted 
crystal violet can be measured (354, 355). Remark that the crystal violet proliferation assay reg-
ularly gives an overestimation of the cell survival rate compared to the colony formation assay, 
since the measurement of dividing cells can be contaminated a bit by the presence of non-dividing 
cells. The presence of non-dividing cells may further result in tailing of the survival curves at 
higher radiation doses (353, 355). 
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6 Aim of the research
Breast tissue is prone to the development of cancer and radiation is known to be an inducer of 
cancer. However, irradiation of breast tissue is often used in a useful manner: mammography to 
detect breast cancer in an early stage or radiotherapy to eradicate breast cancer.
The effectiveness of radiotherapy in cancer treatment is mainly based on the ability of high doses 
of ionizing radiation to induce DNA damage and kill cancer cells. In diagnostic imaging, the goal 
is to get a clear image, based on density differences between tissues. Different types of radiation 
have different properties, mainly determined by the LET, mass and charge of the particles used 
and can therefore be used with different goals in mind. Low-energy 30 kV X-rays are good in 
producing good contrast images of the breast. High-LET radiation qualities are used increasingly 
in radiotherapy due to their high RBE and because particle beams have a good dose deposition. 
Notwithstanding the dose to the healthy tissue in radiotherapy is kept to a minimum and the im-
portant organs are spared as much as possible, the healthy tissue will also receive an amount of 
radiation. In diagnostic imaging doses are low, although while doing so there is the risk to induce 
DNA damage. The advantages of using radiation qualities with a higher LET compared to conven-
tional γ-rays or X-rays might come with a cost for the healthy tissue and it is important to know 
the efficiency of these types of radiation to induce DNA damage. 
While breast cancer isn’t commonly treated with high-LET radiotherapy, the use of it is rising 
for a variety of cancer-types. Furthermore, research into the distinct characteristics of high-LET 
radiation and the differences with low-LET radiation can help to further unravel the DNA damage 
response pathways activated by radiation-induced DNA DSB. 
A first aim of this thesis was to investigate the biological efficiencies of different radiation qual-
ities in different cell types using different cellular endpoints. 
We analyzed the efficiency of 30kV X-rays and neutrons to induce DNA DSB (γH2AX foci as-
say). Furthermore, we investigated the repair kinetics of the DSB induced by the above mentioned 
radiation qualities and to what extent an increased number of persistent foci correlated with an 
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increased number of chromosomal aberrations (micronucleus assay). Finally we analyzed the dif-
ferences in efficiency of the different radiation qualities to inhibit cell proliferation (crystal violet 
cell proliferation assay). For these studies peripheral blood lymphocytes from healthy donors, 
MCF-10A human mammary epithelial cell lines and mammary epithelial cells in dissected breast 
tissue were used. 
Dose is of a different order of magnitude in radiotherapy or diagnostic imaging. Since RBE is 
function of dose, we analyzed the influences of the above mentioned parameters on RBE in the 
higher dose range and in the low dose range, with special emphasis on the very low dose range in 
light of mammography screening. 
Cell cycle phase is also a parameter that will influence the RBE. The cell cycle phase will de-
termine which DSB repair pathways can be activated. To investigate the relationship between 
cell cycle phase, DSB repair pathway and RBE, we constructed DSB repair deficient MCF-10A 
cell lines. These cell lines were irradiated with neutrons and γ-rays as synchronized G1 cultures 
and mixed cultures containing cells in G1, S, G2 and M phase of the cell cycle. We analyzed the 
impact of repair pathway deficiencies and cell cycle on MN-induction after irradiation with both 
neutrons and γ-rays. 
The term radiosensitivity is used to describe many different phenomena such as normal tissue 
radiosensitivity, susceptibility to radiation carcinogenesis and cellular radiosensitivity. In the first 
part of this study, we investigated how cellular radiosensitivity, which refers to phenomena such 
as cell proliferation, chromosomal aberrations and apoptosis, is linked to RBE. The second and 
third aim of this thesis is dealing with individual radiosensitivity. Individuals vary in radiosen-
sitivity and their ‘intrinsic or inherent radiosensitivity’ is determined by the genetic background 
(mutation, single nucleotide polymorphisms (SNP) in repair genes,…). Non-genetic modifying 
factors, such as smoking, life style but also tissue-volume irradiated, will further influence the 
individual’s response to radiation. A clinical endpoint of individual radiosensitivity is for instance 
the reaction of normal tissue to radiotherapy, called ‘normal tissue radiosensitivity’. This is a re-
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sponse from the normal, healthy tissue to radiation, and mostly refers to early or late toxic effects 
of the healthy tissue following radiotherapy. Different individuals will show different degrees of 
radiation toxicity, influenced by their inherent radiosensitivity and modifying factors. Another 
clinical endpoint of individual radiosensitivity is the susceptibility to radiation carcinogenesis. 
This refers to the susceptibility of an individual to develop radiation-induced cancer in specific 
tissues. 
The health effects of radiation are influenced by a person’s inherent radiosensitivity, but are also 
tissue specific. Different tissues will have different sensitivities to develop radiation-related toxic 
effects or cancer. Breast tissue is known to be sensitive to radiation and especially the mammary 
epithelial cells are prone to the development of radiation-induced cancer. 
The second aim of this thesis was to investigate if the late toxic normal tissue radiation response 
of breast cancer patients is related to cellular radiosensitivity. When receiving radiotherapy to treat 
breast cancer, a small subgroup of women exhibits a late toxic reaction of the healthy tissue to the 
radiation. This limits the dose which can be safely administered during radiotherapy. Using lym-
phocytes from breast cancer patients we investigated if biomarkers for cellular radiosensitivity 
can be used to predict which women will develop late toxic reactions of the healthy tissue. 
The third aim of this thesis was to investigate the radiosensitivity of BRCA1 and BRCA2 mu-
tation carriers. A long standing discussion is whether or not BRCA1 and BRCA2 mutation carri-
ers are more sensitive to develop breast cancer following radiotherapy or mammography. Most 
studies on this subject are either cohort-studies with often a low power or studies performed on 
lymphocytes, which are different from breast epithelial cells. To assess the impact of a BRCA1 
or BRCA2 mutation on radiosensitivity we used mammary epithelial cells (MCF-10A) in which 
we induced of knockdown of the BRCA1/2 proteins of approximately 50%, which is comparable 
with the BRCA1/2 protein levels in heterozygous mutation carriers. As endpoints we investigated 
micronucleus formation and cell proliferation. 
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Outline of the research
Article 1
Induction and disappearance of gamma H2AX foci and formation of micronuclei after expo-
sure of human lymphocytes to Co-60 gamma-rays and p(66) + Be(40) neutrons
Vandersickel V, Beukes P, Van Bockstaele B, Depuydt J, Vral A, Slabbert J.
International Journal of Radiation Biology 2014; 90, 149-58.
The induction of γH2AX foci and the formation of micronuclei were analyzed in human lympho-
cytes from 10 healthy donors after exposure to γ-rays and neutrons with doses ranging between 0 
and 4 Gy. Also the kinetics of foci-disappearance were followed up to 24h after a dose of 0.5Gy 
of neutrons and γ-rays in a single donor. We observed a lower number of radiation-induced DNA 
DSB (γH2AX foci) for neutron radiation compared to γ-rays until about 4h post-IR, however, 
foci repair was slower and more residual foci were present at later time points. Furthermore, mi-
cronucleus yields following neutron exposure were consistently higher compared to micronucleus 
yields following γ-ray exposure. 
Article 2
The impact of a BRCA1 and BRCA2-mutation on the radiation response induced by gamma 
rays and neutrons in MCF10-A cells.
Depuydt J, Beukes PR, Baert A, Verstraete B, Van Heetvelde M, Vandersickel V, Thierens H, 
Slabbert J.P., Vral A.
Submitted to: International Journal of Radiation Biology
Downregulation of BRCA1, BRCA2 and Ku70 proteins in human mammary epithelial MCF-10A 
cell was obtained using RNA interference transduction. Mock transduced (CONBRCA and CON-
Ku70) and knockdown (BRCA1i, BRCA2i and Ku70i) MCF-10A cell were irradiated as mixed 
cell cultures (G1, S, G2 and M) and as synchronized G1 cultures with γ-rays and fast neutrons. 
Cellular and chromosomal radiosensitivity was measured with the crystal violet (CV) cell prolif-
eration assay and the micronucleus (MN) assay, respectively. We found that neutrons were more 
efficient in inducing MN and inhibiting cell proliferation. Furthermore, the BRCA1i, BRCA2i and 
Ku70i cell lines were characterized by an increased radiosensitivity which is dependent on LET, 
dose and cell cycle. 
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Article 3
Relative biological effectiveness of mammography X-rays at the level of DNA and chromo-
somes in lymphocytes.
Depuydt J, Baert A, Vandersickel V, Thierens H, Vral A.
International Journal of Radiation Biology 2013; 89, 532-38.
The induction of γH2AX foci and the formation of micronuclei were analyzed in human lympho-
cytes from 5 healthy donors after exposure to γ-rays and 30kV X-rays with doses ranging between 
0 and 2 Gy. We found that 30kV X-rays are slightly more efficient in inducing γH2AX foci. Mi-
cronucleus yields following 30kV exposure were consistently higher compared to micronucleus 
yields following γ-ray exposure and a low-dose RBE value between 3 and 4 was determined. 
Article 4
Relative biological effectiveness of mammography X-rays in breast tissue
Depuydt J, Viaene T, Blondeel P, Roche N, Thierens H, Vral A.
Article in preparation for Radiation Research
The induction of γH2AX foci in mammary epithelial cells in breast tissue from healthy donors 
was analyzed after irradiation with 30kV X-rays and γ-rays. The dose response curve following 
30kV X-ray irradiation was biphasic, showing a hypersensitive response in the 0 to 20 mGy re-
gion, probably caused by the bystander effect. The RBE in the 20-500 mGy dose range was 1 and 
the RBE in the 0-40 mGy dose range was 3.7.
Article 5
In vitro cellular radiosensitivity in relationship to late normal tissue reactions in breast can-
cer patients: a multi-endpoint case-control study
Vandevoorde C*, Depuydt J*, Veldeman L, De Neve W, Sebastia N, Wieme G, Baert A, De Lange 
S, Philippe J, Vral A, Thierens H.
* These autors contributed equally to this work
Submitted to: International Journal of Radiation Biology
The radiosensitivity of 12 cases exhibiting late toxic effects following radiotherapy and 12 
matched controls who showed no or minimal effects was assessed with four cellular assays us-
ing lymphocytes from the patients: radiation-induced late apoptosis (8Gy, 48h), residual γH2AX 
foci (4Gy, 24h), G0 and G2 MN assay. A significant difference was observed between cases and 
controls for all endpoints, with the apoptosis-assay being the most promising assay. Our results 
suggest that patient’s intrinsic radiosensitivity is involved in the development of late normal tissue 
reactions after radiotherapy. 
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Article 1
Induction and disappearance of γH2AX foci 
and formation of micronuclei after exposure 
of human lymphocytes to 60Co γ-rays and 
p(66)+Be(40) neutrons
108
Original research
Article 1
Abstract
Purpose: To investigate both the formation of micronuclei (MN) and the induction and subse-
quent loss of phosphorylated histone H2AX foci (γH2AX foci) after in vitro exposure of human 
lymphocytes to either 60Co γ-rays or p(66)+Be(40) neutrons. 
Materials and methods: MN dose response (DR) curves were obtained by exposing isolated 
lymphocytes of 10 different donors to doses ranging from 0 to 4 Gy γ-rays or 0 to 2 Gy neutrons. 
Also, γH2AX foci DR curves were obtained following exposure to doses ranging from 0 to 0.5 
Gy of either γ-rays or neutrons. Foci kinetics for lymphocytes for a single donor exposed to 0.5 
Gy γ-rays or neutrons were studied up to 24 hours post-irradiation.
Results: Micronuclei yields following neutron exposure were consistently higher compared to 
that from 60Co γ-rays. All MN yields were over-dispersed compared to a Poisson distribution. 
Over-dispersion was higher after neutron irradiation for all doses > 0.1 Gy. Up to 4 hours post-ir-
radiation lower yields of neutron-induced γH2AX foci were observed. Between 4 and 24 hours 
the numbers of foci from neutrons were consistently higher than that from γ-rays. The half-live 
of foci disappearance is only marginally longer for neutrons compared to that from γ-rays. Foci 
formations were more likely to be over-dispersed for neutron irradiations. 
Conclusion: Although neutrons are more effective to induce MN, the absolute number of induced 
γH2AX foci are less at first compared to γ-rays. With time neutron-induced foci are more persis-
tent. These findings are helpful for using γH2AX foci in biodosimetry and to understand the repair 
of neutron-induced cellular damage.
Introduction
Exposure of cells to ionizing radiation (IR) in-
duces different types of DNA damage, of which 
double-strand breaks (DSB) are considered the 
most genotoxic. As it is important to maintain 
the genomic integrity of DNA, eukaryotic cells 
developed a complex network of signalling and 
effector pathways to reconstitute these DSB as 
accurately as possible to their original pre-ir-
radiated state. This sophisticated and highly 
coordinated network is referred to as the DNA 
damage response. In this response, the induc-
tion of a DSB will lead to the activation of 
sensor molecules that detect the damage and 
transduce this signal to different downstream 
effector pathways. The latter include pathways 
that lead to cell cycle arrest and repair of the 
break or cell death if the damage is irrepara-
ble (Khanna and Jackson 2001). Under normal 
circumstances induction of a DSB immediately 
results in the activation of a phosphatidylin-
ositol-3-OH-kinase-like kinase member, the 
Ataxia Telangiectasia Mutated (ATM) protein 
(Stucki and Jackson 2006). Within minutes fol-
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lowing exposure to ionizing radiation ATM’s 
kinase activity leads to the phosphorylation of 
the H2AX histone protein, a variant of the nu-
cleosomal H2A histone core protein, at the site 
of the DSB. This phosphorylation of the H2AX 
protein, referred to as γH2AX, rapidly spreads 
over an extensive region surrounding the DSB 
leading to the formation of so called γH2AX 
foci (Rogakou et al. 1998, 1999). With the use 
of an appropriate phospho-specific antibody 
these foci can be easily detected and visualized. 
Off all IR-induced DNA lesions, only DNA 
DSB induce H2AX phosphorylation. Due to 
the close relationship between the number of 
γH2AX foci and the number of radiation-in-
duced DNA DSB (Rogakou et al. 1998, Sedel-
nikova et al. 2002, Rothkamm and Löbrich 
2003), formation of γH2AX foci have been 
exploited as being a sensitive and quantitative 
marker of radiation-induced DNA DSB (Kin-
ner et al. 2008). Besides H2AX, ATM phos-
phorylates and activates numerous other dam-
age response proteins (Cann and Hicks 2007). 
Initiation of ATM dependent and independent 
damage response pathways (Jeggo and Löbrich 
2006, Jeggo and Lavin 2009) results in the ac-
tivation of repair pathways and restoration of 
the break. Despite the attempt of this cellular 
machinery to properly repair the break, some 
breaks escape accurate repair and erroneously 
rejoining of free DNA DSB ends occurs. When 
breaks are not repaired or misrepaired, this can 
lead to the formation chromosomal aberrations 
(including micronuclei), which, depending on 
their nature can cause cell death (Olive 1998) 
or underlie tumorigenesis (Pierce et al. 2001, 
Rothkamm and Löbrich 2002).
To investigate and describe differential biologi-
cal effects of different radiation qualities, anal-
ysis of cell death (cell survival) and formation 
of chromosomal aberrations are used widely. 
It is well known that the effectiveness of in-
ducing cell death and producing chromosomal 
aberrations depends on the ionization density 
of the radiation beam. Radiation types with a 
high-linear energy transfer (LET) are more ef-
fective than sparsely ionizing radiation in in-
ducing cell lethality and chromosomal aberra-
tions for a given absorbed dose. 
To describe this increased efficiency of high-
LET radiation types compared to low-LET 
beams when using these biological endpoints, 
the relative biological effectiveness (RBE) is 
specified. Since it is generally acknowledged 
that induction of DSB can lead to both phenom-
ena, understanding and identifying the underly-
ing mechanisms resulting in RBE differences 
frequently involves the study of induction and 
loss (i.e. repair/rejoining kinetics) of DSB (eg, 
Leatherbarrow et al. 2006). 
Before the discovery of H2AX phosphoryla-
tion, physical methods such as neutral sucrose 
density gradient centrifugation, neutral filter 
elution, gel electrophoresis techniques includ-
ing pulsed field gel electrophoresis (PFGE) 
– were standard methods used to investigate 
DSB induction and repair/rejoining kinetics 
(Prise et al. 1998, 2001, Kinner et al. 2008). 
Because these assays require high doses of ra-
diation to assess rejoining kinetics, analysis of 
γH2AX foci at clinical relevant doses is now 
frequently applied to monitor DSB induction 
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and repair (Rothkamm and Löbrich 2003, Kin-
ner et al. 2008).
When investigating the use of new particle 
beams like carbon ions in radiotherapy as well 
as estimating the health risk during long-term 
space flights, knowledge of the biological effects 
and their underlying mechanisms of actions for 
different radiation qualities are very important. 
In addition, in the field of biological dosimetry 
there is an urgent need for more information 
about the effects of different radiation types on 
the induction and loss of γH2AX foci in human 
lymphocytes (Rothkamm and Horn 2009).
To address this need, the induction and loss of 
DSB as well as chromosomal damage result-
ing from unrepaired or misrepaired DSB were 
investigated in this study. This after exposure 
of human lymphocytes in vitro to either 60Co 
γ-rays or p(66)+Be(40) neutrons. 
Analysis of induction and loss of DSB was 
done by applying the γH2AX foci assay. Chro-
mosomal damage was assessed using the MN 
assay because radiation-induced micronuclei 
contain mainly acentric chromosome frag-
ments that are unstable aberrations resulting 
from unrepaired or misrepaired DSB (Vral et 
al. 2011, Depuydt et al. 2013, Fenech 2011, 
Boei et al. 2000). 
The radiobiological properties of the p(66) 
+Be(40) clinical neutron beam (mean energy 
29 MeV) used in this study are different from 
that of lower neutron energy sources – e.g. 
d(14)/Be (mean energy 5.5 MeV) that have 
been used previously to analyze the induction 
of micronuclei (Slabbert et al. 2000, 2010; Vral 
et al. 1994).
Materials and Methods
Study design
Blood samples of 10 healthy donors aged be-
tween 29 and 60, both males (7) and females 
(3) were used for this study. This work was 
conducted with ethical approval by the Health 
Research Ethics Committee of the University 
of Stellenbosch, South Africa (Ethics Refer-
ence #: S12/04/091). Informed consent was 
obtained from each donor before the start of 
the study. Blood samples were collected by 
venipuncture in lithium-heparin coated tubes. 
Peripheral blood lymphocytes were separated 
from whole blood using low density gradient 
centrifugation. Separated lymphocytes were 
diluted in Roswell Park Memorial Institute 
(RPMI) medium (Life Technologies, Johan-
nesburg, Gauteng, South Africa) supplemented 
with 10% fetal calf serum (FCS) (Life Tech-
nologies) and the final cell concentration was 
adjusted according to the assay used. 
This study was divided in two parts. In a first set 
of experiments, dose response (DR) data were 
generated for both the induction of γH2AX foci 
and the formation of MN, using isolated lym-
phocytes from 10 donors. To reduce experimen-
tal / intra-donor variability, both dose response 
curves for γH2AX foci and MN were obtained 
from the same pool of isolated lymphocytes. 
In a second part of the study, repair kinetic 
(RK) experiments were conducted to analyze 
induction and disappearance of γH2AX foci. 
These experiments were done using lympho-
cyte samples obtained on two occasions from 
a single donor. 
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Irradiation experiments
Lymphocyte suspensions were kept at 37°C in 
a waterbath prior to irradiation. The suspension 
cultures were irradiated at room temperature 
with either 60Co γ-rays or a clinical neutron 
beam. 
Lymphocyte suspensions were exposed to 60Co 
γ-rays using a teletherapy unit (Theratron 780). 
Cell suspensions were placed on a 0.5 cm thick 
Perspex table to ensure dose build-up and a 10 
cm thick 30 x 30 cm Perspex block was placed 
on top of the cells to provide backscatter. A 
source to surface distance (SSD) of 75 cm ap-
plies using a 30 x 30 cm field. A vertical beam 
pointing upwards was used with a dose rate of 
0.5 Gy/min to cell suspensions. The latter was 
measured using a Nuclear Enterprises (NE) 
farmer-type 0.6 cc ionization chamber and 
electrometer. 
Lymphocyte suspensions were exposed to a 
clinical neutron beam which is produced by 
the reaction of 66 MeV protons on a Beryllium 
target: p(66)+Be(40). The neutrons used in this 
study have an average energy of 29 MeV and a 
mean LET of about 20 keV/µm (Slabbert et al. 
1989). Neutron exposures were performed using 
a vertical beam directed downwards. Test tubes 
containing cell suspensions were positioned on 
a 15 cm-thick backscatter block of Perspex and 
irradiated in a 29 x 29 cm field. A 20 mm thick 
sheet of polyethylene was used as build-up ma-
terial. Under these conditions the γ-ray compo-
nent in the beam is 6.9 % and the total neutron 
dose rate to the samples was 0.4 Gy/min. The 
dose rate was determined by using a 0.5 cm3 
tissue equivalent ionization chamber. Neutron 
dose conformations at the irradiated position 
were done as part of the routine quality control 
measures used for daily radiation therapy.
Micronucleus assay
For the micronucleus assay, 1 million cells 
were diluted in 2 ml of RPMI for each treat-
ment sample. Duplicate cultures were exposed 
to doses ranging from 0 to 4 Gy of γ-rays or 0 
to 2 Gy of neutrons. After irradiations, phyto-
haemagglutinin (PHA, M form, 20 µg/ml final 
concentration; Life Technologies) was added to 
stimulate the growth of T-lymphocytes. Twenty 
four hours after placing cultures in a humidi-
fied 5% CO2 incubator at 37°C, cytochalasin B 
(6 µg/ml final concentration; Sigma-Aldrich, 
Aston Manor, Gauteng, South Africa) was add-
ed to the cultures to block cytokinesis. After 
harvesting cells 72h post-IR (for details see 
Depuydt et al. 2013), concentrated cell suspen-
sions were dropped on clean slides and stained 
with Vectashield® containing 4’,6-diamidi-
no-2-phenylindole (DAPI) (Vectorlab, Club-
view, Gauteng, South Africa). For each culture, 
slides were prepared in duplicate. Slides were 
then scanned automatically using the MSearch 
software module of the Metafer 4 scanning 
system (MetaSystems, Altlussheim, Germany) 
as described by Willems et al. (2010). Using 
pre-defined cell classifiers consisting of pa-
rameters that precisely describe the appearance 
of the nuclei of binucleated (BN) cells, the 
MSearch module allows automated detection 
and visualization of BN cells with or without 
MN. After completion of the automated image 
acquisition, an overview of the selected BN 
112
Original research
Article 1
cells is available in an image gallery. For each 
slide, where possible, 1000 BN cells were an-
alysed for the appearance of MN by inspecting 
those displayed in the image gallery. In total 
between 13936 and 32480 BN cells were ana-
lysed per dose point for the 10 donors used in 
the study.
γH2AX foci assay
For the γH2AX foci assay, 0.8 million lympho-
cytes were diluted in 2 ml of RPMI medium 
for each treated sample. For the dose response 
experiments, 2 ml cultures were irradiated with 
different doses ranging from 0 to 0.5 Gy of 
γ-rays or p(66)+Be(40) neutrons. For the repair 
kinetics experiments, cultures were irradiated 
with a dose of 0.5 Gy. After irradiation, cell 
cultures were incubated at 37°C to allow foci 
formation. For the dose response experiments, 
cultures were stopped 30 min post-irradiation 
by placing the cultures in ice water. For the re-
pair kinetics experiments, cells were put on ice 
at different time points post-irradiation (2 min, 
15 min, 30 min, 1h, 2h, 4h, 8h, 16h, 24h). After 
15 min on ice, 250 µl of each cell suspension 
was centrifuged onto poly-L-Lysine coated 
slides (VWR, Leuven, Belgium). For both the 
DR and RK experiments, 2 slides were prepared 
for each measurement. Cells were then fixed 
and incubated with anti-γH2AX (Biolegend, 
Clubview, Gauteng, South Africa) followed by 
rabbit anti-mouse tetramethyl rhodamine iso-
thiocyanate (RAM-TRITC; Dako, Honeydew, 
Gauteng, South Africa) antibodies as described 
by Depuydt et al. (2013). Finally, slides were 
scanned automatically using the MetaCyte 
software module of the Metafer 4 scanning sys-
tem as described by Vandersickel et al. (2010a). 
Briefly, automated image acquisition is done 
by first capturing the DAPI images using a 
well-defined cell selection classifier and subse-
quently capturing TRITC signals in the select-
ed nuclei. All TRITC signals were acquired as 
a z-stack with a total of 10 focal planes and a 
step size of 0.35 µm between planes. The com-
bined DAPI-TRITC images are simultaneously 
stored and displayed in the image gallery. For 
each slide, ~2000 lymphocytes were captured. 
After coding of the slides, 100 randomly dis-
tributed nuclei on each slide were analyzed 
manually for the presence of γH2AX foci by 
visual inspection of the image gallery.
Data analysis
MN frequencies (Y) for 60Co γ-rays (γ) as a 
function of dose (D) were best fitted to a linear 
quadratic model, with α, the coefficient of the 
linear term and β the coefficient of the quad-
ratic term 
Y
γ
 = c
γ
 + α
γ
D
γ
 + β
γ
D
γ
2
The coefficient of the constant term cγ is the 
background micronuclei frequency.
MN frequencies (Y) for neutrons (n) as a func-
tion of dose (D) were best fitted to a linear 
function,
Yn = cn + αnDn
To compare the effectiveness of different radia-
tion qualities, the RBE values were calculated. 
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The RBE is given by the ratio of the γ-ray dose 
(Dγ) to the neutron dose (Dn) to obtain an equal 
level of biological effect (iso-effect). Because 
of the different shapes of the dose response 
curves for the different radiation qualities, no 
single RBE value for neutrons with respect to 
γ-rays, covering the whole dose range, can be 
given. Therefore isoeffect RBE values have 
been calculated for different doses by solving
c
γ
 + α
γ
D
γ
 + β
γ
D
γ
2 = cn + αnDn
for Dγ and substituting the result in the RBE 
expression (iso-effect RBE = Dγ/Dn) (Vral et 
al. 1994). This yields 
Foci frequencies (Y) as a function of dose (D) 
were best fitted for both radiation qualities to a 
linear quadratic model,
Y = c + αD + βD2
Isoeffect RBE values have been calculated for 
different doses by solving
c
γ
 + α
γ
D
γ
 + β
γ
D
γ
2 = cn + αnDn+ βnDn2
for Dγ. Substituting the result in the RBE ex-
pression then yields (Vandersickel et al. 2010b), 
Dose response and repair kinetic data were 
plotted using Graphpad Prism 4 software. The 
same software was used for linear and non- 
linear regression analysis. Analysis of the fre-
quency distribution of MN and γH2AX foci 
following exposure to the different radiation 
qualities was done by calculating the relative 
variance using Dose Estimate (Ainsbury and 
Lloyd, 2010). Statistical analysis of the data 
was performed using Statistical Package For 
Social Sciences (SPSS) software. Repeated 
measures Analysis of Variances (ANOVA) and 
paired samples t-tests were used to analyse sta-
tistical significant differences in MN or foci 
numbers and distributions between the differ-
ent radiation qualities. 
Results
Dose response experiments
Micronuclei formation
A repeated measures ANOVA was performed 
to analyze the influences of both Dose and 
Radiation Quality on MN formation. The sig-
nificant main effect of Dose, F(6, 4) = 79.53, 
p < .001, showed that MN gradually increase 
with dose. This is so for both radiation qual-
ities (Table I, figure 1). The main effect of 
Radiation Quality was also found to be sig-
nificant, F(1, 9) = 89.85, p < .001, illustrating 
that the number of MN for the same absorbed 
dose was higher after neutron irradiation than 
after γ-irradiation. The interaction between 
Dose and Radiation Quality was also signifi-
cant, F(6, 4) = 47.26, p < .001, indicating that 
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the dose dependent increase in the formation 
of MN is different for the different radiation 
qualities. Regression analysis further showed 
that the mean number of MN as a function of 
γ-ray dose follows a linear quadratic response. 
By contrast the shape of the MN dose response 
curve following neutron irradiation is linear 
(figure 1). The coefficients for the best regres-
sion analysis for the respective data are listed 
in Table II. No significant differences were 
found between the spontaneous number of MN 
observed in the sham-irradiated cell samples 
for γ-ray treatments and neutron irradiations 
(t(9) <1, p = .57). Thus the c coefficient used 
in subsequent fits of dose-response data is the 
mean of all spontaneous MN values. RBE val-
ues calculated at levels of iso-effect using the 
respective dose-response parameters, range 
between 3.6 and 1.6 for neutron doses of 0.05 
Gy and 2 Gy respectively (Table III). 
Next, paired samples t-tests were done to 
determine the threshold doses at which the 
two  radiation qualities induce MN. In the 
dose range  studied, a dose of 0.05 Gy of ei-
ther γ-rays or neutrons yields MN significantly 
higher than background readings – t(9) = 3.08, 
p < .05 for γ-rays and t(9) = 12.47, p < 0.001 
for neutrons. 
To compare the distribution of MN in cells 
irradiated with γ-rays or neutrons, the disper-
sion index (i.e. ratio of variance to the mean) 
was calculated for each dose (Table I, figure 
2A). When the ratio of the variance (σ2) to 
the mean (µ) = 1, MN follow a Poisson distri-
bution. If the ratio σ2/µ > 1, MN are overdis-
persed compared to that expected for a Poisson 
distribution. If the ratio σ2/µ < 1, MN are un-
derdispersed. To determine whether the mean 
dispersion indices per dose point are different 
from unity, one sample t-tests were used. These 
showed that dispersion indices for all γ-ray and 
neutron doses were significantly higher than 1 
(all t > 2.95, all p < .05 for γ-rays, all t > 3.43, 
all p < .01 for neutrons). 
TABLE I
Dose response data for MN following exposure to γ-rays or neutrons. All data represent the mean values obtained for 10 different donors.
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FIGURE 1
Dose response curves for MN in human lymphocytes following exposure to 60Co γ-rays or p(66)+Be(40) neutrons. Each data point represents 
the mean number of MN (± SEM) for 10 different donors.
TABLE II
Best-fit values for coefficients of dose response curves for MN and γH2AX foci following exposure to graded doses of 60Co γ-rays or 
p(66)+Be(40) neutrons. 
* c-values represent the mean spontaneous number of MN/1000 BN cells or foci/cell resp. Dn neutron dose
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TABLE III
RBE values calculated at levels of iso-effects using MN or foci dose-response parameters Dn neutron dose
FIGURE 2
Schematic representation of the mean values of the dispersion indices. Each data point represents the mean dispersion index ± SEM for MN 
(A) or γH2AX foci (B) counted in lymphocytes of 10 different donors. * σ2/µ values are significantly higher for neutrons compared to γ-rays. 
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A repeated measures ANOVA was then used 
to compare the dispersion indices noted for the 
different radiation qualities used in the study. 
This analysis showed a significant main ef-
fect for Radiation Quality, F(1, 8) = 16.52, p < 
.001. Therefore, on average a higher degree of 
overdispersion is noted for neutrons compared 
to γ-rays. Neither the effect of Dose, F(6, 3) = 
4.15, p = .14, nor the interaction between Dose 
and Radiation Quality is significant – F(6, 3) 
= 2.44, p = .25. Paired samples t-tests showed 
that overdispersion was significantly higher for 
neutrons compared to γ-rays for doses of 0.2, 
0.5, 1 and 2 Gy – all t > 3.55, all p < .01. Over-
dispersion did not differ between neutrons and 
γ-rays for doses 0, 0.05, and 0.1Gy – all t < 
2.26, all p > .05.
γH2AX foci formation 
A repeated measures ANOVA was performed 
for γH2AX foci formation for data obtained 
from 10 donors. This analysis showed a signif-
icant main effect of Dose, F(6, 4) = 244.123, p 
< .001. This main effect indicates that γH2AX 
foci gradually increase with increasing dose 
(Table IV, figure 3). A significant main effect 
of Radiation Quality, F(1, 9) = 92.70, p < .001, 
was also noted illustrating that foci formation 
after γ-irradiation was higher than after neutron 
irradiation. Both main effects were subsumed 
under a significant interaction between Dose 
and Radiation Quality, F(6, 4) = 6.41, p < .05, 
indicating that the dose dependent increase in 
the formation of foci is different for the differ-
ent radiation qualities (figure 3). Regression 
analysis showed that the mean number of foci/
cell after exposure to graded doses of either 
radiation qualities was best fitted to a second 
order polynomial equation. (Figure 3, Table II). 
The c coefficient represents the mean spontane-
ous value of all sham-irradiated samples. This 
as no significant difference (t < 1, p = .66) was 
found between the spontaneous number of foci 
scored in sham-irradiated samples for γ-rays 
and neutron experiments. Calculated RBE val-
ues range between 0.70 and 0.64 for a neutron 
dose of 0.01 Gy and 0.5 Gy respectively (Table 
III). Using a paired samples t-test, a threshold 
detection dose of 0.01 Gy could be determined 
for γ-rays (t(9) = 6.22, p < .001). The same 
threshold dose was determined for neutrons 
(t(9) = 3.31, p < .01). 
TABLE IV
Dose response data for γH2AX foci following exposure to γ-rays or neutrons. All data represent the mean values obtained for 10 different 
donors. 
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Dose response curves for the mean number of γH2AXfoci/cell for lymphocytes exposed to 60Co γ-rays and p(66)+Be(40) neutrons. Each data 
point represents the mean number of foci ± SEM of lymphocytes obtained from 10 different donors.
Calculation of dispersion indices shows that 
foci frequencies were overdispersed for all 
neutron doses (all t > 6.20, all p < .001). Fol-
lowing γ-irradiations, foci frequencies were 
overdispersed for the lower doses up to 0.1 Gy 
(all t > 4.02, all p < .005). For a dose of 0.2 
Gy, foci frequencies followed a Poisson distri-
bution as the σ2/µ did not differ from 1 – t(9) 
<1, p = .42. Underdispersion was noted for the 
highest γ-ray dose of 0.5 Gy used in the study 
(t(9) = 6.77, p < .001) (figure 2B).
Repeated measures ANOVA were used to com-
pare the dispersion indices of γH2AX foci for-
mation following γ-ray and neutron exposures. 
This analysis shows a significant main effect for 
Radiation Quality, F(1, 9) = 138.36, p < 0.001 
and Dose, F(6, 4) = 35.61, p < 0.05. These main 
effects were subsumed under a significant inter-
action, F(6, 4) = 8.35, p < 0.05, indicating a dif-
ference in dispersion between gamma and neu-
tron irradiations. Paired sample t-tests showed 
that the dispersion of foci was higher for neu-
trons compared to γ-rays for all doses (all t > 
3.27, all p < .05). No differences in dispersions 
indices could be detected for repeated sham-ir-
radiated samples t < 1, p = .76 (Table IV). 
Repair kinetics of γH2AX foci 
Foci formation at different time points post-ir-
radiation were studied following the exposure 
of isolated lymphocytes of a single donor to 
either γ-rays or neutrons (figure 4A). The max-
imum number of foci/cell was reached at 30 
minutes post-irradiation. This for both γ-rays 
(mean value of 9.21 ± 0.38) and neutrons 
(mean value of 7.06 ± 0.08). After 30 minutes, 
the number of foci decreased gradually for 
both radiation qualities. Foci induced by neu-
trons disappeared slower than those induced 
by γ-rays. Eight hours post-irradiation the foci 
frequencies for neutron irradiated samples ex-
ceeded that of γ-rays. 
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FIGURE 4
The number of γH2AX foci as a function of time for isolated lymphocytes exposed to 0.5 Gy of neutrons or 0.5 Gy of γ-rays. Data points 
represent the mean number of foci/ cell ± SEM of 2 independent experiments. In figure 4B foci numbers were normalized to the maximum 
number of foci induced 30 minutes post-irradiation and fitted to an equation for one-phase exponential decay.
To better compare the results of the different 
radiation qualities, the foci numbers were nor-
malized to that assessed at 30 minutes (figure 
4B). Differences in the relative number of foci/
cell are noted at different time points post-irra-
diation. At 4 hours post-irradiation and beyond 
the number of remaining foci is higher after 
neutron irradiation compared to γ-irradiation. 
Although DSB repair kinetics have been de-
scribed by a second order exponential decay 
(Horn et al. 2011, Iliakis et al. 2004), the data 
were best fitted to a one-phase exponential de-
cay equation (Y = (Y0 – Plateau) * exp (-K*X) 
+ Plateau, with K the rate constant; Graphpad 
Prism Software). From this analysis a repair 
half-life of 2.8 hours (95% confidence interval 
(CI): 2.1 to 4.1h) is estimated for γ-rays. For 
neutrons a repair half life of 3.0 hours (95% CI: 
2.3 to 4.4h) is calculated. The estimated plateau 
values were 0.12 (95% CI: 0.043 to 0.20) and 
0.25 (95% CI: 0.18 to 0.32) for γ-rays and neu-
trons respectively.
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Discussion
Understanding the mechanisms underlying 
the biological effects observed for different 
radiation qualities is very important in the 
field of radiotherapy, biological dosimetry and 
risk estimation during long-term space flights. 
Differences in induction and repair of DSB 
are considered fundamental in the outcome of 
biological effects noted after irradiations with 
different radiation qualities. Therefore, we 
investigated micronucleus formation and the 
induction and disappearance of γH2AX foci 
after in vitro exposures of human lympho-
cytes to either 60Co γ-rays or p(66)+Be(40) 
neutrons. 
As expected, analysis of MN dose response 
data shows that the yield of MN induced by 
high energy neutrons was higher compared to 
60Co γ-rays. RBE values calculated from the 
fitted parameters range between 3.6 and 1.6 for 
neutron doses of 0.05 Gy and 2 Gy respective-
ly. Data obtained in this study using an auto-
mated image analysis system for MN scoring 
are consistent with micronuclei data obtained 
by manual scoring in T-lymphocytes exposed 
to the same p(66)+Be(40) neutron beam (Slab-
bert et al. 2010). The higher RBE values show 
that neutrons are indeed more effective than 
γ-rays in inducing MN in human lymphocytes 
and relatively more so at lower doses. A mean 
dose limiting maximum RBE (RBEm) value of 
3.9 can be calculated from the data and this is 
in agreement with that noted by Slabbert et al. 
(2010). It is also consistent with higher RBEm 
reported for a lower energy 5.5 MeV neutron 
beam (Vral et al. 1994). 
In biological dosimetry the distribution anal-
ysis of chromosomal aberrations is important 
because treatment modalities of different ion-
ization densities are expected to produce dif-
ferent distributions of chromosomal damage 
(International Atomic Energy Agency (IAEA) 
2011). This is indeed the case for dicentrics, 
where irradiation with low-LET X- or γ-rays 
produces a spreading that follows a Poisson 
distribution (Edwards et al. 1979). By contrast, 
irradiations with neutrons or other high-LET 
radiation types results in overdispersion (IAEA 
2011). In this study MN frequency distribu-
tions in the affected cell populations show to 
be overdispersed compared to a Poisson dis-
tribution after irradiation with either neutrons 
or γ-rays. Although the formation of MN does 
not display the same distribution patterns as di-
centrics for low-LET radiation, the observation 
that MN are overdispersed even for low-LET 
radiation is generally reported (Vral et al. 1994, 
IAEA 2011). In this study we did however ob-
serve that overdispersion indices were signifi-
cantly higher after neutron exposure compared 
to γ-irradiations for all doses > 0.1 Gy. This 
observation is also in line with previous stud-
ies (Vral et al. 1994 and references herein) and 
indicates that to a certain extent MN frequency 
distributions do reflect differences in ionization 
densities of different radiation qualities.
To further investigate the underlying mech-
anism of MN formation, the induction of 
γH2AX foci, was simultaneously analysed. 
Lower yields of foci were observed after neu-
tron irradiation and this was seen repeatedly in 
cell samples analysed from different donors. 
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RBE values ranging between 0.70 for low dose 
irradiation to 0.64 for higher doses were calcu-
lated from the dose response data. This implies 
that high energy neutrons used in radiothera-
py are less effective in inducing γH2AX foci 
compared to γ-rays. Furthermore the range of 
RBE values obtained for foci induction (i.e. 
0.70 – 0.64) was much narrower compared to 
that for MN formation (i.e. 3.57 – 1.56). Since 
photons and neutrons – as well as other high-
LET radiation types – are reported to induce a 
higher or at least a comparable number of DSB 
(RBE ≥ 1) (Britten et al. 2001), the RBE value 
< 1, found in our study was at first unexpect-
ed. However, differences in methodology may 
explain this discrepancy. It has indeed been 
shown that results obtained by PFGE – based 
on separation of DNA fragments with different 
sizes, cannot be directly compared with results 
obtained by γH2AX foci analysis – based on 
the analysis of cellular responses to the induc-
tion of damage. Close inspection of literature 
data on foci induction after high-LET radia-
tion revealed variable results. For instance, 
Franken et al. (2011) observed RBE values 
of about unity after exposure of human lung 
carcinoma cell lines to α-particles (130 keV/
µm) or γ-rays. By contrast, Costes et al. (2006) 
detected fewer foci after exposure of human 
foreskin fibroblasts to nitrogen ions (130 keV/
µm) compared to X-rays (i.e. RBE < 1). Sim-
ilar findings were made by Asaithamby et al. 
(2008) who reported lower maximum numbers 
of foci after exposure of human skin fibroblasts 
to either iron ions (150 and 236 keV/µm), sil-
icon ions (44 keV/µm), oxygen ions (14 keV/
µm) compared to γ-rays. Okumura et al. (2013) 
further detected similar numbers of p53 bind-
ing protein 1(53BP1) foci, known to colocalize 
with γH2AX foci (Lassman et al. 2010), after 
exposing hamster ovary cells to a mixed neu-
tron beam and γ-rays (i.e. RBE about 1). Im-
portantly, to date no studies have been reported 
on the yield of γH2AX foci after exposure of 
human lymphocytes to high energy neutrons. 
The lower than unity RBE values for γH2AX 
foci noted in this and other studies can however 
in part be explained when considering the bio-
logical basis of the formation of radiation-in-
duced foci. Manifestation of γH2AX foci can 
be the outcome of different scenarios occur-
ring at the level of the formation of DSB, or 
at the level of foci formation, or a combination 
thereof. Since energy depositions of high-LET 
radiation are more clustered along the particle 
tracks, this can result in the induction of more 
closely spaced DSB. On the one hand, several 
data suggest that multiple DSB are very likely 
to cluster into common repair centres. These 
individual repair centres then appear as a sin-
gle focus but may contain more than one DSB 
(Neumaier et al. 2012). A single focus may thus 
not represent the actual number of radiation-in-
duced DSB. Support for this is idea also comes 
from the observation that none of the DSB 
marker proteins, including γH2AX foci, exam-
ined by Jakob et al. represented the total num-
ber of expected DSB after heavy ion irradiation 
(Jakob et al. 2003, 2009). On the other hand, 
it is also possible that each DSB does result in 
the formation of a focus, despite the occurrence 
of several DSB in close proximity. Aten et al. 
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(2004) analysed the track morphology after ex-
posure of HeLa cells to α-particles at different 
time points post-IR. These results suggested 
that clusters of foci can indeed form as a result 
of relocation of the H2AX foci along high ener-
gy density tracks. Therefore, it is possible that 
closely spaced individual foci cluster together 
and consequently make clear discrimination of 
individual foci difficult (Rübe et. 2011). Oth-
erwise, discrimination of closely spaced and/
or overlapping foci can also be limited by the 
optical resolution of the microscope system 
and lead to an underestimation of actual foci 
numbers (Okumura et al. 2013). 
Regardless of which hypothesis applies to our 
observations, it is clear that the probability 
of clustering of either DSBs or foci is high-
er when cells are exposed to high-LET radi-
ation compared to low-LET radiation quali-
ties. The same argument applies when using 
progressively higher doses of either radiation 
modalities. Indeed, in this study, foci numbers 
counted for both radiation qualities were best 
fitted to a second order function instead of a 
linear function. This deviation from linearity 
indicates that foci levels saturate at higher dose 
levels and supports the argument that cluster-
ing of DSB and/or foci occurs (Horn et al. 
2011). Further support for the idea that clus-
tering occurs resides in the distribution of foci. 
Foci distributions show a decreasing tendency 
for overdispersion with increasing dose and 
this after both gamma and neutron irradiation. 
Since the number of DSB per cell increases 
as the dose increases, the likelihood of 2 foci 
coalescing and combining into 1 also increas-
es. When further comparing foci distributions 
between the two radiation qualities, we ob-
served that overdispersion of foci was higher 
for all neutron doses compared to γ-rays. This 
indicates that physical differences in the ener-
gy depositions patterns for the neutrons and 
γ-rays seem to be reflected in the distribution 
of foci in irradiated cells. 
Further differences in foci formation between 
neutrons and γ-rays are noted when analysing 
repair kinetic data. After neutron irradiation, 
lower absolute foci numbers are apparent for 
time slots 2 minutes up to 2 hours. In addition, 
more variation in foci induction and loss for 
γ-rays is clear during the first 2h after irradia-
tion. At 4 hours, foci numbers for the same dose 
of neutrons and γ-rays are about the same (fig-
ure 4A). At 8, 16 and 24 hours after irradiation, 
the number of foci remain higher after neutron 
irradiation compared to γ-irradiation resulting 
in RBE values greater than 1. Normalizing foci 
yields to the maximum number of foci noted 
at 30 minutes after radiation, demonstrates less 
disappearance of neutron-induced foci com-
pared to these induced by γ-rays. Assuming 
that foci disappearance reflects DSB repair/
rejoining, our results are in agreement with the 
observation that the extent of repair of DSB 
induced by neutrons or high-LET radiation is 
less than that induced by low-LET radiation 
(for a review, see Britten et al. 2001). Notwith-
standing the above, the half-life of foci disap-
pearance is only marginally longer for neutrons 
than that for gammas and not significantly dif-
ferent on the 95% confidence level. A possible 
explanation for more persistent foci following 
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neutron exposure can be the consequence of the 
more clustered energy depositions that form 
along the particle tracks of high-LET radiation. 
This can not only cause the production of more 
closely spaced breaks/lesions, but also an in-
crease in break/lesion complexity. Indeed, the 
rejoining of DSB and the extent of unrejoined 
damage has been correlated to the complexity 
of the break (Pastwa et al. 2003). On the other 
hand, Costes et al. (2010) hypothesized that the 
increasing probability of clustering of closely 
spaced DSB in one focus with high-LET radia-
tion results in slower repair kinetics as multiple 
DSB residing in one focus take longer to repair 
than one DSB in one focus.
Nevertheless, a slower disappearance of DSB 
has been associated with an increase in misre-
joining events and thus the formation of chro-
mosome aberrations – such as dicentrics – as 
there is more time for exchange between the 
ends of free DNA DSB. Formation of dicentric 
chromosomes are accompanied by the forma-
tion of acentric fragments which are detected 
as MN in binucleated cells. Therefore, slow-
er disappearance of γH2AX foci supports the 
higher MN yields observed after neutron irra-
diation. It should however be kept in mind that 
higher MN yields may not only be related to 
a slower disappearance of DSB, but may also 
be related to the induction of more closely 
spaced DSB. Indeed, the production of multi-
ple breaks in close proximity may well facili-
tate exchange formations since the probability 
of breaks rejoining incorrectly increases with 
the coincidence of multiple breaks (Rothkamm 
and Löbrich 2002). 
In summary, this study investigated the forma-
tion of micronuclei and the induction and loss 
of γH2AX foci after in vitro exposure of human 
lymphocytes to either 60Co γ-rays and high-
LET p(66)+Be(40) neutrons. Despite neutrons 
being more effective in inducing MN compared 
to γ-rays, less γH2AX foci were observed for 
high-LET radiation between 2 minutes and 
about 4h post-IR. Differences in the extent of 
foci loss for radiation modalities with different 
ionization densities were also observed. 
These results have important implications to-
wards the use of the γH2AX foci assay in bio-
dosimetry. Both the observations that different 
radiation qualities yield (a) different numbers of 
foci per unit dose (see also Depuydt et al. 2013, 
Beels et al. 2010) and (b) differences in foci 
disappearance necessitate the establishment of 
distinctive dose-effect curves at different time 
points as previously suggested by Horn et al. 
(2011). In addition, to apply foci formation in 
neutron biodosimetry additional readings at dif-
ferent time points post- irradiation are desired 
to detect qualitative differences in foci forma-
tions from different ionization densities. More 
precisely, additional studies using γH2AX foci 
should attempt to detect different overdisper-
sions for low-LET partial body exposures than 
that for high-LET radiation (Rothkamm 2007, 
2009, Horn et al. 2011). Also, besides describ-
ing the distribution patterns of foci with respect 
to radiation quality and uniformity, qualitative 
analysis of foci size and intensity may proof 
useful (Costes et al. 2006, Whalen et al. 2008).
Finally, considering that patients are treat-
ed daily, the higher number of foci noted for 
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neutrons at 24 hours post treatment has con-
sequences for high-LET particle radiotherapy. 
The neutron source used in this study has an 
ionization density similar to that of modern car-
bon ion beams used in radiotherapy (Gueulette 
et al. 2010). Also, the extensive repair seen in 
this study for neutron damage during the first 8 
hour post-irradiation suggests that double frac-
tion treatments with high-LET particle thera-
py beams should not be attempted during this 
time. More studies with tissue types resulting 
in late radiation damage/effects should be con-
ducted to further understand the implications of 
inter-fraction treatment times.
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The impact of a BRCA1 and BRCA2-mutation 
on the radiation response induced by 
gamma-rays and neutrons in MCF-10A cells
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Introduction
The advantages of the use of ionizing radiation 
for diagnostic imaging as well as for therapeu-
tic purposes are well described (1-3). Howev-
er, there is also no doubt that breast exposure 
to ionizing radiation is associated with an in-
creased risk of breast cancer. Evidence for this 
can be found in epidemiological studies on 
atomic bomb survivors of Hiroshima and Na-
gasaki, in follow-up studies of patients treated 
with radiotherapy for hematological malignan-
cies and in studies performed on patients inten-
sively monitored by x-rays e.g. for scoliosis or 
tuberculosis (4-11). 
Several of studies have highlighted a number 
of individual factors that modify the radia-
tion-induced (RI) breast-cancer risk. Factors 
suggested to enhance the RI breast cancer risk 
in the literature are: age at irradiation and at-
tained age, age of menarche or the time of first 
pregnancy, nulliparity, obesity, family history 
of breast cancer, benign breast diseases and ge-
Abstract
Purpose: BRCA1 and BRCA2 play an important role in DNA double strand break (DSB) repair: 
BRCA2 in homologous recombination (HR) and BRCA1 in non-homologous end-joining (NHEJ) 
and HR. The radiosensitivity of BRCA1 and BRCA2 mutation carriers is a long standing question 
and can have implications for the treatment and screening procedures of BRCA1 and BRCA2 
mutation carriers. In this study we investigated the impact of the knockdown of the BRCA1 and 
BRCA2 proteins in a spontaneous immortalized non-tumorigenic human mammary epithelial cell 
line (MCF-10A) on HR and NHEJ after in vitro exposure to ionizing radiation. 
Methods: Downregulation of BRCA1, BRCA2 and Ku70 proteins in MCF-10A cell was ob-
tained using RNA interference (RNAi) transduction. Mock transduced and knockdown (BRCA1i, 
BRCA2i and Ku70i) MCF-10A cells were irradiated as mixed cell cultures (G1, S, G2 and M) and 
as synchronized G1 cultures with 60Co γ-rays and fast neutrons. Cellular and chromosomal radio-
sensitivity was measured with the crystal violet (CV) cell proliferation assay and the micronucleus 
(MN) assay, respectively. 
Results: We observed an increased radiosensitivity in BRCA1i and Ku70i cells in both G1 cell 
cultures and mixed cell cultures, which was most pronounced at low doses. For BRCA2i cells, the 
radiosensitivity was only increased in the mixed cell cultures. Relative biological effectiveness 
(RBE) values were comparable or slightly lower for the knockdown cell lines compared to the 
mock transduced control cell lines. 
Conclusion: BRCA1i and BRCA2i cell lines are characterized by an increased radiosensitivity, 
which is dependent on LET, dose and cell cycle. Our results imply that caution should be taken 
when administering ionizing radiation to heterozygous mutation carriers. 
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netic factors (12-16). However, some of these 
factors modify the radiation risk only margin-
ally and reproduction of the results seems chal-
lenging (16, 17). 
Carriers of mutations in genes like BRCA1, 
BRCA2 or ATM, are suspected to have a high-
er risk for radiation-induced breast cancer. The 
evidence for enhanced risk is stronger for ATM 
mutation carriers, thought the evidence is not 
univocal (16, 18-20). 
Age at exposure and attained age seem to have 
the highest modifying effect on radiation-in-
duced breast-cancer risk. Compared to expo-
sure of young adults (30-40 years) the risk in 
children appears to be three fold in the Hiro-
shima lifespan study population (5, 21). After 
exposure at young age the risk continues to be 
elevated throughout the remainder of a wom-
an’s life, with the largest excess rates occurring 
at ages similar to those at which breast can-
cers are seen in the absence of exposure (22). 
Dose-time exposure parameters (total dose, 
dose rate, fractionation, dose per fraction) and 
radiation quality can also modify the risk. The 
beam quality has been widely discussed in the 
case of mammography X-rays, which have a 
much lower energy than conventional X-rays 
(23-25). The importance of radiation quality 
on breast cancer risk is even more pronounced 
with the use of e.g. neutrons, protons or carbon 
ions in radiotherapy (26-28). The relative bio-
logical effectiveness (RBE) of a radiation qual-
ity for a specific cell type or tissue is not only 
determined by the linear energy transfer (LET) 
of the radiation used, but is also dependent on 
several other factors, like the phase of the cell 
cycle, the inherent radiosensitivity linked to ge-
netic mutations and the oxidation of the tissue. 
The main target of radiation in the cell is the 
DNA. Radiation induces the formation of in-
ter- and intra-strand crosslinks, damage at the 
level of single bases, single-strand breaks and 
double strand breaks (DSB), the latter being 
considered the most lethal form of DNA dam-
age (29). A cell has different pathways to re-
pair DNA DSBs, the major being non-homol-
ogous end joining (NHEJ) and homologous 
recombination (HR) (30, 31). NHEJ ligates the 
break ends without the need for a homologous 
template and is therefore prone to errors. It is 
available during the whole cell cycle and is 
considered the main pathway for repair of radi-
ation-induced DSB in mammalian cells. DNA 
repair by HR on the contrary is more accurate 
because it uses the undamaged sister chromatid 
sequence to repair the DSBs. Consequently HR 
is only active in the S and G2 phase of the cell 
cycle. According to recent literature, only the 
more complex DSB in the S or G2 phase will 
be repaired by HR (32-36). In the DNA damage 
response, not only repair proteins are activated 
but also proteins involved in the control of the 
cell cycle checkpoints (37, 38). 
The DNA damage response pathways involve 
many proteins amongst which are the two ma-
jor breast cancer predisposition genes BRCA1 
and BRCA2, who’s functions are extensively 
reviewed by Roy et al (39). BRCA1 is involved 
in the very early stages of the HR DNA repair 
pathway and seems to play a role in NHEJ and 
single strand annealing as well. BRCA2 has its 
main function in facilitating HR. The crucial 
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role of BRCA1 and BRCA2 in DNA DSB re-
pair suggest a higher sensitivity to ionizing ra-
diation when those proteins are not fully func-
tional or lacking, as DNA DSB will be repaired 
less efficiently. DSB can be transformed into 
chromosomal aberrations during cell division 
and subsequently can cause cell death or trigger 
tumorigenesis (40-42). 
Patient studies are mostly focused on the as-
sociation between the medical radiation bur-
den and the occurrence or recurrence of breast 
cancer in persons with and without a BRCA1 
or BRCA2 mutation. Results are inconclusive, 
partly because of the big variation in doses, 
radiation qualities, age and irradiated tissue. 
Some studies find an increased sensitivity to 
radiation in BRCA1/2 mutation carriers (43-
45), often closely linked to age at the time of 
exposure, while other studies don’t (46-49). To 
overcome the difficulties of in vivo studies, in 
vitro experiments investigating the radiosensi-
tivity of lymphocytes, fibroblasts or EBV cell 
lines (Epstein Barr virus immortalized cell 
lines) derived from patients with and without 
a BRCA1 or BRCA2 mutation have been per-
formed. These studies lead again to contradic-
tory results, with some studies pointing to an 
increased sensitivity (50-52), and others not 
(52, 53). Human mammary epithelial cells are 
however different from lymphocytes or fibro-
blasts both in cell characteristics and cellular 
environment and therefore their response to 
ionizing radiation may be different to the latter. 
In this study we investigated the impact of 
BRCA2 knockdown on HR and BRCA1 knock-
down on HR and NHEJ after exposure in vitro 
to ionizing radiation. Since it would be very 
interesting to compare this with the expres-
sion-impact of a protein solely playing a role in 
NHEJ, we also investigated the impact of Ku70 
expression (54, 55) after exposure to ionizing 
radiation. We obtained a downregulation of the 
BRCA1, BRCA2 and Ku70 proteins in a spon-
taneous immortalized non-tumorigenic human 
mammary epithelial cell line (MCF-10A) using 
RNA interference (RNAi) transduction. Protein 
levels of about 50%, which corresponds to the 
situation present in heterozygote mutation car-
riers, were obtained. Cellular and chromosomal 
radiosensitivity was measured with the crystal 
violet (CV) cell proliferation assay and the 
micronucleus (MN) assay, respectively. Since 
BRCA1, BRCA2 and Ku70 have different func-
tions in the DNA damage response pathway de-
pending on the nature of the DSB and the cell 
cycle phase, mock transduced and knockdown 
MCF-10A cells were irradiated as mixed (G1, 
S, G2, M) cultures and as synchronized G1 cul-
tures with 2 different radiation qualities: 60Co 
γ-rays or p(66)+Be(40) neutrons. 
Material and methods
Cell lines 
MCF-10A cells were cultured as monolayer 
in DMEM/F12-ham (Invitrogen, Belgium) 
supplemented with 5% fetal calf serum (Invit-
rogen), antibiotics and growth factors (10µg/
ml insulin (Sigma, Belgium); 0.5µg/ml hydro-
cortisone (Sigma); 20ng/ml epidermal growth 
factor (Tebu-bio, Belgium); 50 U/ml penicillin 
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and 50µg/ml streptomycin (Invitrogen)) as de-
scribed by Debnath et al (56). 
The knockdown BRCA1 and BRCA2 cell lines 
(hence forward called BRCA1i and BRCA2i) 
together with their mock-transduced control cell 
line (CONBRCA), were kindly provided to us by the 
VIB (Laboratory for Mechanism of Cell Trans-
formation, KULeuven, Belgium). To generate 
repair deficient MCF-10A cell lines, MCF-10A 
cells were transduced with lentiviral particles 
harboring DNA sequences encoding for short 
hairpin RNA specific for BRCA1 or BRCA2 
RNA interference. Lentiviruses were construct-
ed using pLKO.1-puro vectors. The sequence 
used for BRCA1 was CCCTAAGTTTCACT-
TCTCTAAA and TACAATGTACACATGTAA-
CAC for BRCA2. Together with the RNAi se-
quences, resistance to puromycin was built into 
the vector. Transduction was done by adding 1µg/
ml DNA, TurboFect (1.5µl/ml) and polybrene 
(1µl/ml) to a 30% confluent culture of MCF-10A 
cells. Two days after transduction puromycin 
(2µg/ml) was added to the medium, cells were 
grown in medium containing puromycin during 
15 days to obtain stably transduced cell lines. 
The knockdown Ku70 cell line and it’s control 
were used previously by Vandersickel et al (54) 
and an elaborate description about their construc-
tion can be found there. Cells infected with lentivi-
ral particles generated with the pLVTHM/shKu70/
GFP vector are labeled Ku70i, cells infected 
with lentiviral particles generated with the empty 
pLVTHM/GFP control vector are called CON
Ku70
. 
Stable knockdown of the protein expression of 
the silenced genes was evaluated by western 
blot analysis. 
Determination of the cell cycle distribution at 
the moment of irradiation was done by flow cy-
tometry. Cells were harvested, resuspended in 
0.5ml PBS and fixed by slowly adding 3 ml of 
95% EtOH. Before analysis, cells were washed 
and resuspended in hypotonic DNA staining 
solution (0.1% tri sodium citrate, 0.3% Triton, 
0.01% propidium iodide and 0.002% ribonu-
clease A, dissolved in water). Cells were incu-
bated for 30min at 4°C before being analyzed 
by flow cytometry. 
Western blot
For the western blots, protein was extracted 
from each cell line with TE lysis buffer (0.1M 
Tris; 50mM EDTA; 1% NP-40; 1% protease in-
hibitor (Sigma P8340)). 50µg of protein togeth-
er with LDS sample buffer (ThermoScientific 
NP0008; 25%) and dithiothreitol (DDT; Sigma 
Aldrich 43816; 10%) were loaded on a 3-8% 
tris-acetate gel. Gels were run for 5h at 25mA 
in tris-acetate running buffer complemented 
with 2.5% anti-oxidant. PVDF membrane was 
pretreated with methanol and proteins were 
transferred to it in tris-glycine transfer buffer 
with 10% methanol (17h; 30V; 4°C). 
After one hour of blocking (3% BSA, 5% dried 
milk powder, 0.1% tween in tris buffered sa-
line (TBS)), the membrane was incubated 
(overnight, 4°C) with the primary antibodies 
(mouse mAb α-BRCA2 (Millipore OP-95; di-
luted 1/500); rabbit pAb α-BRCA1 (sc-642; 
diluted 1/1000); mouse mAB α-actinine (sc-
17829; diluted 1/30000)), followed by washing 
and incubation with hrp-conjugated secondary 
antibodies (1.5h, 20°C) (BRCA1: GAR-hrp 
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(Perbio 34160; diluted 1/1000); BRCA2 and 
actinin: RAM-hrp (ThermoScientific 31450; 
diluted 1/1000)). Visualisation was done using 
chemoluminescence (ThermoScientific 34076) 
and detection was done with the Chemidoc-it 
imaging system (UVP) and Software Vision 
Works. Protein concentration was determined 
based on band intensity, using ImageJ software 
(ImageJ 1.48v). 
Sample preparation 
Three days before each experiment, the 
BRCA1i, BRCA2i and CONBRCA cells were 
grown for 48h in medium containing puromy-
cin (2µh/ml). The Ku70i and CON
Ku70
 cells 
were checked for their GFP-fluorescence. 
Experiments performed on synchronized G1 
cultures
For the experiments on synchronized G1 cells 
(hence forward called G1 cultures), cells were 
seeded three days prior to irradiation and let 
grown to confluence in order to establish a 
population of G1 cells. Just before irradiation, 
these confluent cells were trypsinized and seed-
ed in a concentration of 300.000 cells per well 
in 6-well plates for the MN-assay and in 24-
well plates for the CV cell proliferation assay 
(2500 cells per well). Approximately 2h after 
seeding, the cells were attached to the plate and 
the cultures were irradiated.
Experiments performed on mixed cultures
For the experiments on mixed cultures, 
sub-confluent cultures of exponentially divid-
ing cells were needed at the moment of irradi-
ation. For the MN assay cells were trypsinized 
and seeded in 6-well plates (200.000 cells per 
well) 1 day prior irradiation. For the CV cell 
proliferation assay exponentially growing cul-
tures were trypsinized and seeded in 24-well 
plates at a concentration of 2500 cells per well 
2h prior to irradiation. 
All MN-assays were done in duplicate and the 
proliferations assays in quadruplicate. Each ex-
periment was repeated three times. 
Irradiations
All cells were irradiated with a 60Co γ-source 
or a clinical neutron beam. Doses from 0.2 up 
to 6 Gy were given and in each experiment sh-
am-irradiated cultures were included. The 60Co 
γ-rays were produced at a dose rate of 0.5Gy 
per minute by a teletherapy unit (Theratron 
780). Samples were irradiated under charged 
particle equilibrium conditions, achieved by 
placing a 0.5 cm thick Perspex table which 
served as build-up and a 10 cm thick Perspex 
block for backscatter. The neutron beam was 
produced by the reaction of 66 MeV protons 
on a beryllium target producing (p66)+Be(40) 
neutrons. A 20mm thick sheet of polyethylene 
was used for dose build-up and a 15cm thick 
block of Perspex as backscatter. The γ-ray 
component in the beam was 6.9% and the total 
neutron dose rate to the samples was 0.4 Gy/
min. The neutrons produced by this beam have 
a mean energy of 29MeV and a mean LET of 
20keV/µm (57). 
Micronucleus (MN) Assay
Chromosomal damage was assessed with the 
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MN assay. Immediately after irradiation cyto-
chalasin B (2.25µg/ml; Sigma) was added to 
block cytokinesis. The irradiated cells were 
kept at 37°C in a humidified 5% CO2 atmos-
phere incubator for 16h (mixed cultures) or 48h 
(G1 cultures). After incubation, the cells were 
harvested by trypsinization, followed by a cold 
hypotonic shock with 0.075 M KCl and fol-
lowed by overnight fixation in 3/1/4 methanol/
acetic acid/ringer solution (ringer: 9g NaCl, 
0.42g KCl and 0.24g CaCl2 in 1l water). Subse-
quently, the cells were fixed three times in 3/1 
methanol/acetic acid. For further analysis, a 
suspension of cells was dropped on clean slides 
and stained with DAPI Vectashield (Lab Con-
sult). Slides were scanned with the MSearch 
software module of the Metafer 4 scanning 
system (MetaSystems), using a Zeiss Imager.
Z2 microscope (Zeiss) and a CoolCube1 cam-
era (MetaSystems). The MSearch software al-
lows automated detection of binucleated cells 
and scoring of MN. Two slides per culture 
were automatically scanned and analyzed with 
a 10X magnification. The scanned images with 
the BN cells were coded and the MN score of 
all BN cells detected by MSearch were checked 
manually. Per slide approximately 400 BN 
cells were scored.
Crystal violet (CV) cell proliferation assay
While the clonogenic assay is considered the 
golden standard to evaluate the in vitro re-
sponse of cells to ionizing radiation, it is not 
suited for MCF-10A cells due to their inabili-
ty to form well defined colonies. In a previous 
study, we showed that the CV cell proliferation 
assay provides a useful alternative (58, 59). 
The same protocol was used here. 
In short, after irradiation cells were incubated 
at 37°C and 5% CO2 for approximately 4 days 
until the sham irradiated plates nearly reached 
confluence. Cells were then fixed for 10 min in 
a solution of buffered formalin (3.7%), washed 
with PBS (pH 7.3) and stained with a 0.01% 
crystal violet solution. After removing excess 
stain, the stain was overnight dissolved in 1 ml 
of 10 sodium dodecyl sulfate (SDS). The opti-
cal density of the dissolved stain was measured 
with a spectrophotometer at 590 nm. 
Analysis
For the analysis of the MN data, a dose re-
sponse curve was determined for each condi-
tion assuming a linear-quadratic model (Y = c 
+ αD + βD²). When no quadratic component 
was found, a linear response model was used 
(Y = c + αD). 
Cell survival was analyzed by fitting log cell 
surviving fractions (S) as a function of ra-
diation dose (D) to a linear-quadratic model 
(loge(S) = – αD – βD2). When no quadratic 
component was found, a linear model was used 
(loge(S) = – αD). 
To evaluate the effect of knocking down the 
repair proteins on the radiation response, the 
dose modifying factor (DMF) is calculated. The 
DMF quantifies the radiation response of the 
knockdown cell line compared to the response 
of the control cell line. When dose response 
curves are linear-quadratic in shape the DMF is 
dose-dependent and can be calculated for differ-
ent dose points by using the following formula: 
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The DMF increases as the dose decreases and 
reaches its maximum when the dose reaches 
zero. This DMFM is calculated with the follow-
ing formula: . In the analysis the 
DMF is calculated for a dose of 2 Gy ( DMF2Gy) 
and the DMFM is calculated. The 2Gy dose-
point was chosen because of its relevance for 
radiotherapy as often fractions of 2Gy are giv-
en, while the DMFM is important in the frame 
of low-dose irradiations, like those used in di-
agnostics.
Whenever the dose response curves are line-
ar in shape for both the control cell line and 
the knockdown cell line, the DMF becomes 
dose-independent and equal to DMFM. 
To compare the effects of the different radiation 
qualities (γ-rays versus neutrons), the relative 
biological effect (RBE) of neutrons beam com-
pared to γ-rays is calculated. When the dose-re-
sponse curves are linear-quadratic, the RBE is 
dose-dependent and can be calculated using the 
following formula: 
An increase in RBE is noted as the dose de-
creases. The maximal RBE (RBEM) is reached 
when the dose approaches zero and is calculat-
ed as follows: . In this study the RBE 
has been calculated at a dose of 2Gy (RBE2Gy) 
and the RBEM has been calculated.
When the dose response curves are linear in 
shape for both neutron-irradiation and 60Co 
y-irradiation, the RBE becomes dose-inde-
pendent and equal to RBEM. 
Statistical analysis was done using a Student 
t-test or Mann-Whitney Rank Sum Test, which-
ever was appropriate depending on the normal 
distribution of the data. When a pairwise anal-
ysis was done, a two sided paired t-test or Wil-
coxon Signed Rank Test was used, again de-
pending on the normal distribution of the data. 
Results
Western blot
Western blot showed a knockdown of the 
BRCA1 protein of 70% in the BRCA1i cells 
and 51% for the BRCA2 protein in the BRCA2i 
cells. The Ku70 protein has a knockdown of 
43% in the Ku70i cells (fig 1). 
Cell cycle
At the moment of irradiation the distribution of 
the cells over the cell cycle was determined for 
each cell line. For the G1-cultures, 86 ± 4 % of 
the cells were in G1 after synchronization, 7 ± 
2 % in S and 7 ± 2 % in G2. The mixed cultures 
had 37 ± 4 % of the cells in G1, 25 ± 8 % in G2 
and 39 ± 10 % in S phase of the cell cycle. 
FIGURE 1
Western blot of MCF-10A cells after lentiviral transduction of shRNA 
for BRCA1, BRCA2 and Ku70 silencing (BRCA1i, BRCA2i and Ku70i) to-
gether with their control cell lines (CONBRCA and CONKu70). Actinin 
was used as a protein loading control.
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Micronucleus assay
No significant difference in the radiation response 
was observed between the two mock-transduced 
cell lines (CONBRCA and  CONKu70) (p = 0.24). 
The MN dose response curves of both cell lines 
are depicted in figure 2a. 
The spontaneous MN yield (MN/1000 BN 
cells) ± SEM for CONBRCA, BRCA1i, BRCA2i, 
CON
Ku70
 and Ku70i were 28.1 ± 2.5; 31.7 ± 4.2, 
26.0 ± 1.7; 30.4 ± 2.9 and 39 ± 3.6 respective-
ly. There was no significant difference between 
the two control cell lines (p=0.56), between 
the BRCA1/2i cell lines and the CONBRCA 
(p=0.47 and p=0.52) and between the Ku70i cell 
line and the CON
Ku70
 (p=0.07). For further cal-
culations the number of spontaneous MN was 
subtracted from the number of MN obtained in 
the irradiated samples in order to obtain the ra-
diation-induced number of MN. 
After γ-irradiation of the knockdown cell lines 
the radiation-induced MN yields displayed a lin-
ear-quadratic response, while for neutrons a linear 
response was observed. The α and β values are 
listed in table1. The BRCA1i cell line didn’t re-
cover after irradiation of the cells in the G1 phase 
of the cell cycle and gave a very low number of 
BN cells. This behavior was observed in the 3 re-
peated experiments and no MN results are availa-
ble for the G1 cultures of the BRCA1i cell line. All 
dose-response curves are depicted in figure2 b-d. 
	  
(a) CONBRCA and 
CONKu70 
(b) 
BRCA1i 
(c) 
BRCA2i 
(d) 
Ku70i 
FIGURE 2 
MN dose response curves for γ-rays and neutrons of the different cell lines. (a) CONKu70 (dark grey, dashed line) and CONBRCA (light grey, 
full line) (b) BRCA1i (c) BRCA2i (d) Ku70i. The light grey curves in b and c represent the MN dose response curves of CONBRCA, the dark grey 
curves in d are the MN dose response curves of CONKu70. The black curves are the MN dose response curves of the knock down cell lines. 
: gamma irradiation of the mixed cultures;  : neutron irradiation of the mixed cultures;  : gamma irradiation of the synchronized G1 
cultures;  : neutron irradiation of the synchronized G1 cultures 
136
The DMF quantifies the effect of the knock-
down of the repair protein on the radiation-in-
duced MN response. In table 2 the DMF with 
the 95% confidence limits are given for all cell 
lines for the 2 Gy dose point (DMF2Gy) and when 
the dose reaches zero (DMFM). The 2Gy dose-
point (DMF2Gy; relevant dose for radiotherapy) 
and when the dose reaches zero (DMFM; relevant 
for diagnostic imaging). Due to the absence of 
a β-component in the MN dose response curve 
for neutron irradiation, the DMF is dose-in-
dependent and there is no difference between 
the DMFM and the DMF2Gy. The overview of the 
DMFs in table 2 shows that all knockdown cell 
lines were more sensitive than the control cell 
lines (DMF>1), with the exception of BRCA2i 
cells synchronized in G1 (DMF approx. 1). The 
effect of the knockdown of the repair proteins 
was more pronounced when the mixed cultures 
were irradiated ( DMFmix>DMFG1). The absence 
of BN cells when G1 cultures of BRCA1i cells 
were irradiated and the high DMFmix point to a 
high radiosensitivity of BRCA1 defective cells. 
Table 3 lists the RBEs with the 95% confi-
TABLE 1
Overview of the α and β values ± SEM of MN dose response curves and crystal violet cell survival curves for all cell lines and irradiation 
conditions. 
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TABLE 2
Overview of the DMF
2Gy
 [95% LCL – 95% UCL] and DMF
M
 [95% LCL – 95% UCL] for the MN assay and the crystal violet assay for all cell lines 
and radiation qualities. 
dence limits for all cell lines at 2 Gy (RBE2Gy, 
radiotherapy relevant dose) and when the dose 
reaches zero (RBEM; relevant in diagnostics). 
For all cell lines neutron irradiation was more 
effective in inducing MN than γ-irradiation 
(RBE>1), with higher RBE values when G1 
cultures were irradiated compared to mixed 
cultures (RBEG1>RBEmix). The lowest RBE 
values were found in the BRCA1i cells. 
Crystal violet cell proliferation assay (CV)
No significant difference in CV cell survival 
was observed between the two control cell lines 
(CONBRCA and CONKu70) (p=0.14). The cell sur-
vival curves of CONBRCA and CONKu70 after irra-
diation of mixed cultures and G1 cultures with 
γ-rays and neutrons are depicted in figure 3a.
The CV cell survival curves of the knockdown 
cell lines together with their control cell lines 
are shown in figure 3 b-d. They followed a 
linear-quadratic response, except for BRCA1i 
(y and neutron irradiation) and BRCA2i and 
Ku70i (neutron irradiation), where there was a 
linear response. It is apparent that the shoulder 
of the cell survival curves, which is a meas-
ure of repair capability, was reduced for all 
knockdown cell lines compared to their con-
trols related to a lower or absent β-value. A less 
efficient repair also resulted in an increased 
failure of the knockdown cell lines to continue 
to proliferate at higher doses. Due to the pres-
ence of non-proliferating cells, tailing could be 
observed for Ku70i and BRCA1i (above 3 or 
4Gy). For these cell lines the higher dose points 
have been omitted for the regression, the points 
itself are however plotted on the graph. The α 
and β values of the survival curves are listed 
in table 1. 
138
In table 2 an overview can be found of the 
DMFs, which quantify the effect of knockdown 
of the repair proteins on radiation-induced cell 
survival, with the 95% confidence limits of all 
cell lines at 2Gy (DMF2Gy; relevant dose for 
radiotherapy) and when the dose reaches zero 
(DMFM; relevant for radiodiagnostics). Due to 
the presence of a quadratic component in the 
survival curves of the control-cell lines for 
both γ and neutron irradiation, all DMFs were 
dose dependent. The radiosensitizing effect of 
the knockdown could be observed to different 
extents in all cell lines (DMF>1). The differ-
ence between the DMFs in the mixed cultures 
and the DMFs in the G1 cultures was limited, 
with the exception of Ku70i, which had higher 
DMFM in the G1 cultures than in the mixed cul-
tures (DMF
M;G1
 > DMF
M;mix
). 
In table 3, an overview is given of all RBEs 
(RBE2Gy and RBEM). In the BRCA1i cell line, 
the RBE was dose-independent due to the ab-
sence of a β-component in the cell survival 
curves and there was no difference between 
the RBEM and the RBE2Gy. For all cell lines 
neutrons were more effective in reducing cell 
proliferation/increasing cell death compared 
to γ-rays (RBE >1). The impact of RBE was 
relatively constant over all cell lines and dose 
points, with the exception of the BRCA1i cells 
which had a lower RBE. 
TABLE 3 
Overview of the RBE
2Gy
 [95%LCL-95%UCL] and the RBE
M
 [95%LCL-95%UCL] for the MN assay and the crystal violet assay for all cell lines and 
radiation qualities. 
Original research
Article 2
139
	  
(a) CONBBRCA and 
CONKu70 
(b) 
BRCA1i 
(c) 
BRCA2i 
(d) 
Ku70i 
FIGURE 3 
CV cell survival curves for γ-rays and neutrons of the different cell lines. (a) CONKu70 (dark grey, dashed line) and CONBRCA (light grey, 
full line) (b) BRCA1i (c) BRCA2i (d) Ku70i. The light grey curves in b and c are the survival curves of CONBRCA, the dark grey curves in d are 
the survival curves of CONKu70. The black curves are the survival curves of the knock down cell lines.  : gamma irradiation of the mixed 
cultures;  : neutron irradiation of the mixed cultures;  : gamma irradiation of the synchronized G1 cultures;  : neutron irradiation of 
the synchronized G1 cultures. 
Discussion
Whether or not BRCA1 and BRCA2 mutation 
carriers are more sensitive to ionizing radiation 
and how this is influenced by LET or cell cycle 
stage is an important matter, due to its impli-
cations in radiotherapy, radiodiagnostics and 
mammography breast screening. BRCA1 ho-
mozygous mutations are embryonically lethal 
and no homozygous BRCA1 mutation carriers 
have been described in any species. A group of 
Fanconi Anemia (FA) patients have been found 
to carry a homozygous mutation in BRCA2 (FA 
patients with mutation in FANCD1). While 
there is still controversy about radiosensitivity 
of FA patients, there is a consensus about the 
fact that they are clinically radiosensitive when 
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exposed to radiotherapy for cancer treatment 
or in the conditioning regimen for hematopoi-
etic stem cell transplantation (60-64). In vivo 
studies or in vitro experiments performed on 
lymphocytes or fibroblasts of heterozygous 
mutation carriers of BRCA1 or BRCA2 don’t 
seem to give a clear answer on whether BRCA1 
and BRCA2 mutation carriers are more sensi-
tive to ionizing radiation. As stated in the in-
troduction, due to small populations and the 
many variables involved, in vivo studies of-
ten lack the power to ultimately demonstrate 
a connection between the presence of BRCA1 
or BRCA2 mutations and increased radiosensi-
tivity (65). Lymphocytes or fibroblasts derived 
from heterozygous mutation carriers, which 
are mostly used in in vitro studies, are different 
from breast epithelial cells and their inherent 
radiosensitivity could be different. From in vit-
ro functional studies we got a good insight in 
the roles of BRCA1 and BRCA2 in DNA re-
pair, which clearly suggest the possibility of a 
high sensitivity to ionizing radiation. However, 
these studies seldom investigated the impact of 
BRCA1/2-expression specific to ionizing irra-
diation and again often the results seem to be 
inconclusive or contradictory (66-68).
The MCF-10A cell-line used in this study con-
sisted of spontaneously immortalized but non-
transformed human breast epithelial cells, and 
is very suitable to investigate the intrinsic sen-
sitivity of mammary epithelial cells to differ-
ent irradiation conditions. A 70% knockdown 
of BRCA1 and a 51% knockdown of BRCA2, 
allowed to mimic the condition present in the 
mammary epithelial cells of heterozygous 
mutation carriers, thus allowing to investigate 
the effect of lowered functional BRCA1 and 
BRCA2 proteins levels on radiosensitivity 
and breast cancer development. The main re-
sults obtained in this study with the BRCA1i, 
BRCA2i and Ku70i mammary epithelial cell 
lines point to an increase in radiosensitivity 
following BRCA1, BRCA2 and Ku70 knock-
down. 
Depending on the nature of the DSB and the cell 
cycle phase, the DNA damage response path-
way functions differently. BRCA1, BRCA2 
and Ku70 have different functions in the DSB 
repair pathway, and the radiation response of 
the knockdown cell lines could be influenced 
by cell cycle phase and the radiation quality. 
We investigated the radiation response in the 
knockdown and control cell lines after irradia-
tion of G1 synchronized or mixed cell cultures 
exposed to a low-LET γ-source or a high-LET 
neutron source.
With the MN assay we found neutron-RBE val-
ues in the control cell lines (CONBRCA/CONKu70) 
cell line of 1.85/1.91 and 1.75/1.82 (RBE
2Gy;mix
 
and RBE
2Gy;G1
) rising to an RBEM of 2.81/3.44 
and 4.90/6.94 (RBE
M;mix
 and RBE
M;G1
). Using 
the same CON
Ku70
 cell line and the same neu-
tron beam, Vandersickel et al (55) found an 
RBE
MN;2Gy
 in mixed cultures of 2.16 and an 
RBE
CV;2Gy
 in mixed cultures of 2.07, which 
compares well to our RBE
2Gy;mix
 values of 1.91 
(MN assay) and 1.90 (CV assay). 
Vral et al reported an RBE
M;MN
 of 7.6 in G0 
lymphocytes irradiated with 5 MeV neutrons 
(69). Our reported RBEM-values were lower, 
which can be due to the higher energy of the 
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neutrons used in this study (29 MeV), which 
is in agreement with the energy dependence 
of the radiation weighting factor (70). The dif-
ference can also be attributed to differences in 
inherent radiosensitivity between lymphocytes 
and MCF-10A cells. The same 29 MeV beam 
was used by Slabbert et al (71) and by Vander-
sickel et al (72) on unstimulated G0 lympho-
cytes from different donors, resulting in RBEM 
values between 1.8 and 8. The RBEM of 4.9 
obtained in synchronized G1 MCF10-A cell 
cultures lies in this range. 
The results of the CV cell proliferation assay 
are in agreement with the results of the MN 
assay. However, the DMF and RBE values ob-
tained with the CV cell proliferation assay are 
generally lower than those obtained with the 
MN assay. Presumably this is because the MN 
assay focuses specifically on chromosomal ab-
errations, which are the result of misrepaired 
or non-repaired DNA DSB, while the crystal 
violet proliferation assay gives a more general 
picture of the cell’s sensitivity to ionizing ra-
diation. 
BRCA2 has an important function in HR, a 
DSB repair pathway which is only active in the 
S and G2 phases of the cell cycle. The BRCA2i 
cell line used in this study showed no increased 
MN formation compared to its control cell line 
when synchronized G1 cultures were irradiated 
(DMF
2Gy;y
=1.14; DMF
2Gy;n
=0.99), but showed 
increased sensitivity when mixed cultures were 
irradiated (DMF
2Gy;y
=1.97; DMF
2Gy;n
=2.44). 
These observations are in line with the prom-
inent role of BRCA2 in HR, as in the G1 cul-
tures approximately 87% of the cells were in 
G1 phase in which HR is not active. In mixed 
cultures, where approximately 65% of the cells 
were in S or G2, HR can be activated in re-
sponse to DSB. The results obtained with the 
CV cell proliferation assay are less straightfor-
ward, with a DMF2Gy,y of 1.5 and DMF2Gy,n 1.34 
in mixed cell cultures and a DMF2Gy,y of 1.33 
and DMF2Gy,n 1.28 in synchronized G1 cell cul-
tures (table 2).
Studies have shown that the NHEJ pathway re-
mains the primary option for DSB repair in all 
phases of the cell cycle, and that cells switch 
to HR as a function of chromatin condensation 
and complexity of the break. More complex 
breaks, like those produced by higher LET ra-
diation qualities (e.g. neutrons), will typically 
be repaired by HR (32, 73-76). Therefore the 
effects of the down regulation of the BRCA2 
repair protein could be expected to be more 
pronounced after neutron-irradiation. Taka-
hashi et al demonstrated that this is not the case 
for a HR-deficient mouse embryonic fibroblast 
(MEF) cell line, which had approximately the 
same LET-RBE relationship as the control cell 
line (77). Similarly, in our study we found that 
the efficiency of neutrons versus γ-rays to in-
troduce MN and cell death is not clearly altered 
in cells defective in BRCA2 compared to the 
control cell line, as comparable RBE values 
were obtained (table 3)
BRCA1 is involved in HR, but also has a role 
in detection and signalization of DSB in NHEJ, 
in single strand annealing (SSA) and in cell cy-
cle control. The results obtained in this study 
seem to confirm the broader role of BRCA1 in 
DSB repair since the BRCA1i cell line showed 
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a higher sensitivity to ionizing radiation, com-
pared to the control cell line and this in both G1 
and mixed cultures. 
After irradiation of BRCA1i G1 cultures, the 
number of binucleated cells dropped quickly in 
a dose-dependent fashion, making it impossi-
ble to set up a MN dose-response curve. With 
the CV cell proliferation assay, data could only 
be collected for the lower dose points (up to 
3Gy), due to a marked reduction in cell pro-
liferation at higher dose points. The BRCA1i 
survival curve obtained for y irradiations was 
characterized by the absence of a shoulder, 
indicating a strongly reduced repair capacity 
of the BRCA1i cells (78), which resulted in 
a dose-related failure of the BRCA1i cells to 
continue to proliferate. This is in agreement 
with the low number of binucleated cells ob-
tained in the MN assay. Such strong inhibition 
of cell proliferation was not observed in the 
Ku70 and BRCA2 knockdown cell lines. This 
may point to the fact that BRCA1 depletion se-
riously affects the repair of radiation-induced 
DSB in G1, by which the damaged cells are 
irreversibly blocked in G1 and will probably 
undergo cell death by apoptosis or senescence 
(54, 79). However, the high radiosensitivity 
of the BRCA1i cell line can also be caused by 
the knockdown of 70% of the BRCA1 protein 
compared to only 51% and 43% of the BRCA2 
and Ku70 proteins respectively. 
After irradiation of the BRCA1i mixed cell 
cultures, cell proliferation was less affected 
and a MN dose-response curve could be ob-
tained. BRCA1i mixed cultures were found to 
be highly radiosensitive compared to CONBRCA, 
with DMFMN values exceeding 3. The reduc-
tion in cell proliferation at higher dose points 
in the CV cell proliferation assay and the high 
DMFCV values in the range of 2.4-4.6 showed a 
marked increase in radiosensitivity of BRCA1i 
cells compared to CONBRCA cells in the mixed 
cultures. It is clear that the knockdown of 
BRCA1 affects the radiosensitivity of the cells 
severely, especially in the low-dose region. The 
effect was more pronounced than upon deple-
tion of BRCA2, presumably because depletion 
of BRCA1 does not only affects HR, but also 
affects NHEJ and SSA (80-82). However, no 
absolute comparison is possible as the extent 
of the BRCA1 and BRCA2 knockdowns are 
different. 
The difference in efficiency of both radiation 
qualities used in this study was less pronounced 
for BRCA1i cells compared to all other cell 
lines. Although RBE values higher than 1 were 
observed in BRCA1i cells, they were lower 
than those observed in the control and other 
knockdown cell lines and this effect is more 
pronounced in the low-dose regions. This has 
been described previously for MEF cells being 
deficient in both NHEJ and HR (77). 
In the present study we also compared the 
knockdown of BRCA1 and BRCA2 with the 
knockdown of another DNA repair protein, 
Ku70, involved in NHEJ (54, 55). Vandersick-
el et al also used the KU70i cell line, demon-
strating an increase in radiosensitivity. DMFs 
and RBEs obtained by Vandersickel et al are 
comparable with our results (55). From table 2 
and 3 it can be observed that the radiation re-
sponse obtained in the BRCA1i cells was sim-
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ilar or more pronounced than the response of 
the Ku70i cells. Increased radiosensitivity was 
obtained for both mixed and G1 cultures. Al-
though the effect is smaller than the one shown 
by the BRCA1i cells, the RBE values obtained 
in the Ku70i cell line were lower than those of 
the CON
Ku70
. This can be explained by the fact 
that this cell line is deficient in NHEJ and pro-
ficient in HR, as reported by other researchers 
(77, 83, 84). However, again no absolute com-
parison is possible as the extent of the knock-
downs are different. 
Although both NHEJ and HR play an important 
role in the repair of radiation-induced DSB, it is 
still a matter of debate which pathway is used 
as backup for the repair of radiation-induced 
DSB in cells carrying inactivating mutations 
genes involved in NHEJ or HR. BRCA2-de-
fective cells are deficient in HR and proficient 
in NHEJ. However, BRCA2 only plays a role 
in HR after DNA end-resection, and it has been 
shown that switching back to NHEJ after this 
stage is impossible (32, 66). In BRCA2 defi-
cient cells, SSA has been proposed as a back-
up repair pathway (81, 85, 86). BRCA1i cells 
are deficient in both HR and NHEJ and also 
need a back-up pathway. Studies have shown 
the involvement of BRCA1 in SSA, ruling 
SSA out as back-up pathway (82, 87, 88). Most 
probably an annealing-dependent pathway like 
Microhomology Mediated End-Joining may be 
activated (33, 65, 75, 76, 89, 90). 
In conclusion, our study shows increased radi-
osensitivity of human mammary epithelial cells 
containing a 70% knockdown for BRCA1 and 
a 51% knockdown for BRCA2. This reduced 
protein level is comparable with the BRCA1 
and BRCA2 levels in heterozygous mutation 
carriers. Our results may imply that caution 
should be taken when administering ionizing 
radiation to heterozygous BRCA1 or BRCA2 
mutation carriers. When comparing neutrons 
and γ-rays there seems to be no significant dif-
ferences in RBE values, as the knockdown cell 
lines showed similar (BRCA2i) or slightly low-
er (BRCA1i and Ku70i) RBE values compared 
to their controls. The increased radiosensitivity 
observed in the BRCA1 and BRCA2 knock-
down cell lines is most pronounced at low dos-
es. Radiosensitivity is increased in both G1 and 
mixed cultures of BRCA1i and Ku70i cells, but 
only in mixed cultures of BRCA2i cells. This 
is in accordance with the different functions of 
BRCA1, BRCA2 and Ku70. The dependence 
of the radiation response of the repair deficient 
cell lines on LET, dose and cell cycle might 
have implications in radiotherapy and diagnos-
tic screening. However, further research must 
clarify the practical consequences and possible 
advantages of the different response of BRCA1 
and BRCA2 mutation carriers to ionizing radia-
tion. Which back-up pathways are used in cells 
defective in BRCA1 and BRCA2, and how a 
cell will switch from one DSB repair pathway 
to another is not yet elucidated, but alternative 
NHEJ pathways such as MMEJ and SSA may 
be involved. 
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Introduction
Breast cancer is the most prevailing cancer 
among women and about 1 in 9 women will 
be confronted with it (1). 23% of cancer cases 
in women are breast cancers and they are the 
leading cause of cancer death in females world-
wide (2). In many countries an increase in the 
incidence of breast cancer since the late 1980s 
and early 1990s is observed. This is likely to be 
the result from changes in reproductive factors 
like the increased use of postmenopausal hor-
mone therapy as well as an increased screening 
intensity. In contrast, over the past 25 years, 
breast cancer mortality has been decreasing in 
North America and several European countries 
largely as a result of early detection through 
mammography screening and improved treat-
ment (3-5). 
In many countries, breast cancer screening pro-
grams based on periodic mammography exist 
for women aged between 50-70 years to diag-
nose breast cancer in an early stage. Detection 
and treatment in an early stage gives a better 
prognosis and a reduction in mortality. Breast 
Abstract
Purpose: In many countries, breast cancer screening programs based on periodic mammography 
exist, giving a large group of women regularly a small dose of ionizing radiation. In order to assess 
the benefit/risk ratio of those programs the relative biological effectiveness (RBE) of mammogra-
phy X-rays needs to be determined. 
Materials and Methods: Blood of 5 healthy donors was irradiated in vitro with 30kV X-rays and 
60Co γ-rays with doses between 5 and 2000mGy. The γH2AX-foci technique was used to quantify 
the number of DNA double strand breaks (DSB) after irradiation. Chromosomal damage resulting 
from non- or misrepaired DNA DSB was quantified with the micronucleus (MN)-assay and the 
sensitivity was improved by counting only centromere negative micronuclei (MNCM-). 
Results: The threshold detection dose obtained with the γH2AX-foci test was 10mGy for mam-
mography X-rays compared to 50mGy for γ-rays. With the MN-assay respectively MN-cen-
tromere-assay threshold detection doses of 100 respectively 50mGy were obtained for mammog-
raphy X-rays compared to 200 respectively 100mGy for γ-rays. 
An RBE of 1.4 was obtained with the γH2AX-foci assay. With the MN-assays low-dose RBE 
values between 3 and 4 were determined. 
Conclusion: Our results indicate that exposure to mammography X-rays resulted in a modest 
increase in the induction of DSB compared to γ-rays. However, due to the higher LET nature of 
mammography X-rays more clustered DNA damage is produced that is more difficult to repair and 
results in a more pronounced increase in micronucleus formation. 
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glandular doses are low and typically 2-4 mGy 
per two-view mammography (6-8). The use of 
ionizing radiation always implies a risk for ra-
diation-induced breast cancer and although the 
dose is small, this cannot be neglected in view 
of the large population size and the repetitive 
character involved in this type of asymptomatic 
screening. 
Current radiation risk estimates for low linear 
energy transfer (LET) radiations are based on 
epidemiologic datasets observed in populations 
exposed to X-rays with significantly higher en-
ergies than are used in breast cancer screening 
programs, e.g. a pooled analysis of eight co-
horts of women exposed to ionizing radiation 
varying from 80 kVp X-rays to 60Co and 226Ra 
γ-rays can be found in Preston (9). 
Mammography X-rays are low-energy X-rays 
with a peak and mean photon energy typical-
ly 28-30 kV and 15-20 keV, compared to 60Co 
γ-rays which have a high energy of approx-
imately 1.25 MeV. As a result, 30 kV X-rays 
have a denser ionization pattern resulting in a 
higher LET (LET 4.34 keV/µm) compared to 
60Co γ-rays (LET 0.3 keV/µm). The impact on 
the biological effect of the higher LET of low 
energy X-rays like mammography X-rays com-
pared to 60Co γ-rays is still a matter of debate. 
The International Commission on Radiological 
Protection acknowledges that, based on in vitro 
experiments on cells, there seem to be signif-
icant differences in relative biological effec-
tiveness RBE in radiation qualities of low-LET 
radiations, but still recommends the use of an 
RBE value of 1 for 30 kV X-rays (10). 
In breast cancer screening programs based 
on mammography X-rays it is important to 
demonstrate that benefit, arising from reduced 
mortality due to early diagnosis, exceeds any 
potential risk arising from future radiation-in-
duced breast cancers. Although there are sev-
eral ways to assess benefit/risk ratios, a simpli-
fied approach is to calculate the breast cancer 
detection over induction ratio (DIR). These cal-
culations are essentially based on epidemiolog-
ical data of breast screening programs, breast 
radiation doses and cancer induction risk fac-
tors (10-12). Although such calculation models 
are subject to a certain degree of statistical un-
certainty, they can be used to assess benefit/risk 
taking into account that the number of breast 
cancers detected must exceed the number of 
induced cancers by a significant margin. The 
magnitude of this margin is still under discus-
sion (11), but for women included in most na-
tional screening programs, being over 50 and 
having a 2-year screening-interval, the DIR is 
over 100 which seems to be ample (13, 14). 
Several recent in vitro radiobiological studies 
have reported that if we take into account the 
reported higher radiobiological efficacy of the 
low-energy X-rays used for mammography 
compared to conventional higher kV X-rays 
or 60Co γ-rays it seems that the risk could be 
underestimated by a factor of 4 ((15-17) for a 
review see (18)) which obviously will have a 
huge impact on the DIR. Since DIR-values are 
used to justify low doses of low energy radia-
tion exposures to a large asymptomatic popula-
tion it is necessary to have a correct estimation 
of the RBE of 30 kV X-rays, since this has an 
impact on the safe use of mammography. 
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One of the most important biological endpoints 
to consider for calculating RBE values related 
to radiation-induced breast cancer is the dam-
age at the level of the DNA. The most geno-
toxic radiation-induced lesion is the DNA dou-
ble strand break (DSB) as information is lost 
in both strands of the DNA. Although DSB 
can be repaired by different repair-pathways, 
some will not or will be misrepaired resulting 
in chromosome aberrations (eg. dicentrics, 
translocations, micronuclei) which are good 
biomarkers for cancer risk assessment (19-22). 
In this study we investigated the RBE of mam-
mography X-rays at the DNA and chromosomal 
level in comparison to 60Co γ-rays in peripheral 
blood lymphocytes (PBL) starting from doses 
as low as 5 mGy. PBL were chosen as they are 
easy to obtain and they represent a homogene-
ous cell population (G0 phase) at the moment 
of in vitro irradiation. Moreover, several stud-
ies have shown that the degree of radiation sen-
sitivity of an individual is detectable in cells of 
a type different from the tissues suffering the 
adverse effect (23). By using the γH2AX-foci 
assay we quantified the number of DNA DSB 
induced by radiation in PBL (24). Chromosom-
al damage was quantified by means of the in 
vitro micronucleus (MN) assay and the more 
sensitive micronucleus-centromere assay. Ra-
diation-induced micronuclei in PBL contain 
mainly acentric chromosome fragments which 
are unstable chromosome aberrations resulting 
from unrepaired (terminal deletions) or mis-
repaired DSB (interstitial deletions, acentric 
fragments arising from assymetrical exchanges 
such as dicentrics and centric rings). By this 
the MN assay is an easy, alternative method to 
study chromosomal damage (18, 25-30). The 
application of the yH2AX-foci assay and the 
MN assay gives us on the one hand informa-
tion about the initial number of radiation-in-
duced DSB and on the other hand information 
about the residual chromosomal damage that 
remained after repair took place.
Material and Methods
Irradiations
Per experiment, a blood sample was taken by 
venipuncture from a healthy donor, divided in 
small volumes and irradiated at room tempera-
ture with mammography X-rays or 60Co γ-rays, 
with doses ranging from 5 to 2000 mGy. In to-
tal, blood samples of 5 different donors were 
analysed in 10 experimental set-ups (2 exper-
iments per donor, one for each radiation qual-
ity). Ethical clearance was received from the 
commission for medical ethics from the Ghent 
university hospital. Informed consent, allow-
ing the analysis of the effects of irradiation in 
PBL, was obtained from each volunteer. All 
donors stated that, to their knowledge, there is 
no history of breast cancer in the family. The 
irradiations with 60Co γ-rays were performed 
at a dose rate of 0.15 Gy/min in a water bath. 
Mammography-irradiations were performed 
with a Siemens Mammomat3 producing a 30 
kV Mo/Mo X-ray spectrum at a dose rate of 
0.125 Gy/min. A layer of exactly 2mm whole 
blood was irradiated. Within each experiment 
sham-irradiated controls were included. After 
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each irradiation the γH2AX-foci assay and the 
MN-assay were applied. 
γH2AX-foci assay
The γH2AX-foci assay was used to quantify 
radiation-induced DNA DSB. After irradia-
tion with doses ranging from 5 to 500 mGy the 
blood was incubated at 37°C for 30 minutes 
to allow maximal foci formation. This incuba-
tion period was followed by cooling the blood 
in ice water to block DNA repair processes. 
T-lymphocytes were isolated with the Ro-
setteSep blood separation technique (StemCell 
Technologies, Grenoble, France). Cells were 
centrifuged onto poly-L-lysine slides (VWR, 
Leuven, Belgium), fixed in paraformaldehyde 
(PFA) 3% during 30 min and kept at 4°C in 
PFA 0.5% overnight. Slides were washed in 
Dulbecco’s phosphate buffered saline (D-PBS) 
and permeabilized in D-PBS with 0.2% Triton 
X-100 (Sigma Aldrich, Bornem, Belgium). 
Cells were blocked with D-PBS with 1% bo-
vine serum albumin (BSA; Roche, Vilvoorde, 
Belgium) (3 times 10 minutes). Immunostain-
ing was done by incubating the cells during 1h 
using a mouse-anti-γH2AX primary antibody 
(ImTec Diagnostics, Antwerpen, Belgium) di-
luted 1/500 in blocking buffer, followed by an 
incubation with RAM-TRITC secondary anti-
body (DakoCytomation, Heverlee, Belgium) 
during 1h diluted 1/1000 in blocking buffer. 
The cells were washed in D-PBS (3 times 10 
minutes) and the nuclei were counterstained 
with 2% DAPI (Sigma Aldrich) dissolved 
in Fluoromount Mounting Medium (Sigma 
Aldrich). Slides were scanned using a Metafer 
4 scanning system (MetaSystems, Altlussheim, 
Germany) as described by Vandersickel et al. 
(31). This system uses a Zeiss Imager.Z2 mi-
croscope (Zeiss, Zaventem, Belgium) and the 
images are captured by a CoolCube1 camera 
(MetaSystems). The metacyte software module 
of the Metafer allows automated interphase nu-
cleus recognition and cell signal detection and 
counting. First the nuclei are selected and cap-
tured as DAPI images using a well defined cell 
selection classifier with a 40X magnification. In 
a second step, the fluorescence filter is changed 
to TRITC and the TRITC signals are captured 
in the selected nuclei as a z-stack with a total 
of 10 focal planes and a step size of 0.35µm 
between planes. Per experimental condition 2 
slides were scanned. The scanned images were 
coded and 100 cells per slide were analyzed 
manually for the presence of foci. Foci size 
was not considered as overlapping foci edges 
resulting in underscoring due to ‘foci fusion’ is 
only occurring at higher doses (32).
Micronucleus (MN)-assay
The MN-assay was used to quantify residual 
chromosome damage resulting from mis- or 
non-repaired DSB (18, 25-30). After irradiation, 
blood cultures were set up and T-lymphocytes 
were stimulated by adding 100 µl phytohae-
magglutinin (PHA) (Life Technologies, Gent, 
Belgium). 24 hours later 6µg/ml cytocholasin 
B (Sigma Aldrich) was added to block cytoki-
nesis. Cells were harvested 70h post irradiation 
by a cold hypotonic shock with 0.075 M KCl, 
followed by overnight fixation in 4/1/5 Meth-
anol/acetic acid/ringer solution. Subsequently, 
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the cells were fixed another three times in 4/1 
methanol/acetic acid. Suspension of cells was 
dropped on clean slides and stained with DAPI 
Vectashield (Lab Consult, Brussel, Belgium) 
for further analysis. Slides were scanned with 
the MSearch software module of the Metafer 
4 scanning system (MetaSystems) as described 
by Willems et al (33), using a Zeiss Imager.Z2 
microsope (Zeiss) and a CoolCube1 camera 
(MetaSystems). The MSearch software allows 
automated detection of binucleated (BN) cells 
and automated scoring of MN. 2 slides per cul-
ture were automatically scanned with a 10X 
magnification and analyzed. The scanned gal-
lery-images were coded and all BN cells were 
checked manually on their MN-score. Per slide 
approximately 2000 BN cells were scored. 
In a population of healthy individuals the back-
ground MN frequency is rather high and vari-
able (34) , limiting its use for the detection of 
very low doses. The sensitivity of the MN-as-
say in the low dose range can however be in-
creased by applying a protocol that allows to 
distinguish between spontaneously occurring 
MN harboring whole chromosomes and MN 
induced by radiation containing only acentric 
chromosome fragments (35, 36). Therefore 
fluorescent in situ hybridization (FISH) stain-
ing with a pancentromere probe was applied 
on the MN-slides (dose range 0-500 mGy). 
A home-tailored probe based on polymerase 
chain reaction (PCR) technology and labeled 
by the nick-translation method was used (37). 
Before hybridization MN slides were dehydrat-
ed through consecutive solutions of 70, 90 and 
100% ethanol, each for 5 min. 20 µl of probe 
dissolved in 120 µl hybridization buffer was 
placed on a slide under a coverslip and denatur-
ation (76°C; 5 min) and hybridization (38°C; 
20h) was done using a thermocycler (Ther-
mobrite; Abbott, Wavre, Belgium). Coverslips 
were removed by soaking in a 2X Sodium Salt 
Citrate (SSC) solution (room temperature; 1-5 
min) and were washed in 0.4X SSC+0.1% 
tween20 (Sigma Aldrich) (70-72°C; 1min) 
and 2X SSC (room temperature; 5 min). Slides 
were mounted in a drop of DAPI Vectashield 
(Lab Consult). For the analysis, MN were 
first identified by the MSearch module of the 
Metafer 4 scanning system (MetaSystems). 
In a second step the BN cells with MN were 
selected for Autocapt Analysis. During Auto-
capt analysis the selected cells are scanned at 
40X magnification, first with a DAPI filter to 
visualize the nuclei and next with a TRITC fil-
ter to visualize the pancentromeric probe. The 
presence of a centromeric signal was checked 
manually on the two colored images shown on 
the display and in the image gallery. 
Data analysis
For both radiation qualities, the foci-frequen-
cies (Y) as a function of dose (D) were best 
represented by a linear function. 
 
From this, the RBE for foci (RBEfoci), equal to 
the maximal low-dose RBE (RBEM), is calcu-
lated:
  
(1)
(2)
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FIGURE 1
Dose-response curves for the mean number of radiation-induced γH2AX-foci per cell for 60Co γ-rays ( ) and 30 kV X-rays ( ). Error bars 
indicate the standard error of the mean (SEM) for 5 independent experiments.
The MN-frequencies (Y) as a function of dose 
(D) were best represented by a linear-quadratic 
model:
  
From this fit, the RBE for MN (RBEMN), which 
is function of the dose, is calculated by the fol-
lowing formula (38, 39): 
  
The micronucleus dispersion index (σ2/μ), 
evaluating the distribution of micronuclei com-
pared to the Poisson distribution, was calculat-
ed using Dose Estimate (40). 
A Wilcoxon test was used to determine the dif-
ferences in the dose response data for foci, MN 
and MN without centromeric signal  (MNCM-) 
between 30 kV X-rays and 60Co γ-rays. All 
other statistics were done using the two-sided 
paired t-test.
Results
Applying the γH2AX foci-assay resulted in an 
average number of background foci of 0.43 ± 
0.29 for 60Co γ-rays and 0.33 ± 0.28 for mam-
mography X-rays. A significantly higher num-
ber of radiation-induced foci was found after 
irradiation with mammography X-rays com-
pared to 60Co γ-rays (p≤0.001; Wilcoxon-test). 
For both radiation-qualities, a linear dose-re-
sponse curve was best fitted through the data 
(figure1). The α-values are listed in Table I. 
From these linear regressions an RBE-value of 
1.36 was calculated (Table II). 
(3)
(4)
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TABLE I 
a, b and c values of the linear (γH2AX; figure 1) and linear-quadratic (MN assays; figure 2 and 3) curve fittings. 
For the MN-assay, the average number of back-
ground MN was 18 ± 7 for 60Co γ-rays and 15 ± 
6 for mammography X-rays. Linear-quadratic 
dose-response curves were best fitted through 
the data. In figure 2 the MN dose-response 
curves are shown and the α and β values are 
listed in table I. A significantly higher number 
of radiation-induced MN is seen after irradi-
ation with mammography X-rays compared 
to 60Co γ-rays (p≤0.001; Wilcoxon-test). MN 
dispersion indices were lying between 1.084 ± 
0.019 and 1.164 ± 0.018 for 60Co γ-rays and 
1.094 ± 0.021 and 1.165 ± 0.021 for mammog-
raphy X-rays, indicating a slight overdisper-
sion as would be expected (38). No significant 
differences in MN dispersion were observed 
between the two radiation qualities. 
TABLE II
RBE-values of mammography X-rays relative to 60Co γ-rays for the γH2AX –foci and the micronucleus data. The numbers between brackets 
give the 95% upper and lower confidence limit of the RBE. 
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Dose-response curves for MNCM- are given in 
figure 3. The results are in line with the results 
of the standard MN-assay and a significantly 
higher number of MNCM- was found after irra-
diation with mammography X-rays compared 
to 60Co γ-rays (p≤0.001; Wilcoxon-test). Also 
here a linear-quadratic curve was best fitted 
through the data points and the α and β values 
are listed in Table I. 
RBE values, calculated according to formu-
la (4) are given in Table II for both MN and 
MNCM- assays. 
For each radiation quality and biological end-
point studied the threshold detection doses, 
leading to a significant increase in DNA-dam-
age compared to sham-irradiated controls at the 
95% confidence level, were determined and the 
values are given in Table III. 
To better understand the correlation between 
foci and MN, the radiation-induced foci were 
plotted against the radiation-induced MN for 
30kV X-rays and 60Co γ-rays in figure 4. 
FIGURE 2 
Dose-response curves for the mean number of radiation-induced MN per 1000 BN cells for 60Co γ-rays ( ) and 30 kV X-rays ( ). The 
dose-response curves are fitted using a weighted linear-quadratic regression. Error bars indicate the standard error of the mean (SEM) for 
5 independent experiments. 
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Discussion
During one mammographic screening session 
the average dose delivered to the breast glan-
dular tissue is typically 2 – 4mGy (two-view 
mammography) and screening will be repeated 
ten times in a two year screening program. In 
most RBE studies higher doses have been used 
to study the damaging nature of mammography 
X-rays and these results are then extrapolated 
to the low-dose range. 
In the present study we used actual mammogra-
phy-equipment for the irradiations and focused 
on the low-dose range using two different bio-
logical endpoints. The γH2AX-assay, used to 
quantify the number of radiation-induced DSB, 
is a very sensitive assay that allows the study of 
low dose effects (41). As a second endpoint for 
studying RBE, micronuclei, representing resid-
ual chromosomal damage, were used. As the 
presence of high and variably spontaneous MN 
yields hinders low dose effect estimation, MN 
slides were stained with a pancentromere probe 
to discriminate between radiation-induced MN 
(MNCM-) and spontaneous MN (MNCM+) 
(33, 35, 37). 
	  
FIGURE 3 
Dose response curves of the mean number of radiation-induced centromere negative MN per 1000 BN cells for 60Co γ-rays ( ) and 30 
kV X-rays ( ). Dose-response curves are best fitted through the data using weighted linear-quadratic regression. Error bars indicate the 
standard error of the mean (SEM) for 5 independent experiments.
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The dose-response curves obtained for 
yH2AX-foci formation (figure 1) show that for 
each dose point a higher number of foci (≈ DSB) 
was obtained after irradiation with 30 kV X-rays 
compared to 60Co γ-rays . This finding is in 
line with the physical characteristics of 30 kV 
X-rays. 30 kV X-rays indeed produce ionization 
tracks more dense compared to 60Co γ-rays, by 
which the chance of one ionization track pro-
ducing two or more single strand breaks in close 
proximity leading to a double strand break is 
higher compared to 60Co γ-rays (42). 
This higher efficiency of 30 kV X-rays to in-
duce DSB is reflected in RBE values higher 
than 1 (Table II) and in a lower threshold de-
tection dose (Table III). A dose of 10 mGy can 
be detected after irradiation with 30 kV X-rays, 
while for 60Co γ-rays the low dose detection 
limit is 50 mGy. This dose detection threshold 
of 50 mGy for 60Co γ-rays was also found by 
Beels et al. (43). Literature studies reporting 
on the RBE of mammography X-rays with the 
induction of DNA DSB as biological endpoint 
are scarce. The RBE of 1.36 found in our study 
corresponds with the RBE of 1.15 ± 0.05 re-
ported by Kühne after irradiation of primary 
skin fibroblasts with doses between 16 and 64 
Gy and analysis by specialized pulsed field 
gel electrophoresis (PFGE) (44). In the study 
of Colin et al. (2011), DSB induction by 28 
kVp X-rays in exact conditions of mammog-
raphy irradiation procedures was investigated 
in primary mammary epithelial cell cultures. 
By means of the γH2AX-foci assay they could 
demonstrate a significant dose effect after 
exposure to a single dose of 4mGy and a re-
peated 2+2 mGy dose simulating a two-view 
mammography (45). The lower dose detec-
tion threshold of 4 mGy found by Colin et al. 
compared to the 10mGy found in our study for 
mammography X-rays in lymphocytes can be 
due to differences in the γH2AX-foci protocol 
or may point to a higher sensitivity of mamma-
ry epithelial cells compared to lymphocytes. 
In comparison with our DSB-results, the ra-
diation quality effect of 30 kV X-rays com-
pared to 60Co γ-rays was much stronger for 
chromosomal damage represented by the MN 
or MNCM- numbers (figure 2) and this for all 
dose points. This higher efficiency translates 
TABLE III 
Threshold detection doses obtained with the γH2AX foci assay and MN assays for 30 kV X-rays and 60Co γ-rays.
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FIGURE 4
Radiation-induced MN as a function of radiation-induced γH2AX-foci for 30 kV X-rays ( ) and 60Co γ-rays ( ). 
in a lower threshold detection doses for 30 kV 
X-rays compared to 60Co γ-rays (50mGy ver-
sus 100 mGy (MNCM-) and 100 mGy versus 
200 mGy (MN)) (Table III) and meaningful 
RBE-values between 3 and 4 taking the thresh-
old detection doses for mammography X-rays 
as limiting dose point (Table II). 
Different studies investigating the RBE of low 
energy X-rays by means of cytogenetic assays 
have been published, but comparison is diffi-
cult due to differences in the physical charac-
teristics and energies (25-50kV) of the X-rays, 
the reference radiation quality, the cell type and 
cytogenetic assay used. Using 200 kV X-rays 
as reference radiation, RBEM values vary from 
1.2 to 1.7 with MN or dicentrics as endpoint 
(46-48); RBEM values ranging between 2 
and 6 were found for MN or dicentrics when 
60Co γ-rays were used as reference (49, 50).
The higher RBE values obtained in our study for 
mammography X-rays compared to 60Co γ-rays 
with the γH2AX-assay and the MN-assay clear-
ly point to the higher efficiency of this type of 
photon radiation to induce DNA damage. Fig-
ure 4 demonstrates that the same number of 
induced foci results in more induced MN af-
ter irradiation with 30 kV X-rays compared to 
60Co γ-rays. This is also reflected in higher RBE 
values for MN and implies that mammography 
X-rays not only induce more DSB compared 
to 60Co γ-rays but also that DSB arising from 
30 kV X-rays are more difficult to repair, prob-
ably because they are more complex. These re-
sults are in line with the results of Kühne et al. 
Original research
Article 3
163
who analyzed misrejoining using specialized 
PFGE after irradiation of primary human skin 
fibroblast with doses ranging between 16 and 
80 Gy and found that DSB produced by 29 kV 
X-rays are misrejoined more frequently than 
those induced by 60Co γ-rays (44). Mestres et 
al. investigated the complexity of radiation-in-
duced chromosomal-breakages by FISH after 
irradiation of whole blood with doses ranging 
between 2 and 6 Gy. They came to the conclu-
sion that exposure to 30 kVp X-rays resulted in 
a 1.6 time increase in incomplete and complex 
aberrations observed compared to 80 and 120 
kVp X-rays, which would suggest that the orig-
inal DNA damage induced by 30 kVp X-rays is 
more difficult to repair (51). Although in both 
studies much higher doses were used, it seems 
that the higher efficiency of 30 kV X-rays to 
produce more complex breaks also applies to 
the lower dose area. 
Conclusion
With the MN assay, a good biomarker assay for 
estimating cancer risk, a low dose RBE value of 
at least 3 was obtained for mammography X-rays. 
These results confirm recent literature data re-
garding a higher RBE for mammography X-rays 
and indicate that the currently used DIR values 
based on an RBE of 1 (10) are too high. Although 
in vitro radiobiological experiments using lym-
phocytes cannot be used directly as a basis for 
reviewing breast cancer screening programs, our 
results may assist those who design screening 
programs for groups of younger women.
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Introduction
Breast tissue consists mainly of adipose 
and fibroglandular tissue. 15 to 25 glandu-
lar units consist each of a single large duct 
which branches repeatedly to form a terminal 
duct-lobular unit (TDLU). Each TDLU con-
sists of a terminal duct and a lobule consisting 
of multiple acini. Invasive ductal carcinoma 
originates in the ducts of the glandular tissue 
and is by far the most common type of breast 
cancer, representing 80% of the invasive breast 
cancers. 10% of the invasive breast cancers are 
invasive lobular carcinomas. 
Breast cancer is the most prevailing cancer 
among women and about 1 in 9 women in 
Europe will be confronted with it (1). 23% of 
cancer cases in women are breast cancers and 
they are the leading cause of cancer death in 
females worldwide (2). In many countries an 
increase in the incidence of breast cancer since 
the late 1980s and early 1990s is observed. 
This is likely to be the result from changes in 
reproductive factors like the increased use of 
postmenopausal hormone therapy as well as an 
increased screening intensity. In contrast, over 
the past 25 years, breast cancer mortality has 
been decreasing in North America and several 
European countries largely as a result of ear-
ly detection through mammography screening 
and improved treatment modalities (3-5). 
In many countries, breast cancer screening pro-
grams based on periodic mammography exist 
Abstract
Purpose: Most studies investigating the RBE of mammography X-rays use blood lymphocytes, 
primary fibroblasts or cell lines. Breast tissue is however a very specific tissue, which is very 
sensitive to radiation due to the presence of reproductive hormones like estrogen. In this study we 
investigated the efficiency of mammography X-rays to induce DSB in the low-dose range (0-500 
mGy) in mammary epithelial cells present in freshly resected healthy breast tissue. 
Methods: Not cancerous, freshly resected breast tissue was irradiated with mammography X-rays 
in the dose range 0-500mGy with a special emphasis on the very low doses (0-20mGy). With the 
yH2AX-foci assay we quantified the number of DNA DSB induced by radiation in the glandular 
tissue. 
Results: Foci-induction by 30kV X-rays followed bi-phasic linear dose-response curve, with the 
low-dose part (0-40mGy) being 8.7 times steeper than the higher dose part (20-500mGy). This 
resulted in an RBE of 3.75 in the low-dose range. 
Conclusions: Our results indicate the existence of a low-dose hypersensitive response observed 
for DSB induction in the dose range representative for mammography screening which is prob-
ably caused by the bystander effect. This could affect the risk calculations for mammography 
screening.
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for women aged between 45-50 to 70-75 years 
to diagnose breast cancer in an early stage (6). 
Detection and treatment in an early stage gives 
a better prognosis and a reduction in mortality. 
Breast glandular doses are low and typically 
3-5 mGy per two-view mammography (7-9). 
The use of ionizing radiation always implies 
a risk for radiation-induced breast cancer and 
although the dose is small, this cannot be ne-
glected in view of the large population size and 
the repetitive character (annual or biannual) in-
volved in this type of asymptomatic screening. 
Mammography X-rays are low-energy X-rays 
with a peak and mean photon energy typical-
ly 28-30 kV and 15-20 keV respectively. 30 
kV X-rays have a more dense ionization pat-
tern resulting in a higher LET (LET 4.34 keV/
µm) compared to high energy photons such 
as e.g. 60Co γ-rays (LET 0.3 keV/µm, energy 
1.25MeV). The impact on the biological ef-
fect of the higher LET of low energy X-rays 
as mammography X-rays compared to high 
energy photons is still a matter of debate. The 
International Commission on Radiological Pro-
tection acknowledges that, based on in vitro ex-
periments on cells, there seems to be significant 
differences in relative biological effectiveness 
(RBE) in radiation qualities of low-LET ra-
diations related to the energy, but still recom-
mends the use of a radiation weighting factor 
of 1 for 30 kV X-rays (10). 
In the high dose range upwards from 100mGy 
as applied in radiotherapy, there is a linear re-
lationship with the dose received and the long 
term effects of radiation (11). The effects of low 
(<100 mGy) and very low doses (<10 mGy), as 
applied in medical diagnostics, are less clear. 
Available epidemiological data do not have 
sufficient statistical power to assess the radia-
tion risks of the low and very low exposure lev-
els (8). However, the inability to quantify these 
risks does not imply that the risk to the popula-
tion is negligible. A very small risk, if applied 
to a large number of healthy individuals, can 
result in a significant health problem (8). 
In vitro studies investigating cellular and ge-
netic effects can highlight the consequences 
of low and very low doses of ionizing irradia-
tion. After an exposure to just a few mGy, e.g. 
γH2AX foci, which are representative for DNA 
DSB, can be demonstrated (12-14), even in 
primary breast epithelial cells (15) or changes 
in transcription level of genes can be detected 
(16-18). Doses as low as a few mGy have an 
impact on the cell physiology and gene expres-
sion analysis demonstrated that different gene 
profiles are activated after low and high doses 
of X-rays in whole blood (19). However, how 
these effects translate into low-dose risks, and 
whether they have detrimental or beneficial 
effects, is still a matter of debate. In radiation 
protection practice a linear no threshold extrap-
olation is used (LNT) to calculate the risks at 
low doses using data from higher doses. How-
ever, this is just a working hypothesis which 
might underestimate or overestimate the effects 
of low dose radiation (8). 
Most data on the low dose effects of mammog-
raphy X-rays are derived from blood lympho-
cytes, primary fibroblasts or cell lines. Howev-
er, breast tissue is a very specific tissue, which 
is very sensitive to radiation due to the pres-
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ence of reproductive hormones like estrogen. 
Estrogens might be complete carcinogens as 
estrogens stimulate both estrogen receptor-me-
diated cell proliferation and induce DNA dam-
age by the formation of genotoxic metabolites 
such as reactive oxygen species (ROS) (20-23). 
In this study we investigated the effect of mam-
mography X-rays in the low-dose range (0-500 
mGy) in mammary epithelial cells present in 
freshly resected healthy breast tissue. By using 
yH2AX-foci assay we quantified the number of 
DNA DSB induced by radiation in the glandu-
lar tissue (24). To study the RBE 60Co γ-rays 
were used as reference radiation quality. 
Material and methods
Patients, preparation of the breast tissue 
and irradiations
No cancerous, freshly resected breast tissue 
was obtained from the department for plastic 
surgery from the Ghent University Hospital. 
The tissue specimens were collected during 
surgery from healthy individuals undergoing 
a breast reduction or mammectomy related to 
a high risk genetic profile for breast cancer. 
Ethical clearance was received from the com-
mission for medical ethics from the Ghent Uni-
versity hospital. Signed informed consent, al-
lowing the analysis of the effects of irradiation 
on breast tissue, was obtained from each donor.
In total 15 breast tissue-samples from a total of 
18 were of good quality (see further), 11 from do-
nors without an increased risk for breast cancer, 
4 from donors with a high risk profile for breast 
cancer of which 3 have a confirmed BRCA1/2 
mutation. Donors were on average 41 years old.
Immediately after resection, the tissue was pro-
cessed for irradiation. For this, fat tissue was 
removed as much as possible and the remain-
ing connective tissue containing the glands was 
cut in slices between 1.5 and 2mm thick, while 
kept in physiological solution (Ringer’s Solu-
tion: 9g NaCl Sigma-Aldrich, Bornem, Bel-
gium; 0.42g CaCl2 and 0.24g KCl both VWR, 
Leuven, Belgium; 1l aqua dest., pH 7.2). Once 
the slices of breast tissue were prepared for ir-
radiation, they were kept in a 5% CO2-incuba-
tor at 37°C in DMEM/F12-ham medium (Invit-
rogen, Belgium) supplemented with 5% fetal 
calf serum (Invitrogen), antibiotics and growth 
factors (10µg/ml insulin (Sigma, Belgium); 
0.5µg/ml hydrocortisone (Sigma); 20ng/ml 
epidermal growth factor (Tebu-bio, Belgium); 
50 U/ml penicillin and 50µg/ml streptomycin 
(Invitrogen)). 
Samples were irradiated with mammography 
X-rays, with doses ranging from 2 to 500 mGy 
(doses: 2, 4, 10, 20, 40, 100 and 500 mGy). In 
addition samples were also irradiated with 60Co 
γ-rays as reference radiation quality. Mammog-
raphy-irradiations were performed with a Sie-
mens Mammomat3 producing a 30 kV Mo/Mo 
X-ray spectrum at a dose rate of 0.125 Gy/min 
in a warm box at 37°C. A layer of exactly 2mm 
medium with tissue was irradiated. The irradia-
tions with 60Co γ-rays were performed at a dose 
rate of 5mGy/min for doses till 40mGy and at 
0.6 Gy/min for higher doses in a water bath at 
37°C. Within each experiment sham-irradiated 
controls were included.
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Fixation, embedding and  
haematoxylin-eosin staining
Immediately after the irradiation, the tis-
sue-samples were incubated for exactly 30min 
at 37°C, the time at which foci-formation is at 
its maximum. After this time, samples were 
transferred to cold ringer’s solution and kept 
on ice-water to inhibit repair processes. Subse-
quently they were transferred to paraformalde-
hyde (PFA; 4%; VWR) for fixation. 
After 24h in PFA the tissue-samples were de-
hydrated and embedded in paraffin. Tissue 
sections of 5 µm were cut with a microtome. 
Per sample 2 tissue sections were placed on the 
same slide and multiple slides were made. 
The quality of the tissue and the presence of 
glandular tissue was inspected by performing a 
haematoxylin-eosin staining. This staining was 
done automatically using a multipurpose slide 
staining device (Robot stainer: Microm HMS 
740; Walldorf, Germany). 
γH2AX immunostaining
Prior to the γH2AX immunostaining, tissue 
sections were deparaffinised and rehydrated 
using the Robot stainer (Microm HMS 740). 
Antigen retrieval was done in sodium citrate 
buffer (0.2 g citric acid (Merck, Darmstadt, 
Germany) in 1l aqua dest.; pH6). The tissue 
sections were brought in the buffer and boiled 
twice during 5 min using a microwave. After 
washing of the sections in PBS, they were pre-
treated in 3% H2O2 (VWR) to inactivate the 
endogenous peroxidases. Sections were further 
incubated in blocking serum (BS) (PBS 5 ml, 
BSA 50mg (Bovine serum albumin; Roche Di-
agnostics, Vilvoorde, Belgium); NRS 0.250 ml 
(Normal rabbit serum; Dako); Tween 20 (1ml 
10% Tween 20 (VWR)) for 30 min to avoid 
nonspecific binding and to permeabilitize the 
membranes. 
Immunostaining was done using a tri-step re-
action using consecutively mouse-anti-γH2AX 
(primary antibody; Biolegend, Trembodegem, 
Belgium; 2h, 1/1000 in PBS with 10% BS at 
room temperature (RT)), biotinylated rab-
bit-anti-mouse (secondary antibody; Dako, 
30min, 1/200 in PBS with 10% BS at RT) and 
streptavidine-horse radish peroxidase (Dako; 
30 min, 1/200 in PBS at RT). Between the 
steps the tissue-sections were washed in PBS 
(2x5 min). Next, the sections were incubated 
with DAB-NiCl2 (stock solution (ss) DAB: 
25mg/1ml AD; ss NiCl2: 4g/50ml AD; work 
solution: 200 µl DAB ss; 50 µl NiCl2 ss; 10ml 
PBS; 5µl H2O2) during 10 min in the dark to 
visualize the γH2AX foci. Slides were washed 
during 10 min in running tap water before 
dehydrating and mounting the sections with 
mounting medium (Thermo Scientific). Slides 
were sealed with a cover slip. 
Foci scoring
yH2AX-foci scoring was done manually, us-
ing a light microscope (Leica LEITZ-DM-
RB, Diegem, Belgium) at 63X magnification 
(Fluotar 63X/1.25 Oil, Leica). Per breast tissue 
sample and per radiation condition, at least two 
tissue-sections were counted by two experi-
enced researchers. In each section the number 
of γH2AX foci in 100 nuclei was scored, if 
possible in at least 4 different glandular groups. 
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Only the epithelial cells from the inner luminar 
layer were taken into account. 
Analysis
For the analysis of the γH2AX foci data, a dose 
response curve was fitted for 30 kV X-ray in 
the dose range (0-20mGy) and the range (20-
500mGy) assuming a linear model (Y=c+αD). 
For γ-irradiation, a linear dose-response curve 
was fitted. 
To compare the effects of the different radiation 
qualities (γ-rays versus 30kV X-rays), the rel-
ative biological effect (RBE) of 30kV X-rays 
compared to γ-rays is calculated using the fol-
lowing formula: RBE =            . 
Statistical analysis was done using the program 
SigmaPlot (SigmaPlot for Windows Version 
13.0). To compare two groups of data, a Stu-
dent t-test or a rank sum test was used, depend-
ing on the normal distribution of the data. 
Results
Hematoxylin-eosin (HE) staining
Inspection of the samples by HE staining (fig-
ure 1) revealed that some samples contained 
cells with an abnormal morphology. In those 
cases, all tissue samples for that donor were re-
jected from the study. 
FIGURE 1 
Haematoxylin-eosin staining of breast-tissue showing a duct surrounded by connective tissue. Images were taken with a 20X objective. 
Scale bar 50µm. 
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In a number of tissue sections there was no 
glandular tissue present. Especially samples 
taken from elderly individuals tended to con-
tain a very limited amount of glandular tissue. 
Tissue samples containing less than 100 epithe-
lial cells were discarded. As a result, per patient 
not all dose points and sham-irradiated controls 
could be analysed for foci formation. 
yH2AX foci assay
After selection of the good quality samples, im-
munostaining was consistently good. Examples 
of the staining are given in figure2. The use of 
DAB-NiCl2 resulted in very distinct black foci 
and a light background staining of the tissue. 
No counterstain was used, since the immunos-
taining already resulted in sufficient contrast to 
the tissue and counterstaining tended to darken 
the nuclei, reducing the ability to distinguish the 
foci. After selection of the good quality sam-
ples, immunostaining was consistently good. 
Examples of the staining are given in figure 2. 
The use of DAB-NiCl2 resulted in very distinct 
black foci and a light background staining of 
the tissue. No counterstain was used, since the 
immunostaining already resulted in sufficient 
contrast to the tissue and counterstaining tend-
ed to darken the nuclei, reducing the ability to 
distinguish the foci. 
(b)
(d)
(b)
FIGURE2 
γH2AX immunostaining, images were taken with a 63 X objective. (a) Negative control (no primary antibody); (b) unirradiated sample; (c) 
sample irradiated with 100 mGy; (d) sample irradiated with 500 mGy. Scale bar 10 µm.
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In a number of tissue sections there was no 
glandular tissue present. Especially samples 
taken from elderly individuals tended to con-
tain a very limited amount of glandular tissue. 
Tissue samples containing less than 100 epithe-
lial cells were discarded. As a result, per patient 
not all dose points and sham-irradiated controls 
could be analysed for foci formation. 
yH2AX foci assay
After selection of the good quality samples, im-
munostaining was consistently good. Examples 
of the staining are given in figure2. The use of 
DAB-NiCl2 resulted in very distinct black foci 
and a light background staining of the tissue. 
No counterstain was used, since the immunos-
taining already resulted in sufficient contrast to 
the tissue and counterstaining tended to darken 
the nuclei, reducing the ability to distinguish the 
foci. After selection of the good quality sam-
ples, immunostaining was consistently good. 
Examples of the staining are given in figure 2. 
The use of DAB-NiCl2 resulted in very distinct 
black foci and a light background staining of 
the tissue. No counterstain was used, since the 
immunostaining already resulted in sufficient 
contrast to the tissue and counterstaining tend-
ed to darken the nuclei, reducing the ability to 
distinguish the foci. 
(b)
(d)
(b)
Background number of foci could be meas-
ured in all high-risk donors (4) and in 5 donors 
with a normal risk profile. No difference in 
background number of foci could be detected 
between donors at high risk for breast cancer 
and donors without an elevated risk (average 
0.44 foci per cell ± 0.15 (SEM)) for high risk 
patients and 0.36 ± 0.10 for patients without 
elevated risk; p=0.68). Also for all irradiated 
samples (2-500mGy), no significant differenc-
es between donors with and without elevated 
risk could be observed.
As no differences were observed between do-
nors with and without elevated risk, the data of 
all patients was pooled and the average back-
ground number of foci in the pooled samples 
was 0.38 ±0.08 (foci per cell ± SEM). The 
threshold detection dose, leading to a signifi-
cant increase in number of foci per cell, was 
10mGy after irradiation with 30kV X-rays 
(p=0.05) while this was 20mGy after irradia-
tion with 60Co γ-rays (p=0.04).
The dose response curve through the pooled 
data for 30 kV X-rays shows a bi-phasic lin-
ear course, with the low-dose part (0-40 mGy) 
being steeper than the higher dose part (20-500 
mGy) (figure 3, black dots). The dose response 
curve for γ-rays follows a linear course (figure 
3, red dots). Furthermore a linear regression 
omitting the dose-points 2-40mGy is given 
(dashed line), which corresponds to the curve 
which would be obtained if a linear no thresh-
old model would have been used. In figure 4 
a detailed presentation of the dose response 
curves in the 0-20mGy dose-range with the 
95% confidence intervals is given. An over-
view of the α-values of the linear dose response 
curves are given in table 1. The slope increased 
9-fold between the 0-40mGy dose-range and 
the 20-500mGy dose-range after 30 kV X-ray 
irradiation. 
Table 1 lists the RBE values with the 95% con-
fidence limits for both the 0-20 and in the 20-
500 mGy dose range. In the low dose range (0-
40mGy), the 30kV X-rays were more effective 
in inducing DNA DSB than γ-rays (RBE>1). 
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FIGURE 3 
Dose response curve for γH2AX foci-induction after irradiation with γ-rays and 30kV X-rays. The linear regression curves in the high dose 
range and the low dose range are shown (full lines), together with the regression omitting the 2 to 40mGy dose points for 30kV X-rays 
(dashed line) (LNT model). 
Note that the 100mGy dose points for 30kV X and γ irradiation fall on top of each other, making the dose point for 100mGy 30kV X-ray 
irradiation invisible. 
TABLE1 
overview of α-values in both dose-ranges together with the RBE (=α30kV/αy) values in both dose ranges and the ratio of the α-values 
obtained by the linear regression in the 0-40 and 20-500 mGy dose-range (αL/αH). 
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FIGURE 4
Linear dose response curves for γH2AX induction in the low dose range for γ-rays and 30kV X-rays. Error bars indicate the SEM. 
Discussion 
A mammography examination consists of 2 
views of 2mGy each resulting in a glandu-
lar dose of 3-5 mGy. In most screening pro-
grams 10 examinations are performed during 
a screening period of about 20 years, giving a 
total glandular dose of approximately 40 mGy 
which may be considered as a relatively low 
dose. At low doses, phenomena such as hyper-
sensitivity, bystander effect, adaptive response, 
threshold hypothesis and hormetic response 
can play a role (8, 11, 25) and extrapolation of 
radiation-effects from the high-dose range to 
the low-dose range by the LNT model can lead 
to both an underestimation and overestimation 
of the low-dose effects of radiation. 
In this study we wanted to investigate the bi-
ological efficacy of mammography X-rays for 
DNA DSB induction in glandular epithelial 
cells present in resected breast tissue and ex 
vivo irradiated with very low doses. This set-
up corresponds as close as possible to the ex-
act physiological conditions of mammography 
screening. 
As our patient population also consisted of 4 
patients with an increased risk for breast can-
cer, we first investigated if a significant differ-
ence could be observed between patients with 
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a high risk for breast cancer and patients with-
out a high risk for breast cancer in number of 
background γH2AX foci, or in number of radi-
ation-induced foci at any dose. No significant 
differences were detected. These results are in 
contrast with the results of Colin et al who found 
an increased background number of γH2AX 
and an increased radiation-induced number of 
foci (2 mGy, 4 mGy and fractionated 2+2 mGy) 
in cell cultures of primary mammary epithelial 
cells of high-risk patients compared to low-risk 
patients (15). Since γH2AX functions upstream 
of BRCA1 and BRCA2, it is not surprising that 
no differences are found in γH2AX induction 
between donors with and without a BRCA1 or 
BRCA2 mutation. Analysis of the kinetics of 
γH2AX foci, which is closely related to the re-
pair of the DSB, might be better suited to detect 
deficiencies in DSB-repair. 
As no differences were observed the data of all 
the patients was pooled for further analysis. 
Using a γH2AX foci-assay, a threshold detec-
tion dose of 10mGy after irradiation with 30kV 
X-rays was found. In a previous study using 
lymphocytes, we also found a significant in-
crease in γH2AX foci after 10 mGy of 30kV 
X-rays (26). Other research groups showed a 
statistical significant increase of DNA DSB in 
MCF-10A cells after 9 mGy of 30kV X-rays 
(27) and in cultured primary breast epithelial 
cells a threshold detection dose of 4 mGy and 
a fractionated 2+2 mGy was found (15). These 
results seem to indicate that the threshold de-
tection dose of mammography X-rays for DSB 
induction is around or below 10 mGy. 
Beels et al found a hypersensitive response in 
whole blood in pediatric patients exposed in 
vivo to low doses of X-rays for cardiac catheter-
ization (mean dose 6mSv). She later confirmed 
these results with a study on yH2AX-induction 
in whole blood and isolated T-lymphocytes ir-
radiated in vitro with X (100kVp) and y-radia-
tion (28, 29). When whole blood was irradiated 
with X-rays, a very steep response was noted 
in the 0-10mGy dose range, which became less 
steep if doses higher than 20mGy were used. 
After irradiation with γ-rays, the biphasic ef-
fect was still there, but much less pronounced. 
The effects were also less pronounced when 
isolated lymphocytes instead of whole blood 
was used. She concluded that both cellular en-
vironment and radiation quality play a role in 
this hypersensitive response. A strong correla-
tion between cell culture conditions and a low-
dose hypersensitive response was also found 
by Groesser et al (30). 
The results obtained in this study are compara-
ble with those of Beels et al. A clear bi-phasic 
dose response was noted, with a low dose hy-
persensitive component for 30 kV X-rays. Ex-
trapolation of the dose response from 0 mGy to 
100 mGy without taking into account the low-
dose points (0-40mGy; dashed line in figure 3), 
clearly shows that the LNT-model would have 
resulted in an underestimation of the induced 
damage. 
The different response in the 0 to 20 mGy 
dose-range versus the 20-500 mGy dose range 
resulted in different RBE values. An RBE of 1 
was obtained in the 20-500mGy range, while 
an RBE of 3.75 was obtained in the 0-40mGy 
range. 
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This low-dose hypersensitivity is probably 
caused by the bystander effect. The bystander 
effect is largely propagated by damaged cells 
which release signaling molecules to neigh-
boring cells via gap-junction mediated inter-
cellular communication and via the release 
of diffusible factors such as ROS into the ex-
tra-cellular milieu (31-35). In our study, 2mm 
thick slices of breast tissue, including epitheli-
al glandular structures, were irradiated and as 
such, gap-junction mediated communication 
between cells in their natural micro-environ-
ment is still intact. Also, estrogens, which are 
highly available in breast tissue, are an impor-
tant source of ROS. 
Mills et al on the other hand, did not find an in-
creased RBE in the low dose range (0-30mGy) 
for mammography X-rays, on the contrary, 
she found an RBE value of only 1.1 (27). The 
difference between our study and the study of 
Mills could be due to the fact that in the study of 
Mills MCF-10A cells were grown in monolay-
er, which could influence gap-junction mediat-
ed intercellular communication. Furthermore, 
the cells were kept at 0°C some time before, 
during and after the irradiation. From literature 
it is known that hypothermia is a known radio-
protectans and has a protective role against the 
damaging effects of ROS (36, 37). Moreover, 
hypothermia could influence cell processes 
such as cellular communication. 
Overall, it seems that the bystander effect might 
induce a hypersensitive response in breast tis-
sue and that this response is dependent on radi-
ation quality, cell and tissue culture conditions 
and on temperature. 
In conclusion, our results indicate the existence 
of a hypersensitive response in the mamma-
ry epithelial cells of breast tissue in the low-
dose region induced by mammography X-rays. 
Which effects this could have on the risk calcu-
lations for mammography screening is unclear, 
since a lot of parameters will influence the re-
pair of these radiation-induced DSB. However, 
in our previous study, we have shown that the 
DSB induced by the higher LET mammogra-
phy X-rays are more difficult to repair than 
the DSB induced by γ-rays, and that the same 
number of mammography induced DSB result-
ed in a higher number of chromosomal aber-
rations (26). Thus, the low-dose hypersensitive 
response observed for DSB induction in the 
dose range representative for mammography 
screening together with the findings obtained 
with chromosomal aberration-assays at higher 
doses might suggest that also in the 0-20 mGy 
dose range more chromosomal aberrations than 
initially assumed by the LNT model will be in-
duced. 
These results are based on a small patient-pop-
ulation and a future larger study will be needed 
to confirm the obtained results. Furthermore, 
it would be interesting to include more donors 
with a BRCA-mutation and to compare the re-
pair kinetics of yHAX-foci in the group with 
and without an increased risk for breast cancer 
or investigate differences in induction and re-
pair of other DSB repair-proteins such as rad51 
between both groups. This might give a better 
indication about the damaging effects of mam-
mography X-rays in donors with and without 
an increased risk for breast cancer. 
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In vitro cellular radiosensitivity in relationship to 
late normal tissue reactions in breast cancer patients: 
a multi-endpoint case-control study
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Abstract
Purpose: A minority of patients exhibits severe late normal tissue toxicity after radiotherapy 
(RT), possibly related to their inherent individual radiation sensitivity. This study aimed to eval-
uate four different candidate in vitro cellular radiosensitivity assays for prediction of late normal 
tissue reactions, in a retrospective matched case-control set-up of breast cancer patients.
Methods: The study population consists of breast cancer patients expressing severe radiation 
toxicity (12 cases) and no or minimal reactions (12 controls), with a follow-up for at least 3 years. 
Late adverse reactions were evaluated by comparing standardized photographs pre- and post-RT 
resulting in an overall cosmetic score and by clinical examination using the LENT-SOMA scale. 
Four cellular assays on peripheral blood lymphocytes reported to be associated with normal tissue 
reactions were performed after in vitro irradiation of patient blood samples to compare case and 
control radiation responses: radiation-induced CD8+ late apoptosis, residual DNA double strand 
breaks, G0 and G2 micronucleus assay.
Results: A significant difference was observed for all cellular endpoints when matched cases and 
controls were compared both pairwise and grouped. However, it is important to point out that 
most case-control pairs showed a substantial overlap in standard deviations, which questions the 
predictive value of the individual assays. The apoptosis assay performed best, with less apoptosis 
seen in CD8+ lymphocytes of the cases (average: 14.45%) than in their matched controls (aver-
age: 30.64%) for 11 out of 12 patient pairs (p < 0.01). The number of residual DNA DSB was 
higher in cases (average: 9.92 foci/cell) compared to their matched control patients (average: 9.17 
foci/cell) (p < 0.01). The average dose response curve of the G0 MN assay for cases lies above the 
average dose response curve of the controls. Finally, a pairwise comparison of the G2 MN results 
showed a higher MN yield for cases (average: 351 MN/1000BN) compared to controls (average: 
219 MN/1000BN) in 9 out of 10 pairs (p < 0.01).
Conclusion: This matched case-control study in breast cancer patients, using different endpoints 
for in vitro cellular radiosensitivity related to DNA repair and apoptosis, suggests that patients’ 
intrinsic radiosensitivity is involved in the development of late normal tissue reactions after RT. 
Larger prospective studies are warranted to validate the retrospective findings and to use in vitro 
cellular assays in the future to predict late normal tissue radiosensitivity and discriminate individ-
uals with marked RT responses.
Introduction
The use of radiotherapy (RT) reduces the risk 
of local-regional recurrence of breast cancer 
and improves the overall survival of breast 
cancer patients after breast-conserving surgery 
or mastectomy (1, 2). The evolution of RT tech-
niques and the introduction of intensity-mod-
ulated radiotherapy (IMRT) have substantially 
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improved the morbidity among breast cancer 
patients (3-5). However, a minority of patients 
still suffers from severe adverse reactions, 
which are usually divided into acute and late 
reactions (6). During or shortly after the RT 
course, a large portion of the breast cancer pa-
tients will experience a moderate-to-severe skin 
reaction, leading to poor cosmetic outcomes (7-
9). In contrast to acute reactions, most of the 
late reactions are irreversible and occur only 
several months or even years after RT and they 
significantly reduce the quality-of-life (10, 11). 
There exists a direct relationship between ra-
diation dose and tumor control, but the severe 
normal tissue toxicity in a minority of patients 
limits the dose that can be safely prescribed 
(12). Current RT doses are generally limited 
such that less than 5% of the treated patients 
suffer from severe toxicity up to 5 years fol-
lowing RT. The development of a test to predict 
late toxicity would enable individualized radi-
ation dose prescription and would reduce the 
number of survivors suffering from the conse-
quences of treatment (13-16). 
Variation in normal tissue reactions among pa-
tients has been observed since the early days of 
RT and the individual radiosensitivity follows 
approximately a Gaussian distribution (17). 
Despite the fact that potential side effects of 
RT are well described, it remains difficult to 
predict the extent of complications for a giv-
en individual patient. Although there is clinical 
evidence that acute skin reactions are some-
times associated with the development of late 
toxicity as telangiectasia, patients who suffer 
from severe acute reactions do not necessari-
ly or predictably develop significant late reac-
tions (Lilla et al, 2007; Lopez et al, 2005). This 
finding may reflect differences in the underly-
ing mechanisms involved in the development 
of both types of reactions. The pathology of 
late normal tissue reactions in breast cancer 
patients comprises processes such as pigmen-
tation changes, atrophy, fibrosis and vascular 
damage (18).
Several factors associated with an increased 
risk of side effects in breast cancer patients 
were previously described and can be separated 
in two general categories. First, RT related risk 
factors including the total dose and additional 
boost, the irradiated volume, the fractionation 
regimen and the total treatment time (Bentzen 
et al, 2010; Deantonio et al, 2010). Secondly, 
patient-related factors may influence the risk 
and severity of late normal tissue toxicity af-
ter breast cancer treatment: age, concomitant 
chemotherapy or hormonal treatment, trauma 
or surgery in the irradiated site, co-morbidities 
involving impaired vascularity such as diabetes 
and hypertension, and breast size (9, 18, 19). 
It has been estimated that if known extrinsic 
factors are controlled, 80% of the observed var-
iation in the severity of normal tissue responses 
is due to inherent differences among the pa-
tients (20, 21). It has been suggested that the 
observed variability may be due to differences 
in genetic alterations in proteins participating 
in the radiation response. Many studies investi-
gated the association between single nucleotide 
polymorphisms (SNP) in genes with radiotoxic 
effects, but replication of the studies remains 
difficult (13, 16). The association between indi-
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vidual variation in clinical radiosensitivity and 
cellular radiosensitivity and/or genomic insta-
bility could provide a possibility to determine 
the individual sensitivity of patients in terms 
of developing severe treatment-related side 
effects (22). Several studies were initiated and 
reported to a certain extend associations be-
tween a range of cellular biomarker assays and 
clinical radiosensitivity (23-26). These assays 
use peripheral blood lymphocytes and include 
chromosomal radiosensitivity measured with 
G2 and G0 micronucleus assay, kinetics of re-
sidual DNA damage assessed by the γ-H2AX 
foci assay and radiation-induced apoptosis on 
T-lymphocyte subsets (15, 24, 27-34). Among 
those assays, radiation-induced apoptosis (RIA) 
in lymphocyte subsets after in vitro irradiation 
gives the most promising results for correlation 
with late toxicity after RT (15, 25, 33). Further-
more, more recent small studies suggest that 
the scoring of residual DNA damage by using 
the γ-H2AX foci assay may be useful for pre-
diction of reactions to RT (27, 35).
Most of the work published on cellular radio-
sensitivity endpoints was performed on patient 
cohorts taking into account the clinical radiation 
toxicity scores while ignoring therapy and pa-
tient related risk factors. To rule out the strong 
influence of these risk factors on normal tissue 
radiation effects a strict matched case-control 
set-up for these variables was used in present 
study. Breast cancer patients manifesting clear 
late radiotoxic effects and control patients 
showing no or minimal radiation effects were 
selected retrospectively and different endpoints 
for in vitro cellular radiosensitivity were evalu-
ated. Based on the existing literature, protocols 
were selected from previous studies that could 
demonstrate a correlation between a specific 
cellular assay and late normal tissue toxicity: 
RIA levels in CD8+ T-lymphocytes(36), re-
sidual number of DNA double-strand breaks 
(DSB) by means of γ-H2AX/53BP1 foci as-
say (27) and the chromosomal radiosensitivi-
ty using the G2 and G0 MN assays (based on 
our own protocols). The study was designed 
as a small scale proof of principle study on a 
well-defined cohort of case and control breast 
cancer patients in order to evaluate if cellular 
radiosensitivity assays can be of value in the 
prediction of late clinical toxicity.
Material and Methods
Patient selection
The population investigated in this study con-
sists of breast cancer patients who underwent 
breast conserving surgery, followed by adju-
vant systemic treatment and IMRT between 
2010 and 2012. The women were treated with 
a hypofractionated RT scheme (START B, 15 x 
2.67Gy) (37), followed by an additional boost 
(4 x 2.5Gy). All women were selected retro-
spectively after a follow-up period of at least 3 
years. Out of a cohort of 440 patients 12 cases 
with severe late radiotoxic effects were select-
ed and for each case, a control with minimal or 
no reaction was recruited, matching as much as 
possible the case for a number of characteristics. 
The following therapy related factors were tak-
en into account for the case-control matching: 
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boost, therapy position (supine or prone), nod-
al irradiation and adjuvant systemic treatment 
(chemotherapy, hormonal therapy and targeted 
therapy). Patients were also matched for cup 
size and BMI was also taken into account as 
much as possible. Treatment and demographic 
characteristics of the matched case-control pa-
tients are presented in Table I. A paired t-test 
showed that cup-size ranked numerically and 
BMI were not significantly different between 
cases and controls. Four of the patients fulfilled 
the criteria for BRCA1/2 analysis, but no mu-
tation was identified. Ethical approval was ob-
tained through the institutional review board of 
Ghent University Hospital and all participating 
patients signed an informed consent.
Assessment of late normal tissue reactions
A first triage of candidate-cases out of a cohort 
of 440 breast cancer patients was performed by 
comparing post-surgical photographs, under 
standardized conditions, of the patients with 
follow-up photographs (latest photographs: 2 
years after RT). Based on the comparison of 
these photographs a group of patients was iden-
tified with severe radiation-induced changes. 
From these candidate cases, the final selection 
of ‘cases’ for this study was based on the mon-
itoring and documentation of the occurrence 
of late normal tissue effects by the physician 
during follow-up examinations by using the 
breast module of the LENT-SOMA grading 
system (SOMA stands for “subjective symp-
toms, objective signs, management, and ana-
lytical measures” and LENT is an abbreviation 
for “late effects on normal tissue”) (38). The 
LENT-SOMA scores of the 24 case-control 
patients obtained three years after RT are pre-
sented in Table I. It is a comprehensive grad-
ing system in which several toxicity items are 
classified: retraction and atrophy, breast oede-
ma, ulceration, telangiectasia, post-irradiation 
fibrosis, arm lymph-oedema, pigmentation 
change and pain. Since ulceration is very rare 
and none of our patients expressed this late ef-
fect and pain is subjective, both endpoints were 
not included in Table I. Fibrosis is known to 
be slowly progressive and in our patient pop-
ulation it was fairly common. Therefore we 
decided to differentiate the fibrosis scoring in 
fibrosis of the scar area (possibly as result of 
surgery) and fibrosis outside the tumor bed. Pa-
tients were selected as ‘cases’ if an increase in 
grade of minimally 2 was observed for one of 
the LENT-SOMA endpoints when comparing 
pre-and post-RT scores. The matching ‘con-
trols’ showed minimal late effects (increase in 
toxicity score of 0 or 1). In addition, an overall 
4-categories cosmetic score was determined in 
consensus by three different observers based 
on the pre-therapy and follow-up photographs 
(1-excellent, 2-good, 3-fair, 4-poor), see Table 
I (39). 
Sample preparation and in vitro irradiation
From each patient participating in the study 
two 10 ml blood samples were collected into 
sodium heparin blood collection tubes. 3 ml 
whole blood was used for the quantification of 
residual DNA DSB in T-lymphocytes, which 
were isolated by using RosetteSep Human 
T-cell Enrichment Cocktail (Stemcell Tech-
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nologies, France). With this isolation method, 
unwanted cells are targeted for removal with 
Tetrameric Antibody Complexes recognizing 
CD16, CD19, CD36, CD56, CD66b and gly-
cophorin A on red blood cells (RBCs), result-
ing in a highly enriched population of CD3+ 
T-lymphocytes (purity assessed by flow cytom-
etry > 98%). After centrifugation and washing, 
the cells were resuspended at a concentration 
between 0.6 and 1 million cells per ml in cRP-
MI (RPMI-1640 supplemented with 1% L-glu-
tamine and 0.5% penicillin/streptomycin; all 
products Life Technologies, Belgium) contain-
ing 10% Foetal Calf Serum (FCS) (Life Tech-
nologies, Belgium). For the apoptosis assay, 0.5 
ml of the heparinized whole blood samples was 
diluted in cRPMI (1:10) containing 20% FCS. 
For the assessment of the number of residual 
DNA DSB and apoptosis scoring, the samples 
were irradiated with respectively 4 Gy and 8 
Gy x-rays (160 kV, 4mA, 3mm Al filtration; 
dose rate: 1Gy/min). The irradiated samples 
were kept at 37°C in a humidified 5% CO2 at-
mosphere incubator (Thermo Scientific, United 
States). A repair time of 24 h was considered to 
study residual DNA DSB, while apoptosis was 
scored after 48 h of incubation.
For the G0 MN assay 4.5 ml of the blood sam-
ple was aliquoted and irradiated with 60Co 
γ-rays, with 5 doses ranging from 0.2 to 3 Gy, 
in order to establish a dose response curve per 
patient. For the G2 MN assay, blood cultures 
set up from 3 ml of blood in cRPMI were in-
cubated for 72 h in the presence of the mitogen 
phytohaemagglutinin (PHA) (Gibco by Life 
Technologies, Belgium), and subsequently ir-
radiated with 4 Gy 60Co γ-rays. The irradiations 
for the G0 and G2 MN assay were performed 
at a dose rate of 0.14 Gy/min in a water bath at 
37°C. For all in vitro radiosensitivity endpoints 
sham-irradiated controls were included.
Assessment of radiation-induced apoptosis
After irradiation and incubation for 48 h, ap-
optosis was assessed in CD8+ lymphocytes. 
Apoptotic cells were determined by means of 
flow cytometry using the following panel of 
antibodies: V500-CD45, APC-CD8, Annexin 
V-FITC and 7-amino-actinomycin D (7-AAD) 
(all Becton Dickinson (BD) Biosciences, Unit-
ed States). Briefly, 100 µl of the concentrated 
cell suspension was stained with 5% V500-
CD45 and APC-CD8. After 20 min incuba-
tion in dark, red blood cells were lysed (BD 
Pharm LyseTM, BD Biosciences), incubated 
and washed with Cellwash (BD Biosciences). 
Afterwards, the pellet was resuspended in 100 
µl annexin buffer (BD Biosciences) and 5% 
7-AAD and 5% FITC-annexin V were added. 
After incubation, 400 µl annexin buffer was 
added before the samples were analyzed. Data 
were acquired on a BD FACSCantoTM II flow 
cytometer (BD Biosciences) and approximate-
ly 5000 CD8+ events were analyzed.
Assessment of residual radiation-induced 
DNA DSB
After irradiation and incubation, T-lympho-
cytes were centrifuged onto poly-L-lysine 
slides in a concentration of 600,000 cells/ml 
(VWR, Belgium). The slides were fixed in PBS 
(Sigma-Aldrich, United States) containing 3% 
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paraformaldehyde (PFA) (Sigma-Aldrich) for 
20 min and stored overnight in PBS contain-
ing 0.5% PFA. Slides were washed in PBS 
(Sigma-Aldrich) and permeabilized in PBS 
containing 0.2% Triton X-100 (Sigma Aldrich, 
Belgium) for 10 min. Thereafter, cells were 
blocked by washing them three times for 10 
min in PBS containing 1% Bovine Serum Al-
bumin (BSA) (Roche, Switzerland). Immu-
nostaining was performed by incubating the 
cells during 1 h with anti-γ-H2AX (mouse 
mAb, Biolegend) and anti-53BP1 (rabbit pAb, 
Abcam) primary antibodies diluted 1/500 in 
blocking buffer. After washing the cells three 
times in PBS containing 1% BSA, slides were 
incubated with GAM-TRITC (Sigma-Aldrich) 
and GAR-Alexa488 (Invitrogen) secondary an-
tibodies during 1 h diluted 1/1000 in blocking 
buffer. The cells were washed in D-PBS with 
1% BSA (3 times 10 min), the nuclei were 
counterstained with 2% DAPI (Sigma Aldrich) 
dissolved in Fluoromount Mounting Medium 
(Sigma Aldrich) and a coverslip was added. 
Slides were scanned using a Metafer 4 scan-
ning system (MetaSystems, Germany). This 
system uses a Zeiss Imager.Z2 microscope 
(Zeiss, Germany) and the images are captured 
by a CoolCube1 camera (Metasystems) in the 
green (TRITC, γH2AX spots), red (Alexa488, 
53BP1 spots) and blue (DAPI, nuclei) channel. 
Cells are scanned with a 63x/1.30 oil objective, 
a z-stack of 10 focal planes and a step size of 
0.35µm between planes for both the green and 
the red channel. Per experimental condition 
at least 3 different slides were scanned. The 
scanned images were coded and 50 cells per 
slide were analyzed manually on the screen. 
First, cells were selected as positives based on 
the nucleus morphology visible in the DAPI 
channel. Secondly, foci were scored by pro-
jecting TRITC and Alexa Fluor 488 sections on 
top of each other. Only foci with overlapping 
γ-H2AX- and 53BP1-spots were scored as re-
sidual DNA DSB.
G0 and G2 MN assay
For the G0 MN assay two blood cultures were 
set up (0.5 ml blood in 4.5 ml cRPMI comple-
mented with 10% FCS) per dose point immedi-
ately after irradiation and T-lymphocytes were 
stimulated by adding 100 µl phytohaemaggluti-
nin (PHA) (Life Technologies, Gent, Belgium). 
To block cytokinesis, 24 hours later 6µg/ml cy-
tocholasin B (Sigma Aldrich) was added. Cells 
were harvested 70 h post irradiation by a cold 
hypotonic shock with 0.075 M KCl, followed 
by overnight fixation in 4/1/5 Methanol/acetic 
acid/ringer solution. Subsequently, the cells 
were fixed three times in 4/1 methanol/acetic 
acid. 
The G2 MN assay with the addition of caf-
feine was performed as described in (Claes et 
al, 2013). Two blood cultures were set up with 
the addition of PHA to stimulate the T-lym-
phocytes prior to irradiation. After 72 h culture 
time the cultures were irradiated. Immediately 
after irradiation cytochalasin B (6µg/ml) and 
caffeine (Sigma Aldrich, final concentration 
4mM) were added to the cultures. 8 h post-irra-
diation the cultures were arrested and fixed as 
described for the G0 MN assay.
For further analysis, a suspension of cells 
Original research
Article 5
191
was dropped on clean slides and stained with 
DAPI Vectashield (Lab Consult). Slides were 
scanned with the MSearch software module 
of the Metafer 4 scanning system (MetaSys-
tems) as described by Willems et al. (40), us-
ing a Zeiss Imager.Z2 microscope (Zeiss) and 
a CoolCube1 camera (MetaSystems). The 
MSearch software allows automated detection 
of binucleated (BN) cells and automated scor-
ing of MN. 2 slides per culture were automat-
ically scanned with a 10X magnification and 
analyzed. The scanned gallery-images were 
coded and all BN cells were checked manual-
ly on their MN score. Per slide approximately 
1000 BN cells were scored. 
Analysis
For the analysis of the γ-H2AX/53BP1 foci as-
say, the apoptosis assay and the G2 MN assay 
the radiation-induced number of foci, apoptotic 
cells and MN, obtained by subtraction of the 
data of sham-irradiated samples, were used. 
For the analysis of the G0 MN assay data a 
dose response curve was determined for each 
patient assuming a linear-quadratic model:
 
Based on these curves the area under the 
curve (AUC) up to 3 Gy was determined for 
each patient. To quantify inherent differences 
in radiosensitivity at the 95% confidence lev-
el, ellipses have been constructed that delimit 
the covariance between cellular dose response 
parameters which represent the inherent radio-
sensitivity (α), as well as the capacity to accu-
mulate repairable damage (β) for each donor. 
The average values and variances were used 
to calculate a set of α and β coordinates that 
demarcates the 95% confidence interval (Sokal 
and Rohlf 2012). Calculations were performed 
using Matlab (Matlab R2015b). 
Unless otherwise mentioned a paired statistical 
analysis was performed using a paired t-test 
or Wilcoxon Signed Rank test, whichever was 
appropriate. When the group of cases was com-
pared with the group of controls a t-test or Rank 
Sum test was used. 
As only patients with severe late RT changes 
where selected as cases, which represent ap-
proximately 1% of non-syndromic individuals, 
only a relatively small study number was ob-
tained limiting the statistical robustness of the 
study. In order to account for this limitation, 
statistical significance was set at a p-value of 
0.01 (35).
Results
Apoptosis
With the combined use of Annexin V and 
7-AAD only the late apoptotic cells were 
scored. In early stages of apoptosis, the plasma 
membrane excludes viable dyes such as 7-AAD 
(specific for double-stranded DNA) and cells 
will only be positive for Annexin V. During late 
stage apoptosis, loss of cell membrane integrity 
allows Annexin V binding as well as uptake of 
7-AAD. A representative example of the flow 
cytometry analysis is presented in figure 1. 
The effect of radiation exposure on the propor-
(1)
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tion of apoptotic cells is clearly illustrated in 
the data plots. For this analysis, we have first 
drawn gates for the selection of CD8+ T-lym-
phocytes (see figure 1 – c), and thereafter, a fur-
ther selection was made based on the forward/
side scatter (FSC and SSC) and the position in 
de CD45+ plot (figure 1 – a & b). A paired sta-
tistical analysis indicated significantly less ap-
optosis in the cases compared to their matched 
controls (p < 0.001). However, case 11 displays 
a higher apoptosis level than her matched con-
trol and the overlapping error bars for 4 of the 
matched pairs necessitate a large prospective 
set-up to assess the predictive value of the 
assay. Grouped analysis illustrates that cases 
(average 14.45% apoptosis) have significantly 
lower apoptotic responses than controls (aver-
age 30.64% apoptosis) (p < 0.0001) (figure 2).
Residual DNA DSB
Foci representing residual DNA DSB were 
only scored when γ-H2AX- and 53BP1-spots 
overlap (approx. 90% of the spots overlap, see 
(41)) as observed on the Metafer system after 
scanning at 63X magnification (figure 3). The 
scoring of γ-H2AX/53BP1 co-localized foci 
increases the reliability that the observed spots 
are indeed DNA DSB and enhances the sensi-
tivity of foci scoring by reducing the impact of 
artifacts and false positives. A pairwise com-
parison showed a significantly higher number 
of foci for the cases compared to the controls 
(p<0.01). However, case 1 scores lower than 
her control and 9 out of 12 matched pairs show 
overlap in error bars which gives this assay 
only a modest strength to predict normal tissue 
radiosensitivity in a predictive set-up for breast 
cancer patients (see figure 4).
When cases and controls are compared as 
groups, the cases (average 9.92 foci per cell) 
have a significantly higher number of foci than 
the controls (9.17 foci per cell) (p < 0.01) (fig-
ure 4).
G0 MN assay
The cases (average age 68y) have a significant-
ly elevated number of background MN com-
pared to their matched controls (average age 
57y), respectively 50 and 36 MN per 1000 BN 
cells (p = 0.025). When compared to a healthy 
control group of 29 adult donors (the group 
consists of healthy donors at the laboratory 
since 2010; average age of 48 years; 63% fe-
male) with an average of 15 MN per 1000 BN 
cells, the patient group has an elevated number 
of background MN (Rank sum test p < 0.0001). 
The individual data of all patients showed a 
linear-quadratic dose response with weight-
ed regression fits resulting in high R2 values 
(range: 0.959 – 0.999). A comparison between 
the linear quadratic fits of the average dose 
response data of cases and controls, represent-
ed in figure 5, shows clearly that average MN 
yields are systematically higher for cases than 
controls for each dose point. In the insert of fig-
ure 5, the ellipses giving the 95 % confidence 
intervals on the α and β values of the fits to the 
group of cases and controls are depicted: α as 
well as β are higher for cases than controls. The 
ellipses do not overlap, indicating that the dose 
responses of the average case and control data 
are significantly different. For the individual 
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FIGURE 1 
Flow cytometry data analysis of apoptosis in CD8 T-lymphocytes, 48 h post irradiation with 8 Gy x-rays. Cells were first gated on CD8+ 
marker expression displayed in APC (c). Thereafter cells were gated on cell size and granularity on the FSC/SSC data plot (a) and there positive 
staining for CD45+ displayed in HV500 was checked. Eventually Annexin V/7-AAD positive cells were selected in the upper right quadrant of 
data plot presented in (d). The left column illustrates the results for a non-irradiated sample with low late apoptosis levels (2.0%) versus the 
results for an irradiated sample with a remarkable increase in late apoptosis levels (18.9%).
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FIGURE 2
Percentage of cells with radiation-induced late apoptosis in each of the cases (dark grey bars) and controls (white bars). The average of all 
cases (dark grey triangle) and controls (white triangle) with the corresponding spread in data points, is represented at the right end of the 
graph. The horizontal line represents the average over all patients (cases and controls). The error bars represent standard deviations based 
on multiple replicates (generally three, but for some of the measurements only two samples were available). 
FIGURE 3
Illustration of γ-H2AX/53BP1 foci staining, with the blue DAPI stained nuclei of the T-lymphocytes and overlapping green 53BP1 and red 
γ-H2AX foci. The left figure represents a sham-irradiated sample, while the right figure represents the number of residual γ-H2AX/53BP1 
foci 24h post irradiation at 4 Gy x-rays.
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   FIGURE 4 
Number of radiation-induced γH2AX/53BP1 foci per cell in cases (dark grey bars) and controls (white bars). The average of all cases (dark 
grey triangle) and controls (white triangle) with the corresponding spread in case and control γH2AX/53BP1 foci values are represented at 
the right end part of the graph. The horizontal line represents the average over all patients. The error bars represent standard deviations 
based on the scoring of at least three different slides. 
case-control patient data, ellipses also do not 
overlap in 10 out of 12 pairs. There is however 
no systematic shift in the location of the ellipse 
from case to control on an individual basis, in-
dicating that the change in α and β values of 
the individual patient dose response are not di-
rectly correlated with the clinical radiotoxic ef-
fects. A Wilcoxon Signed Rank Test including 
all dose-points showed a significant difference 
between the average case and control MN data, 
presented in figure 5 (p < 0.001). 
For the interpretation of the dose response 
curves at the individual case-control pair level 
the AUC of the dose response up to 3 Gy was 
calculated. Using this quantity 10 out of 12 cas-
es scored higher than their matched control (p = 
0.01), however 6 of the 12 pairs show overlap 
in standard deviations (figure 6). For the MN 
data at a single dose-point, differences in radia-
tion-induced number of MN between cases and 
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FIGURE 5
Dose-response curve for the average number of radiation-induced MN per 1000 BN cells for cases (grey circles) and controls (white circles). 
The dose-response curves are the result of fits using a weighted linear-quadratic regression. In the insert the 95% confidence ellipses for the 
α and β coefficients of the average dose-response curves for cases (grey dots) and controls (white dots) are given.
matched controls were found to be statistically 
different at the p 0.05 level from 1 Gy upwards 
(p1Gy = 0.04; p2Gy = 0.021; p3Gy = 0.018). 
G2 MN assay
A very low binucleated index resulted in a very 
low number of binucleated cells for case 10 
and control 2, which were excluded from the 
analysis. In a pairwise comparison, MN scores 
in the cases were significantly higher than the 
MN yields in the matched control (p < 0.01). In 
9 out of 10 patient pairs, the cases score higher 
than their matching controls (figure 7). Howev-
er, 4 out the 10 pairs show a substantial overlap 
in standard deviation. 
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FIGURE 6
The AUC calculated from the G0-MN dose-response curve for each of the cases (dark grey bars) and controls (white bars). The average of all 
cases (dark grey triangle) and controls (white triangle) and the corresponding spread in case and control AUC values is represented in the 
right part of the graph. The horizontal line represents the average over all patients. The error bars represent standard deviations based on 
the scoring of four different slides per dose point. 
A group analysis showed that the G2 MN yield 
in the group of cases (average 351 MN per 
1000 BN cells) was significantly higher than 
in the group of controls (average 219 MN per 
1000 BN cells) (p < 0.01).
Discussion
In present study the individual cellular ra-
diosensitivity of breast cancer patients who 
expressed severe versus minimal late toxici-
ty after RT was compared in a retrospective 
case-control setting using four different assays. 
The selection of the different cellular radiosen-
sitivity assays was based on existing literature 
and protocols previously used by other research 
groups who were able to successfully show a 
good correlation between in vitro cellular ra-
diosensitivity and late normal tissue reactions 
in cancer patients. An accurate selection of 
patients showing severe late radiotoxic effects 
at the follow-up examinations by the radiation 
oncologist is a prerequisite for the quality of 
this kind of studies. The latter determines the 
strength of the current study as patients were 
carefully assessed for late toxicity and matched 
into case-control pairs. Therefore, this study 
cohort of patient outliers (only no/minimal re-
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sponders and severe responders) could be used 
for this proof of principle study to evaluate 
and estimate the possible clinical value of four 
different radiosensitivity assays to predict late 
normal tissue toxicity following RT. 
Late toxicity is a broad term that includes 
multiple endpoints. In present study, patient’s 
toxicity score was based on the LENT-SOMA 
scale and an overall breast cosmetic score was 
derived from standardized photographs with a 
4-categories cosmetic score as proposed by the 
Harvard Medical School (Table I) (38, 39, 42). 
Patients were selected as cases based on the cri-
terion that the LENT-SOMA score three years 
after RT was increased by 2 compared to pre-
RT for at least one endpoint. This corresponded 
with an overall cosmetic score of 3 or 4 for all 
patients, except for case 11. The latter patient 
was included based on a grade 2 fibrosis score 
in LENT-SOMA. The overall cosmetic score 
focuses on cosmesis and unfortunately, fibrosis 
as such is not taken into account, resulting in 
a cosmetic score of only 2. Scoring of retrac-
tion in this patient population who underwent 
breast conserving surgery was not obvious, as 
this endpoint depends strongly on the volume 
of tissue removed during surgery. This is for 
example a problem in control 11, who had a 
FIGURE 7 
Number of radiation-induced G2 MN per 1000 BN cells in each of the cases (dark grey bars) and controls (white bars). The average of all 
cases (dark grey triangle) and controls (white triangle) and the corresponding spread in case and control G2 values is presented in the right 
part of the graph. No results were available for two patients owing to low BN yields (control 2 and case 10). The horizontal line represents 
the average over all patients. The error bars represent standard deviations based on the scoring of four different slides per dose point. 
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lot of tissue removed during surgery, resulting 
in a high cosmetic score of 3 (fair) and a high 
retraction score of 3 before RT, but no further 
RT-related changes were detected during fol-
low-up. By matching the controls as much as 
possible to the cases for therapy variables, cup-
size, BMI and age, we obtained a case-control 
with minimal impact of variables, known to be 
associated with radiotoxicity. 
The observation that normal tissue damage can 
involve a combination of phenotypes suggests 
that their underlying cellular mechanisms may 
be different (43). The identification of these 
mechanisms could help in clinical response 
prediction, however current literature reports 
are very mixed and confusing. A first study 
that we have to highlight is the study of Fin-
non et al. who used gene expression in addi-
tion to in vitro cellular endpoints similar to the 
assays used in the current study (34). In their 
study on breast cancer patients, 31 cases with 
late normal tissue reactions were matched with 
28 control patients who showed no changes 
in breast appearance. Matching of case-con-
trol patients was also based on RT parameters, 
breast size and adjuvant therapy. Significant 
inter-sample variation was observed for all cel-
lular endpoints, but cases and controls could 
not be distinguished with the different in vitro 
radiosensitivity assays. This difference in study 
results compared to our study may be attrib-
uted, at least in part, to different experimental 
conditions. Finnon et al. used a radiation dose 
of 4Gy x-rays and frozen lymphocytes to as-
sess radiation-induced apoptosis levels, the 
used γ-H2AX flow cytometric assay is not as 
sensitive as the fluorescence microscopic scor-
ing method, used in our study and G0 MN were 
scored for 3.5 Gy x-rays while we used a 5 
point dose response ranging from 0.2 to 3 Gy.
Of all studies on the association between cel-
lular radiosensitivity and normal tissue reac-
tions, the apoptosis assay gives the most im-
pressive and promising results. The decreased 
intrinsic ability to recognize cell damage and 
subsequently initiate apoptosis, is one of the 
proposed mechanisms for patients experienc-
ing late toxicity. Due to the lack of repair or 
removal, the damaged cells linger in the irra-
diated breast tissue or cause genetic damage to 
daughter cells, resulting in late toxicity (15). 
Previous studies showed altered apoptotic pro-
files after in vitro irradiation with doses up to 
8 Gy in patients with increased radiotoxicity 
in various cancer patient cohorts (15, 32, 44, 
45). In a large scale study of patients treated 
for miscellaneous cancers Ozsahin et al. could 
demonstrate a reduced apoptotic response in 
CD4+ and CD8+ lymphocytes after an in vitro 
dose of 8 Gy in patients experiencing radia-
tion-induced toxicity (25). According to these 
authors the CD8+ subpopulation is more sen-
sitive and specific than CD4+ T-lymphocytes. 
Based on the promising results of Ozsahin et al. 
we adopted the irradiation protocol described 
in this paper and we scored CD8+ T-lympho-
cyte apoptosis after an in vitro dose of 8 Gy. 
The results obtained in present study confirm 
the value of apoptosis scoring as cellular assay 
in the prediction of late toxic effects in breast 
cancer patients. However, despite the fact that 
11 out of 12 cases showed lower apoptosis 
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scores compared to their matched control pa-
tients and the observed statistical significance 
for both paired and grouped analysis, there was 
a substantial overlap in standard deviations 
which may hinder the successful translation 
of this assay into clinical practice. In a small 
breast cancer cohort study of Chua et al. the 
average apoptotic fraction after 8 Gy was not 
different for the population of 8 cases with se-
vere late radiotoxic effects compared to 8 con-
trols and this when apoptosis was measured in 
both the total lymphocyte population and the 
CD4+ and CD8+ T-lymphocyte subsets (27). 
In the latter paper, radiation-induced apoptosis 
was assessed using an inhibitor of caspases as-
say (FLICA) while in our study late apoptosis 
was scored by means of Annexin V and 7-AAD 
staining. Measurement of apoptosis after in vit-
ro doses lower than 8 Gy often failed to find 
a correlation with clinical radiation sensitivity 
(15, 34, 46). Furthermore, the use of T-lympho-
cyte subsets for apoptosis scoring is still a con-
troversial issue in the literature. For example, 
Schnarr et al. could find a statistical significant 
difference between cases (38.0%) and controls 
(33.6%) after 8 Gy irradiation for the total 
lymphocyte population. However this obser-
vation could not be made for either the CD4+ 
or CD8+ lymphocyte subsets (15). The authors 
suggest that another lymphocyte population 
(CD4-/CD8-) could affect their findings.
The detection of residual γ-H2AX/53BP1 foci 
24 h post irradiation is a sensitive method to 
determine the number of residual DNA DSB. 
It is generally accepted that the disappear-
ance of foci is representative for the repair of 
DNA DSB while persistence of foci indicates 
impaired DNA repair (35, 47). We know from 
studies on ataxia telangiectasia (AT) and other 
chromosomal breakage syndrome patients that 
their underlying genetic defect in DNA DSB 
repair results in extreme clinical and cellular 
hypersensitivity to ionizing radiation (48, 49). 
It is anticipated that differences in residual foci 
levels are indicative for significant differences 
in DSB repair, however, the assay doesn’t pro-
vide information on the underlying mechanism 
for this difference. Studies on the relationship 
between the number of residual DNA DSB in 
lymphocytes after in vitro irradiation and clin-
ical radiotoxicity published are contradictory. 
In our study we could observe a positive cor-
relation between residual γ-H2AX/53BP1 foci 
levels 24 h after 4 Gy x-rays and late normal 
tissue toxicity, both at individual case-control 
level (p<0.01) and group level (p<0.01). The 
results are in agreement with those reported 
by Chua et al. (31) using the same protocol for 
breast cancer patients and indicate the potential 
of the γ-H2AX/53BP1 foci assay for the pre-
diction of late normal tissue reactions. In the 
study of Chua et al. average foci levels per cell 
24 h after 4 Gy x-rays were 12.78 in cases and 
10.15 in controls compared to respectively 9.92 
and 9.17 in the current study. On the contrary 
different studies could not find an association 
between residual DNA damage and severe late 
toxicity, such as Werbrouck et al. in a cohort of 
gynecological cancer patients and Brzozowska 
et al. in prostate cancer patients (50, 51). 
While significant differences were observed 
between cases and controls, we could not find a 
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correlation between apoptosis levels 48 h after 
8 Gy in CD8+ T-lymphocytes and residual foci 
levels 24 h after 4 Gy in T-lymphocytes (Spear-
man’s R = 0.284, p = 0.178). This confirms ear-
lier observations made by Chua et al. (27).
Cytogenetic assays, such as the MN assay, are 
frequently used to evaluate the damage re-
sponse of the cell to radiation-induced DNA 
damage and to assess radiosensitivity in vitro. 
The elevated background number of MN ob-
served in the patient group (42 MN/1000 BN 
cells) compared to a healthy population (15 
MN/1000 BN cells) is significant (p<0.0001), 
even after correction for age and gender dif-
ferences (males 0.31 MN/1000 BN cells/year; 
females 0.58 MN/1000 BN cells/year) (52-54). 
An elevated number of spontaneous MN or 
chromosomal aberrations in cancer patients has 
been reported by different research groups (55-
58) and is considered to be a hallmark for can-
cer and chromosomal instability. However, in 
this study, the residual effect of RT can also be 
the cause of the higher spontaneous MN yields 
(59), as MN disappear from the body gradual-
ly with a half-life of approximately 1 year (60, 
61). There is also a difference in background 
MN numbers between the case (50 MN/1000 
BN cells) and control group (36 MN/1000 BN 
cells) (p = 0.025). Correcting the MN data for 
the age difference between cases (average age 
68 years) and controls (average age 57 years) at 
a rate of 0.58 MN/1000 BN cells/year reduces 
strongly the difference and renders the differ-
ence statistically not significant. 
Different studies of various cancer patient co-
horts have investigated the correlation between 
the number of chromosomal aberrations (dicen-
trics or MN) induced after in vitro irradiation 
of lymphocytes and late normal tissue toxicity 
to RT, with varying success (29, 34, 62-65). 
Specifically for breast cancer patient cohorts 
some studies report a positive association (31, 
66), while others don’t (24, 34, 67). Factors 
as definition of the groups, the selected cellu-
lar endpoints and differences in experimental 
setup might account for the lack of consisten-
cy in the results. Compared to these studies we 
used a case-control setting with matching of the 
most important variables. Furthermore, instead 
of analyzing one dose point, we determined a 
dose response relationship (0 to 3 Gy) for each 
patient with the G0 MN assay. 
Distinct differences in the average dose re-
sponse curves between both groups are ob-
served. Fitting linear-quadratic functions to the 
dose response data results in α and β values 
which are different at the 95% confidence level. 
This is illustrated by the 95% confidence ellip-
ses, depicted in figure 5, which are clearly sep-
arated for both groups. For the interpretation of 
the individual case-control pairs, the AUC for 
the dose response curves up to 3 Gy was used 
which showed a statistically significant differ-
ence between cases and controls (p = 0.01).
In this study we also applied a G2 MN assay 
(47) to study the association with clinical ra-
diotoxicity. Up to now application of the G2 
assay with scoring of chromatid breaks in lym-
phocytes was unsuccessful in the prediction of 
radiotoxicity in breast cancer patients (34, 66, 
67). In the G2 MN assay we used in this study, 
cells are irradiated in the G2 phase and caffeine 
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is added to abrogate the G2/M checkpoint (68, 
69). The use of caffeine on G2-cells will al-
low heavily damaged and yet unrepaired cells, 
which would otherwise be blocked at the G2/M 
checkpoint, to progress through mitosis. This 
allows us to analyze differences in individual 
repair efficiency independent from differences 
in individual cell cycle control (70, 71). Apply-
ing the G2 MN assay on the patient groups in 
present study results in a significantly higher 
number of MN in cases compared to controls 
(p<0.01). This could indicate that the develop-
ment of late normal tissue toxicity following 
RT is associated with a less efficient DNA re-
pair.
When comparing the performance of the dif-
ferent in vitro cellular radiosensitivity assays to 
distinguish patients with severe radiotoxic ef-
fects in present case-control setting, all assays 
perform relatively well and highlight most cas-
es in the paired setting (Table I). However, it is 
important to note that some of the case-control 
pairs show substantial overlap in standard devi-
ations, which questions the value of the assays 
in clinical RT practice. The results presented in 
this study, serve to strengthen the evidence for 
an association between lower levels of radia-
tion-induced CD8+ apoptosis, increased levels 
of residual DNA damage and chromosomal 
radiosensitivity with severe normal tissue re-
actions following RT. However, the case-con-
trol pairs for which no correlation was found 
between in vitro and in vivo radiosensitivity 
differ for the different assays, showing that the 
failures are not linked to a systematic differ-
ence in intrinsic radiosensitivity. The lack of 
correlation between the different in vitro cellu-
lar radiosensitivity assays may be linked to the 
different radiation doses and time points, which 
were based on previously published studies se-
lected for the different assays. 
In order to overcome the limitations of the cur-
rent study, the different culture conditions and 
radiation doses used in the four assays should 
be further optimized and aligned with each oth-
er. It is anticipated that a number of cells will 
die and disappear during culturing, so it would 
be interesting to test the influence of the dif-
ference in radiation dose, culture condition and 
time point by comparing the total number of 
cells after irradiation with the same samples 
prior to irradiation. The different endpoints 
can be compromised by parallel processes in-
herent to the different methodologies and this 
could theoretically impact the predictive value 
of the used assays in identifying breast cancer 
patients prone to late toxicity.
In a predictive scenario with a large patient pop-
ulation, apoptosis seems to be the most prom-
ising assay of the four different tests used in 
this study. When using the average value of the 
endpoint over the whole patient population as 
threshold value only control 2 scores below the 
average apoptosis value of 22.5% and case 11 
would erroneously be categorized as a non-ra-
diosensitive patient (see figure 2). The current 
study comprised only high and low outliers with 
respect to expression of late normal tissue reac-
tions of the total group of breast cancer patients, 
which does not allow to determine a robust cut-
off value. Large scale prospective studies on RT 
patients are necessary to fill this gap.
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In conclusion, present study of RT breast can-
cer patients using a matched case-control setup 
and different endpoints for assessing in vitro 
cellular radiosensitivity, related to DNA repair 
and apoptosis, suggests that patient’s intrinsic 
radiosensitivity is involved in the development 
of late radiotoxic effects. As the biological 
mechanisms behind the different symptoms of 
late radiotoxicity differ, it can be expected that 
not all clinical manifestations of late radiotox-
icity are linked in the same degree to intrinsic 
radiosensitivity with respect to DNA repair and 
apoptosis. Finally, of the four radiosensitivity 
tests applied, the apoptosis assay seems to be 
most promising in the framework of predicting 
radiotoxic effects in individual patients. How-
ever, the large variation in the data set as reflect-
ed in overlapping standard deviations, warrants 
further research to validate the findings for the 
different cellular radiosensitivity assay in larg-
er patients groups and prospective studies. The 
results of this study can be used to demonstrate 
a possible association between intrinsic radio-
sensitivity and late normal tissue toxicity, but 
confounding experimental variables should be 
taken into account in future association studies 
in order to investigate a possible correlation be-
tween the different biological end points.
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1  Biological efficiency of 
 different radiation qualities
Technological advances in radiotherapy such as IMRT or IPRT and the use of particle radiothera-
py resulted in a maximum dose deposition to the tumor and a reduction of dose to healthy tissue. 
However, some degree of normal tissue injury is still inevitable. High-LET radiotherapy, using 
neutrons or carbon ions, provides a successful approach to treat cancer, where cell killing is the 
main objective. Furthermore, in space travel and airplane traffic, high-LET radiation is critical. 
However, high-LET radiation-induced damage seems to induce a different cellular response than 
low-LET radiation. Reports show that for instance DNA repair pathways, apoptosis and gene 
expression are activated in a different way by high-LET radiation compared to low-LET radiation 
(1). This emphasizes the need for further research into the effects of high-LET radiation. 
1.1 Fast neutrons
Neutrons can have different energies, ranging from 0.0-0.025 eV (cold neutrons) to more than 200 
MeV (ultrafast neutrons) and the ionization density of neutrons varies extensively as a function of 
neutron energy, hence the RBE of neutrons is dependent on their energy. 
Neutrons are used at different radiotherapy facilities around the world among which are Fermilab, 
Washington University and the Karmanos Cancer Center in the USA, iThemba Labs in South 
Africa and different centers in Germany, Japan and Russia (2, 3). Furthermore, their energy dep-
osition pattern is comparable to that of carbon ions and as such neutrons can be used as a model 
system to predict the effects of carbon ion beam radiotherapy (2) (see figure 1.1). Also in space 
their impact is important, the interactions of charged particles and very high energy γ-rays with 
the fuselage of the aircraft cause a shower of neutrons of different energies. 
In light of the very important issue of the astronaut radiation burden, which is at the moment one 
of the important restrictions for long time travel in space and the effects of radiotherapy on healthy 
and cancerous tissue it is important to study the biological effects of neutrons. 
All neutron-experiments in this thesis were done in collaboration with iThemba Labs in South 
Africa. p(66)+Be(40) neutrons were used, which have an energy of 29 MeV and a LET of 20 kev/
µm. They belong to the so called ‘fast neutrons’, which range in energy between 15 MeV up to 
200 MeV. 
In all papers used for this thesis, γ-rays were used as reference radiation. Also in the literature 
referred to, γ-rays were used as reference radiation unless specifically stated otherwise. 
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FIGURE 1.1
Variation of the RBE as a function of the LET for different types of clinical radiation beams (2). 
1.1.1 Induction and repair of γH2AX foci induced by fast neutrons
The phosphorylation and dephosphorylation of the histone H2AX is a key process in DNA DSB 
repair (see introduction 2.3 and 5.1) and immunostaining of γH2AX can be used to quantify the 
number of DNA DSB.
In our study performed on lymphocytes (article 1), we found an RBEM value, which is the maximal 
RBE and is found by extrapolation of the low-dose behavior to zero, for the induction of γH2AX 
foci of 0.70 (4). No other reports on foci induction by fast neutrons have been published. Antonel-
ly et al found a comparable RBE-value for γH2AX induction in human foreskin fibroblasts (HFF) 
after irradiation with carbon ions (5). This fits well with the reports stating that carbon ions have 
a comparable energy deposition pattern as neutrons (see figure 1.1) (2). 
Our results are in accordance with other studies that report that high-LET RBE values, based on 
DSB induction, are equal or lower than unity (6-12). 
Studies investigating the γH2AX foci showed that high-LET radiation-induced foci are larger 
and have a higher staining intensity than low-LET radiation-induced foci (5, 6, 12). Furthermore, 
high-LET radiation-induced foci increase in size up to 2h after induction, while low-LET radia-
tion-induced foci remain constant in size (12). 
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The high ionization density of neutrons and other high-LET radiation qualities produces ‘complex 
damage sites’ (13), which can consist of base lesions, SSB and DSB in very close proximity (14-
20). These complex damage sites can also contain multiple DSB (21). This can explain why the 
RBE for high-LET radiation is equal or lower than unity. Furthermore, the high-LET induced foci 
are larger, which can be caused by a merger of different foci into DNA repair centers (22-25), or 
the large foci can consist of different smaller foci, which overlap and visually form one focus (5, 
12, 23). The large foci which merge or overlap can also explain the low RBE values. 
In article 1 we found that the foci induced by neutrons disappeared slower than those induced by 
γ-rays. Less foci were induced 30 minutes following irradiation by neutrons compared to γ-rays, 
however, 4 hours after irradiation, the number of foci was the same irrespective of the radiation 
quality. At later time-points after irradiation, the number of foci remained higher after neutron 
irradiation compared to γ-irradiation. 24h after irradiation 25% of the neutron-induced foci were 
persistent compared to 12% of the γ-induced foci (4). These results are very similar to the results 
published for carbon ions (5), where a slower repair and higher number of resistant foci after 24h 
were also noted. 
In literature it has been reported that high-LET radiation-induced foci disappear much slower than 
low-LET induced foci (4, 5, 26). 4 to 24 hours after irradiation, a higher number of repair-foci can 
be found after high-LET irradiation compared to lower LET radiation (7, 26-28) and the complex 
damage sites containing DSB, single strand breaks and base damage in very close proximity, 
result in the most persistent foci (29). Also other assays based on the number of DSB, such as 
pulsed field gel electrophoresis (PFGE) and PCC, confirm that high-LET radiation-induced DSB 
disappear with slower kinetics compared to low-LET induced DSB (30-34). The slower rate of 
disappearance and the fact that the most persistent foci contain the most complex damage sites, 
indicate that the large and more intensely stained foci are indicative of complex breaks rather than 
a visual overlap of smaller foci. 
1.1.2  Chromosomal aberrations (MN-assay) and cell proliferation (CV cell proliferation assay)
Misrepaired or unrepaired DSB can lead to chromosomal aberrations, which in turn can underlie 
tumorigenesis and cell dead. Assays based on chromosomal aberrations, like the micronucleus 
assay, translocation or dicentric assay, are good biomarkers for radiation exposure and cancer risk 
assessment (35-39).
With the MN assay we found an RBEM of 3.9 in lymphocytes irradiated with neutrons in the G0 
phase of the cell cycle (Article 1). In article 2 we used mammary epithelial cells (MCF-10A cells) 
which were synchronized in the G1 phase of the cell cycle and found an RBEM value of 4.90 for 
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CON
BRCA
 and 6.9 for CON
Ku70
1. These values are in good agreement with the values of 4.8 and 5.3 
found for the in vitro irradiation of lymphocytes reported by Slabbert et al with the same neutron 
beam (40, 41). Vral et al reported an RBEM of 7.6 in G0 lymphocytes irradiated with 5 MeV neu-
trons (42). Our reported RBEM-values in lymphocytes are lower, which can be due to the higher 
energy of the neutrons used in this study (29 MeV) and are in agreement with what is reported by 
the ICRP (43). 
The RBEM values obtained with the CV cell proliferation assay on MCF-10A cells synchronized 
in G1 (RBEM 2.52 and 2.45; article 2) are lower than those obtained with the MN assay. This can 
be explained by the fact that different end-points are considered: the MN assay focuses specifical-
ly on chromosomal aberrations, while the crystal violet proliferation assay focuses on the ability 
of the cells to proliferate. In general, RBEM values based on chromosomal aberration results are 
systematically higher than those based on cell proliferation assays. 
Assays based on chromosomal aberrations, like the micronucleus assay, translocation or dicentric 
assay, show an incline in RBE value consistent with rising LET-values for high-LET radiation up 
to approximately 100 -200 kev/µm (44), at higher LET the RBE will drop again due to overkill. 
The value of 100-200 kev/µm is however dependent on the cell type and end point used, and can 
be higher for more radioresistant cells (45). 
From the data above, it is clear that, compared to γ-rays, fast neutrons induce a lower number of 
DSB γH2AX foci (RBE <1) which result in a higher number of chromosomal aberrations (RBEMN 
>4), due to mis- or nonrepaired DSB. The complex damage sites induced by the neutrons are more 
difficult for the cell to process correctly and each neutron-induced focus will give rise to more 
chromosomal aberrations than each γ-induced focus (see figure 1.2). Different suggestions why 
these clustered lesions are more difficult to repair have been put forward in the literature. The clos-
er spatial distribution of the DSB makes it more likely for break-termini to be reattached wrongly 
(46, 47). Furthermore, the complexity of the damage delays the processing of the base damage and 
single strand breaks and leads to conformational changes in the DNA which seem to interfere with 
the ability of the repair proteins to bind (29, 48-50). It has been suggested that unrepaired clusters 
of non-DSB DNA damage may generate additional DSB, which can, if unrepaired, lead to even 
more mutations and chromosome abnormalities (51, 52). The slower repair might furthermore ag-
gravate the possibility of misrepair, the longer a break-end stays open, the longer they are reactive 
and available for misrepair (53). 
1  CONBRCA and CONKU70 are two mock-transduced MCF-10A cell lines which are used as control cell lines. For further infor-
mation, see article 2.
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FIGURE 1.2
Radiation-induced MN as a function of radiation-induced γH2AX-foci (30’ after irradiation) for neutrons ( ) and γ-rays ( ). 
Figure based on data obtained in article 1. 
1.2 Mammography X-rays
1.2.1 RBE of mammography X-rays 
30kV X-rays (mammography X-rays) are considered low-LET radiation and the International 
Commission on Radiological Protection (ICRP) still recommends the use of radiation weighting 
factor of 1 for mammography X-rays (54). However, there is general consensus that they are 
qualitatively different from γ-radiation. Mammography X-rays are low-energy X-rays with a peak 
and mean photon energy of typically 28-30 keV and 15-20 keV, compared to 60Co γ-rays which 
have a high energy of approximately 1.25 MeV. Their low energy causes them to lose their energy 
rapidly, resulting in a denser ionization pattern (LET 4.34 keV/µm) compared to 60Co γ-rays (LET 
0.3 keV/µm) and to a certain extent they can be compared with high-LET radiation qualities. 
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In light of mammography-screening programs, in which a large group of asymptomatic women 
receive periodically small doses of radiation to the breast, it is important to demonstrate that the 
benefits, arising from reduced mortality due to early diagnosis exceeds to a large extent any po-
tential risk arising from future radiation-induced breast cancers. Although there are several ways 
to assess benefit/risk ratios, a simplified approach is to calculate the breast cancer detection over 
induction ratio (DIR). These calculations are essentially based on performance data of breast 
screening programs, breast radiation doses and cancer induction risk factors (54-56). Although 
such calculation models are subject to a certain degree of statistical uncertainty, they can be used 
to assess benefit/risk taking into account that the number of breast cancers detected must exceed 
the number of induced cancers to a significant extent. Since DIR-values are used to justify low 
doses of low energy radiation exposures to a large asymptomatic population it is necessary to 
have a correct estimation of the RBE of 30 kV X-rays, since this is used for the calculation of the 
cancer induction risk. 
In article 3 we studied the RBE of mammography X-rays in lymphocytes and found an RBE-value 
for the induction of γH2AX foci of 1.36 (57). In our study on mammary epithelial cells present 
in breast tissue (article 4) we found an RBE of 1.2 (58). These RBE values are in agreement with 
literature, were RBE values between 1.1 and 1.4 with γ-rays as reference radiation have been 
published (59, 60). They are also in the same range as theoretical calculations and simulations, 
which point to an RBE between 1.3 and less than 2 (61-63). It seems that mammography X-rays 
are slightly more efficient in inducing DSB than γ-rays. 
In light of differences in radiosensitivity between tissues, we studied the RBE of mammography 
X-rays in mammary epithelial cells present in dissected breast tissue (article 4). It is interesting 
to confirm that the RBE values which have been obtained in human fibroblasts, peripheral blood 
lymphocytes and MCF-10A’s, are in line with the RBE-value of 1.2 that we found for DSB-induc-
tion in ex vivo irradiated breast tissue (58). 
RBE values between 1.2 and 1.4 for foci induction by 30kV X-rays seems to be in contradiction 
with the RBEfoci <1 after high-LET radiation. However, while the LET of 30 kV X-rays is higher 
than the LET of γ-rays (respectively 4.3 and 0.3 keV/µm), it is considered low-LET and it’s LET 
is considerably lower than the LET of e.g. neutrons (20keV/µm) (see introduction table 1.1 for 
more examples of high and low-LET values). 
Compared to γ-rays, 30kV X-rays will produce ionization tracks which are more dense, by which 
the chance of one ionization track producing two or more SSB in close proximity leading to a DSB 
is higher compared to γ-rays (17). The density of the ionization tracks is however not high enough 
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to induce the complex damaged sites and related RBE values lower than unity as are obtained with 
high-LET radiation. 
Furthermore, for a given number of DSB induced by 30 kV X-rays or γ-rays a higher number of 
MN was obtained after irradiation with 30 kV X-rays compared to 60Co γ-rays (see figure 1.3). 
This implies that mammography X-rays not only induce more DSB compared to γ-rays but also 
that DSB arising from 30 kV X-rays are more difficult to repair, probably because of the density of 
the ionizations (57). This resulted in a higher RBEM-value of 4 for MN induction in lymphocytes. 
FIGURE 1.3 
Radiation-induced MN as a function of radiation-induced γH2AX-foci for 30 kV X-rays ( ) and γ-rays ( ). Figure from article 3. 
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Although different studies investigating the RBE of low energy X-rays by means of cytogenetic 
assays and neoplastic transformation have been published, comparison is difficult due to differ-
ences in the physical characteristics and energies (25-50kV) of the X-rays, the reference radiation 
quality, the cell type and cytogenetic assay used. Especially he quality of the reference radiation 
seems to play a big role in assessing the RBE value and can explain the apparent discrepancy be-
tween sets of RBEM values. For instance, with the dicentric assay an RBEM value of 2.1 has been 
reported for 220 kV X-rays using γ-rays as reference radiation (64). 
Using 200 kV X-rays as reference radiation, RBEM values for 30kV X-rays vary from 1.2 to 1.7 
with MN or dicentrics as endpoint (65-68). RBEM values ranging between 2 and 6 were found for 
MN or dicentrics when 60Co γ-rays were used as reference (57, 69, 70). 
When neoplastic transformation in CGL1-cells (HeLa X skin fibroblast, non-tumorigenic (71)) is 
used as end-point for RBE calculation, the RBE values are situated between 3.6 and approximate-
ly 8 and situate mostly around 4.4 (72-75). 
The above mentioned studies have been performed on CGL1 cells, lymphocytes, fibroblasts and 
keratinocytes and to our knowledge, no studies on the efficiency of mammography X-rays to 
induce chromosomal aberrations are performed using mammary epithelial cells, like MCF-10A 
cells, isolated and cultured mammary epithelial cells or even epithelial cells in breast tissue. Colin 
et al performed an adapted MN assay on isolated and cultured breast epithelial cells (76), however 
the MN assay used in this study contained no cytokinesis-block and cannot be compared to the 
classical MN assay. Furthermore, no reference radiation was used, so the results cannot be used 
for RBE calculation. 
1.2.2 RBE of mammography X-rays after very low dose irradiation
Most of the mammography RBE-studies quoted are based on experiments in the dose-range 0.1 or 
0.5 Gy to 4 or 5 Gy. However, during a mammography screening the average dose delivered to the 
breast tissue is typically 3-4 mGy. Mammographic screening, with a bi-annual mammogram with 
two projections, for women aging between 50 and 70 years, would deliver a total cummulative 
dose of 30-40 mGy to the breast. 
While there seems to be convincing evidence for the presence of an increased RBEchrom ab between 
3 and 4 in the 0.1-4Gy dose range, the question is if this can be extrapolated by the LNT model 
to the very low dose range. As the low-dose threshold for detection of chromosomal aberrations 
is around 0.05-0.1Gy, information can best be obtained by analyzing the induction and disappear-
ance of DNA repair foci. The γH2AX foci assay is sensitive enough to visualize the induction 
of DSB following doses of a few mGy. Furthermore, as discussed above, the repair kinetics of 
γH2AX foci and the number of persistence foci show a clear link to the complexity of the DSB. 
This gives information on how difficult it will be for the cell to repair the DSB correctly. 
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In our study on the RBE of mammography X-rays on breast tissue (article 4) (58), we found a 
low-dose hypersensitive response to 30kV X-rays in the dose range 0 to 20 mGy with the γH2AX 
foci-assay. Following irradiation with γ-rays, this hypersensitive response was absent and a linear 
regression over the complete dose range seemed the most appropriate way to describe the data. 
This lead to an increase in RBE-value from 1.0 in the dose range 20 to 500 mGy to 3.7 in the 0-40 
mGy dose range. 
A very similar low-dose hypersensitive response was described by Beels et al after exposure 
of lymphocytes to X-rays in the 0 to 10 mGy dose range (77, 78). The hypersensitive response 
described by Beels et al was less pronounced when γ-rays were used instead of X-rays and when 
lymphocytes were isolated, pointing to the importance of radiation quality and cellular environ-
ment. A strong link between the low-dose hypersensitive response and cell culture conditions was 
also reported by Groesser et al (79). 
Mills et al on the other hand, did not find a significant difference in number of foci after γ-irradi-
ation or 30 kV X-ray irradiation in the 0 to 30 mGy dose range and calculated an RBE value of 
only 1.1 (60). 
At low doses, phenomena such as bystander effect, adaptive response, threshold hypothesis and 
hormesis response play a role (80-82) (see introduction 1.4). The low-dose hypersensitive re-
sponse observed in mammary epithelial cells in breast tissue (article 4) is probably caused by the 
bystander effect. The irradiated epithelial cells of the mammary glands present in the connective 
tissue of the breast will propagate signaling molecules to neighboring cells via GAP-junction me-
diated signal transduction and via the release of diffusible factors into the extracellular environ-
ment. The different cellular context and cellular environment might explain the different results 
found in our study on mammary epithelial cells in breast tissue and the study of Mills where a 
cell line of mammary epithelial cells (MCF-10A) grown in monolayer was used. Furthermore, 
the cells of Mills et al were irradiated at 0°C and kept at that temperature some time before and 
after irradiation. Hypothermia has a radioprotective effect and can have an influence on cellular 
communication (83). 
It is interesting to note here that at higher doses the same biological effects of 30 kV X-rays were 
observed over a wide range of cell types. At very low doses however, tissue-effects, cellular com-
munication and cellular environment start to play a role and the biological effects observed might 
differ strongly from cell-type to cell-type. This should be kept in mind when performing further 
studies on the very low-dose effects of 30kV X-rays. 
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There have been studies which report that a certain threshold of stress or damage needs to be sur-
passed before efficient repair takes place. DSB induced by very low doses, such as those used in 
mammography screening, might not trigger the repair response, repair is slower and foci persist 
for days after induction (84, 85). This has been contradicted by Asaithamby who did see efficient 
repair at a dose of 5mGy (86). However Asaithamby used γ-rays while Rothkamm and Grudzenski 
used 90 kV X-rays and again, differences in LET might have a significant impact on the results. 
Using 30kV X-rays, Mills et al found a reduction in the number of repair-foci measured 4h after 
irradiation compared to 1h after a dose of 30mGy, showing that repair did start. However, a sig-
nificantly higher percentage of persistent foci was found in the samples irradiated with 30mGy 
of mammography X-rays compared to γ-rays (60). Colin et al also reported persistent foci after 
very low doses of 30kV X-rays (2, 4 and 2+2 mGy), however, since no results for y irradiation are 
given, no comparison is possible (76). 
How these very low-dose effects affect the formation of chromosomal aberrations and neoplas-
tic transformation is difficult to assess. We found a threshold detection dose of 50mGy for the 
induction of centromere-negative MN after irradiating lymphocytes with 30 kV X-rays (article 
3). No studies have been published on MN or dicentric formation in the region 0 to 30mGy after 
irradiation with mammography X-rays. 
Certain characteristics found in foci induced by high doses of 30kV X-rays, such as higher in-
tensity and slower repair of the foci, are also found in foci induced by very low doses (60). This 
suggests that the DSB induced by low-doses might be handled by the cell in more or less the same 
way as DSB induced by higher doses and a higher RBEchrom ab compared to RBEfoci ind can also be 
expected in the low-dose region. Furthermore, we found a low-dose hypersensitivity for DSB 
induction in breast epithelial cells in breast tissue irradiated by very low doses of 30kV X-rays, 
indicating that more DSB were induced than would be assumed by the LNT model and in turn 
even more chromosomal aberrations can be expected. 
While more research is needed to clarify all these results and solve the inconsistencies, we think 
that the high dose RBEchrom ab of 3-4 for mammography X-rays can be extrapolated to the low dose 
range and might even be higher in the very low-dose range due to the bystander effect. 
Applying an RBE of 3 to the detection over induction ratio (DIR) of mammography screening 
programs as they exist today in Belgium would result in a drop of the DIR from 180 to 60 and the 
use of mammography as a screening tool is still justified (55, 56, 87, 88). But our results do warn 
for expanding those programs to younger age-groups. Younger women are more radiosensitive 
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with respect to cancer and need higher doses due to denser breast tissue. If the age group between 
40 and 49 would be included in the current screening program of the Flemish community, the DIR 
for that age group would drop from 52 to 17 if we apply our RBE of 3 (personal communication 
Prof dr. H. Thierens).
In the case of women with an increased risk to develop breast cancer due to a mutation in a breast 
cancer predisposing gene the benefit /risk ratio of mammography screening is even more disput-
able as most of the known breast cancer genes (BRCA1, BRCA2, ATM, CHEK2, PALB2, etc ) are 
all involved in the DNA damage response pathway activated by DSB. Mutations in these genes 
may not only contribute to genomic instability and cancer but also to a radiosensitive phenotype, 
increasing the carcinogenic risk of mammography screening in mutation carriers (87-90) (see 
discussion chapter 2.3)
1.3 Cell cycle dependence of RBE 
The radiosensitivity of the cell is heavily dependent on the cell cycle, since cell cycle phase influ-
ences the DSB repair pathways which are available for the cell. Furthermore, the radiation quality 
plays an important role. High-LET radiation will induce more complex damage compared to low-
LET. These complex damage sites are difficult to repair accurately by NHEJ, particularly when 
there is loss of nucleotides as NHEJ cannot restore genetic information. HR on the other hand can 
repair complex damage sites more efficiently, but is not active in G0/G1. As a result, high-LET 
radiation will be more efficient in inducing chromosomal aberrations in G0/G1. 
In the MCF-10A control cell lines (CONBRCA
2 and CON
KU70
) used in article 2 we found the de-
scribed pattern of changes in inherent radiosensitivity, represented by the α-value of the MN-dose 
response curve. The cells showed an increased radiosensitivity to high-LET radiation in G1 com-
pared to S and G2. Irradiation of CONBRCA and CONKu70, in the mixed cell cultures and in the cell 
cultures synchronized in G1 with γ-rays didn’t induce any significant differences in α-value (see 
squares in figure 1.4). However, when they were irradiated with high-LET neutrons the sensitivity 
increased significantly more in the synchronized G1 cell cultures compared to the mixed cultures 
(see resp. open and black triangles in figure 1.4). 
These differences in cellular radiosensitivity during the cell cycle affect the RBEM. At low dose 
the high sensitivity of the G1 cells irradiated by neutrons translates in much higher RBEM values 
(RBECONBRCA 4.9 and RBECONKu70 6.9) compared to the cells irradiated as mixed cultures (RBE-
CONBRCA 2.8 and RBECONKu70 3.4). At higher doses (2-5Gy) the RBE values drop and are very sim-
ilar for the mixed and the synchronized G1 cultures (RBE2Gy is on average 1.83) (see figure 1.5). 
This is caused by the influence of the β-value of the dose-response curve following γ-irradiation at 
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high doses. This β-value, representing the repair-component in the dose-response, and makes the 
cells relatively more radiosensitive to low-LET radiation at higher doses compared to low doses 
(see figure 1.6) which is caused by an increase in complexity of the damage induced by low-LET 
radiation when the dose increases.
2  CONBRCA and CONKu70 are two mock-transduced MCF-10A cell lines which are used as control cell lines.
3  The response curve for chromosomal aberrations is linear-quadratic. α describes the linear component and is a measure for inherent 
radiosensitivity of the cell. β describes the quadratic component and is a measure for the repair-capacity of the cell. More informa-
tion can be found in figure 1.6 and in the introduction chapter 1
4  The MCF-10A cells were irradiated (i) as exponentially growing cell cultures, which contained cells from G1 (37%), G2 (25%), S 
(39%) (called ‘mixed cultures’) and (ii) as cultures synchronized in G1 (86% G1 cells) before irradiation. For further information, 
see article 2.
FIGURE 1.4
Changes in cellular radiosensitivity, represented by the α-value of the MN dose response, following γ-radiation and neutron radiation in cell 
cultures synchronized in G1 and in mixed cell cultures. Figure based on data obtained in article 2. 
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FIGURE 1.5
RBE of fast neutrons at different doses following irradiation of mixed and synchronized G1 cells. Figure based on data obtained in article 2. 
1.4  Influence of LET on DSB repair pathway choice  
and cellular radiosensitivity
In the introduction we already discussed that DSB repair pathway choice is an interplay between 
different factors among which cell cycle phase is the most important. The complexity of the DSB, 
which will increase with increasing LET of the radiation quality, can also influence repair pathway 
choice and as a consequence cellular radiosensitivity. 
To investigate the influence of cell cycle phase and LET on DSB repair pathway choice, we devel-
oped MCF-10A cell lines containing a knock-down for DSB repair proteins and irradiated these 
cell lines with γ-rays and neutrons in different phases of the cell cycle. 
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FIGURE 1.6
Dose response curve for induction of micronuclei in the CONBRCA cell line (cells synchronized in G1), following low and high-LET irradiation. 
The blue lines represent an RBE at high dose (=Y/X), the red lines at low dose (=B/A). For more information, see introduction chapter 1. Figure 
based on data obtained in article 2.
A knockdown cell line was made for: 
• Ku70 (called Ku70i) a protein which is important in NHEJ
• BRCA1 (called BRCA1i) a protein which is important in NHEJ and HR
• BRCA2 (called BRCA2i) a protein which is important in HR
Furthermore, two mock-transduced cell lines (CONBRCA and CONKu70,) were used as control lines. 
All cell lines were irradiated as exponentially growing cell cultures, which contained cells from 
G1 (37%), G2 (25%) and S (39%) phase (called ‘mixed cultures’), and as cultures synchronized in 
G1 (86% G1 cells; called ‘synchronized G1 cultures’) before irradiation. For further information, 
see article 2.
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1.4.1 Cell cycle and DNA DSB repair (see figure 1.6)
To investigate the importance of HR and NHEJ in different phases of the cell cycle, the knock-
down cell lines were irradiated as mixed and synchronized G1 cultures with γ-rays. The change 
in radiosensitivity was analyzed by comparing the α-values, a measure of inherent cellular radio-
sensitivity, of the knockdown cell lines with the α-values of the control cell lines (figure 1.7 and 
table 1.1). 
Compared to the control cell lines, BRCA2i cells ( ), deficient in HR which is not active in G0/
G1, showed no increased radiosensitivity in the synchronized G1 cultures and a significant in-
crease in radiosensitivity in the mixed cell cultures compared to the control cell lines (2.3 x αCON: 
2.3 fold increase of α-value). The latter can be explained by the importance of the HR pathway in 
the late S and G2 stage. 
The Ku70i cells ( ) on the other hand, showed an increase in radiosensitivity after irradiation of 
both the synchronized G1 cells (1.9 x αCON) and mixed cells (3.5 x αCON). This is consistent with 
the role of Ku70 in NHEJ which is active throughout the cell cycle. 
BRCA1 plays a role in both HR and NHEJ. For the BRCA1i cells ( ) synchronized in G1, no 
MN-results could be obtained due to lack of BN-cells. The cells were probably too radiosensitive 
and underwent cell cycle arrest. The cells irradiated as mixed cultures showed a large increase in 
sensitivity (5.8 x αCON) compared to the control cell lines. 
These results are in line with the results of Hinz et al who showed that, compared to wild type 
cells, HR deficient CHO cells are increasingly radiosensitive as they progress through S and G2/M 
phase. NHEJ deficient CHO cells on the other hand, are clearly more radiosensitive than wild 
type (WT) cells, but they show the same pattern of radiosensitivity as WT cells as they progress 
through the cell cycle (91, 92). 
While direct comparison of the knockdown cell lines is not possible due to differences in pro-
tein-knockdown, BRCA2i shows a tendency to be the least radiosensitive of the three knock-down 
cell lines and BRCA1i the most radiosensitive one. Overall our results show that both NHEJ and 
HR deficiency result in increased cellular radiosensitivity and that this is more pronounced after 
abrogation of NHEJ. A defect in a gene involved in both NHEJ and HR seems to give a cumulative 
effect, resulting in very sensitive cells. Furthermore, these results confirm that NHEJ plays a ma-
jor role throughout the cell cycle. HR on the other hand is not involved in repair of DSB in G0/G1. 
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FIGURE 1.7
Changes in inherent sensitivity, represented by the α-value, of control cell lines and knockdown cells lines, following γ-radiation in cell 
cultures synchronized in G1 and in mixed cell cultures. 
TABLE 1.1
Overview of the α-values, the fold increase compared to the control cell line (x α
CON
), the RBE
M
 and the RBE at 2 Gy (RBE
2Gy
) for the control 
cell line (CON: average of CON
BRCA
 and CON
KU70
) and the repair-deficient cell lines. 
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1.4.2 Effect of LET in DSB repair deficient cells
To investigate the importance of LET on HR and NHEJ in different phases of the cell cycle, the 
mixed and synchronized G1 cultures of the control cell lines and knockdown cell lines were also 
irradiated with fast neutrons. 
Analogous to what we observed for low-LET radiation, the mixed cultures of BRCA2i cells 
showed an increased sensitivity after neutron-irradiation compared to the control cell lines. For 
G1 synchronized cultures no differences in sensitivity were observed between the BRCA2 repair 
deficient and control cell lines (figure 1.8). 
The Ku70i cells showed an increase in α-value after neutron-irradiation of both the mixed and the 
synchronized G1 cultures compared to the control cell line (figure 1.8). 
As mentioned previously the BRCA1i cells didn’t divide after irradiation of the synchronized G1 
cells, probably related to the highly increased radiosensitivity and no MN results were available. 
The mixed cultures of BRCA1i cells also showed a highly increased radiosensitivity after neutron 
irradiation in comparison with the control cell lines (figure 1.8).
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FIGURE 1.8
Changes in inherent sensitivity, represented by the α-value, of control cell lines and knockdown cells lines, following γ-radiation and neu-
tron-irradiation in cell cultures synchronized in G1 and in mixed cell cultures. Figure based on data obtained in article 2. 
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From the different inherent radiosensitivities (represented by the α-values) after neutron and γ-ir-
radiation of the synchronized G1 and mixed cells, the RBEM values can be calculated (Table 1.1).
In the mixed cultures the highest RBEM values are observed for the control cell lines and the 
BRCA2i cell line. The RBEM values of the Ku70i cell line is lower and the BRCA1i cells represent 
the lowest RBEM values. In literature an analogous pattern has been described for mixed cultures 
of CHO, DT40 and MEF cells. High-LET radiation shows an increased efficiency to induce DNA 
damage with increasing LET in wild type and HR-deficient cells compared to low-LET radiation 
(93). This causes an increase in RBE-values with increasing LET till 100-200 keV/µm in wild 
type and HR deficient cell types (see figure 1.9) (94). The efficiency to induce DNA damage in 
NHEJ deficient and NHEJ+HR deficient cells is highly increased after both y and neutron irradia-
tion and as a result RBE-values are close to unity (see figure 1.9 and table 1.1) (94-98). 
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FIGURE 1.9
RBE
M
 values for 10% survival for different LET values in NHEJ and/or HR deficient cells.  : wild type cells;  : Lig4 knock-out cells (NHEJ 
deficient);  : Rad54 knock-out cells (HR deficient);  : double knock-out cells (deficient in NHEJ and HR). Figure adapted from (94). 
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Our RBEM values for the NHEJ and NHEJ+HR knockdown cell lines on the other hand, are high-
er than unity. Differences in inherent radiosensitivity between the MCF-10A cells and the CHO, 
DT40 or MEF cells used in most studies can be an explanation. Furthermore, our cell lines have 
approximately a 50% knock-down of the repair-proteins, where in most studies the cell lines have 
a much higher knock-down. Also, the knock-downs in other papers are for different repair proteins 
(e.g. Lig4, Rad54, DNA-PKcs, XRCC4, XRCC3) which can lead to a stronger abrogation of the 
targeted repair pathway. 
In the cells synchronized in G1 RBEM values are higher compared to the RBEM values calculated 
for the mixed cultures (see table 1.1). This implies that our synchronized G1 cells are more sen-
sitive than the mixed cultures to neutrons and confirms the general picture of HR having a more 
important role in the error-free repair of complex damage sites and only being available in S and 
G2 phase. 
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2  Radiosensitivity in relation 
to breast cancer treatment 
and diagnostics
2.1  Risks of late radiotoxic reactions following radiotherapy  
for breast cancer
The use of radiotherapy reduces the risk of local-regional recurrence of breast cancer and im-
proves the overall survival of breast cancer patients after breast-conserving surgery or mastecto-
my (113, 114). However, some patients will develop adverse effects following radiotherapy. These 
effects range from acute (within 6 months after starting radiotherapy) to late (after six months of 
starting radiotherapy) toxic effects, with a second, radiation induced cancer considered as a very 
late effect (115) (see introduction chapter 3). 
Severe late toxic effects occur in approximately 5 to 10% of the breast cancer patients receiving 
radiotherapy, mostly in the tissue surrounding the tumor which received the highest dose. 
Several studies have reported an increase in risk of a secondary primary cancer of the breast, 
colorectal, endometrial or ovarian cancer after treatment for breast cancer (116-124). A genetic 
predisposition or lifestyle factors could be the cause of both primary and secondary cancer, es-
pecially in the case of contralateral breast cancer (125-127), but the increased risk for a second 
primary cancer could also be the consequence of the treatment of the first cancer, such as the 
development of leukemia after chemotherapy (128) and sarcomas (129) or lung cancer after radi-
otherapy (130). 
The fact that there are inter-individual differences in clinical radiosensitivity was already noted 
shortly after the discovery of X-rays (99-101). It took however till 1956 and the introduction of 
the in vitro clonogenic assay before real research on the subject began (102, 103). Further devel-
opment of molecular, cytogenetic, genomic and cellular assays confirmed the existence of a large 
and continuous spectrum of individual radiosensitivity (99). 
On one side of the spectrum there are extremely radiosensitive patients related to genetic syn-
dromes, such as patients with ataxia telangiectasia (AT) (104, 105), Nijmegen breakage syndrome 
(NBS) (106) or severe combined immunodeficiency (SCID) (107-109). A less severe form of ra-
diosensitivity can be found in patients with e.g. a biallelic mutation in some of the genes from the 
FANC-group (especially FANC-D2) (110, 111) or patients with e.g. Cornelia de Lange syndrome 
(112). However, most individuals only show a slight increase or decrease in radiosensitivity when 
subjected to the standard radiosensitivity tests, but these marginal changes can be translated in an 
enhanced susceptibility to radiation-induced carcinogenesis or the development of severe radiot-
oxic reactions following radiation exposure. 
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Often the risk of a new primary cancer is studied by the occurrence of contralateral breast cancer 
five to fifteen years after treatment for breast cancer. The dose received by the contralateral breast 
during conventional radiotherapy treatment for breast cancer lies between 0.5 and 3Gy (131), al-
though older studies mention doses up to 7Gy (132). The risk of contralateral breast cancer as a 
result of radiotherapy is small and is dependent on the dose received by the contralateral breast and 
the age of the patient. The EBCTCG meta-analysis estimated an absolute risk of 4.4% in 15 years, 
resulting in a relative risk of 1.09 in patients under 50 and 1.25 in patients older than 50 years (133). 
Other cohort or case-control studies estimate the risk higher and relative risks between 2 and 3 for 
young patients (<40) or high breast doses (>4Gy) have been reported (131, 132, 134-137). 
2.2 Radiosensitivity amongst breast cancer patients
A significant proportion of cancer patients shows an enhanced chromosomal radiosensitivity. This 
increased sensitivity has been confirmed in several studies (138-142), with elevated sensitivities 
observed with both G0 MN-assay (25%) and G2 chromatid break assay (40%), but seldom both 
(4%) (143). This elevated in vitro radiosensitivity can be interesting for the risk-assessment for 
second primary cancers, but it could also help to adapt the course of radiotherapy in light of late 
toxic effects from the treatment. As stated in the introduction, dose-deposition in more recent 
radiotherapy techniques as IMRT has evolved in such a way that healthy tissue surrounding the 
tumor is spared much better than in the early days of radiotherapy, but it cannot be denied that the 
healthy tissue is still irradiated. On the other hand, with the new techniques the rest of the body in 
general also gets a low dose, which was not the case with the older techniques. 
In radiotherapy the total dose received and the DNA repair capacity of both healthy and malignant 
tissues are important and will determine the probability of a tumor-killing effect over the risk of 
causing adverse effects in the healthy tissue (144). 
2.2.1 Prediction of the risks of radiotoxic effects 
There exists a direct relationship between radiation dose and tumor control, but the severe normal 
tissue toxicity in a minority of patients limits the dose that can be safely prescribed (145). Current 
RT doses are generally limited such that less than 5% of the treated patients suffer from severe 
toxicity up to 5 years following RT. The development of a test to predict late toxicity would enable 
individualized radiation dose prescription and would reduce the number of survivors suffering 
from the consequences of treatment (146-149). 
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A lot of cytogenetic and cell survival studies have been performed in an attempt to predict late 
toxic reactions following radiotherapy. 
The search for a predictive assay started with fibroblast-based assays such as the colony formation 
assay, since a lot of the late toxic effects occur in fibroblasts (e.g. fibrosis and changes in pigmen-
tation) and it was hypothesized that they would reflect clinical radiosensitivity. However, further 
attempts were abandoned since sampling of a sufficient amount of fibroblasts was problematic and 
results could only be obtained after 2 to 3 months, which is too late for clinical use. In more recent 
studies, lymphocytes were used to assess intrinsic radiosensitivity as they are easier to acquire and 
results of the assays can be obtained within a few days. 
In our study about late radiotoxicity in breast cancer patients (Article 5), we attempted to differ-
entiate patients showing no or very limited late effects (controls) from patients showing extreme 
late effects (cases). It has been estimated that if known extrinsic factors, such as dose per fraction, 
total dose and irradiated volume, are controlled, 80% of the observed variation in the severity of 
normal tissue responses is due to inherent differences among the patients (150, 151). To eliminate 
variables influencing radiotoxicity, in article 5 a retrospective case-control set-up was used. To 
each case a control was matched for therapy variables, cupsize, BMI and age. These variables are 
known to be associated with radiotoxicity and affect clinical radiosensitivity. 
The association between individual variation in clinical radiosensitivity and cellular radiosen-
sitivity could provide a possibility to determine the individual sensitivity of patients in terms 
of developing severe treatment-related side effects (152). In the study (Article 5) four different 
cellular assays were performed after in vitro irradiation of patient blood samples: G0 MN assay, 
G2+caffeine MN assay, residual DNA DSB (γH2AX/53BP1; 4Gy – 24h) and radiation induced 
late apoptosis in lymphocytes (CD8+; 8Gy – 48h). By comparing the results of these assays we 
assessed the efficiency of different pathways that play a role in the DNA damage response. With 
all four assays we found a significant difference between the group of cases and the group of 
controls for both paired and grouped analysis (see figure 2.1) (153). The apoptosis assay showed 
the most impressive and promising results, with less apoptosis seen in CD8+ lymphocytes of the 
cases (average 14.5%) than in the matched controls (30.1%) However, some of the case-control 
pairs showed substantial overlap in standard deviations, which questions the predictive value of 
the assays in clinical radiotherapy practice. 
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FIGURE 2.1
(a) percentage of cells with radiation induced late apoptosis, (b) number of radiation induced foci, (c) the area under the curve calculated 
from the G0-MN dose-response curve, (d) number of radiation induced G2 MN per 1000 BN cells in each of the cases (dark grey bars) and 
controls (white bars). The average of all cases (dark grey triangle) and controls (white triangle) and the corresponding spread in case and 
controls are presented in the right part of the graphs. The horizontal line represents the average over all patients. The error bars represent 
standard deviations. Figure from article 5. 
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Our results are in line with several other studies who also reported to a certain extend associations 
between a range of cellular biomarker assays and clinical radiosensitivity (154-157). These assays 
use peripheral blood lymphocytes and include chromosomal radiosensitivity measured with G2 
chromatid break assay, dicentrics and G0 MN assay, kinetics of residual DNA damage assessed by 
the γH2AX foci assay and radiation-induced apoptosis on T-lymphocyte subsets (148, 153, 155, 
158-165). Among those assays, radiation-induced apoptosis in lymphocyte subsets after in vitro 
irradiation gives the most promising results for correlation with late toxicity after radiotherapy 
(148, 153, 156, 164). Furthermore, more recent small studies suggest that the scoring of residual 
DNA damage by using the γH2AX foci assay may also be useful for prediction of reactions to RT 
(158, 166).
Other studies investigated the association between genetic variation and clinical radiosensitivity 
by analyzing single nucleotide polymorphisms (SNP) in genes involved in DNA damage response 
pathways (167-172). While a number of SNP have been proposed, replication of these studies 
remains difficult (146, 149, 173). Research in this area is now moving towards genome-wide 
association studies. 
Studies using gene-expression profiles to predict late-toxic reactions to breast-cancer radiotherapy 
are emerging (165, 174-177), but at the moment there is a large variability in the results. This work 
is challenging and a lot of questions still exist on the study set-up and used protocols. Especially 
whether to determine gene-expression after irradiation or not and if cells are irradiated, which 
dose and post-irradiation incubation-times should be used. Gene-expression profiles change due 
to irradiation and as a function of time after the irradiation, but also the LET and the dose (178) 
of the irradiation will influence the expression profiles, hence these factors can affect the reported 
patterns of gene expression. 
An increased radiosensitivity to ionizing radiation is linked to a deficiency in DNA DSB repair. 
However, there are several mechanisms by which this can occur. Genetic mutations found in 
radiosensitivity-syndromes, showed that most mutations occur in genes coding for proteins of 
the DNA repair pathways (NHEJ, HR or one of the back-up pathways) or in genes participating 
in the activation of the DNA damage response, the cell cycle checkpoints or apoptosis. But also 
genes involved in response to oxidative stress and cohesins, which function to hold chromosomes 
together during DNA replication and repair, have been implicated. The intrinsic variability in 
clinical radiosensitivity noted between different patients, might have a very different underlying 
genetic cause. Hence, it might be difficult to identify one screening assay to identify all the pa-
tients at high risk for developing late toxic effects to radiotherapy in the normal tissue. This can 
be illustrated with our radiosensitivity results in an atypical AT-patient and her parents. While the 
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G0 MN-assay showed only limited increased radiosensitivity for the patient (x1.8 compared to 
control donor) and non for the parents, the G2 MN-assay showed a marked increase for both the 
patient (x4) and the parents (mother: x2.8; father: x1.4) (179). 
Furthermore, different radiotoxicity endpoints (fibrosis, edema, telangiectasia, etc.) have a differ-
ent underlying cause and as such are linked to different genetic mutations. This can be illustrated 
by Barnett et al., who found in a genome wide association study with 1850 prostate and breast 
cancer patients the strongest associations for individual endpoints rather than to the overall meas-
ure of toxicity (180). This would again explain why we cannot expect one common test to identify 
all individuals who will react toxic to radiotherapy. 
2.3 BRCA-radiosensitivity
2.3.1 Are BRCA mutation carriers radiosensitive?
Mutations in BRCA1 or BRCA2 are well-known risk factors for breast cancer, but the question 
remains whether mutations in these genes imply increased risk for radiation carcinogenesis. While 
radiosensitivity is a hallmark for cancer risk, cancer risk is not a hallmark for radiosensitivity. In 
light of screening and treatment of individuals with a BRCA1/2-mutation, it is important to know 
whether this group of individuals is more sensitive to ionizing radiation.
Patient studies focused mostly on the association between medical radiation burden and the oc-
currence or recurrence of radiation-induced breast cancer in persons with and without a BRCA1 
or BRCA2 mutation. Results are inconclusive due to low statistical performance related to small 
populations and the many variables such as dose, radiation qualities, age and irradiated tissue 
involved. In vivo studies often lack the power to ultimately demonstrate a connection between the 
presence of BRCA1 or BRCA2 mutations and increased radiosensitivity (181). Some studies find 
an increased susceptibility to radiation carcinogenesis in BRCA1/2 mutation carriers (182-184), 
often closely linked to age at the time of exposure, while other studies don’t (144, 185-187). 
To overcome the difficulties of in vivo studies, in vitro experiments investigating the radiosensi-
tivity of lymphocytes, fibroblasts or EBV cell lines (Epstein Barr virus immortalized cell lines) 
derived from patients with and without a BRCA1 or BRCA2 mutation have been performed. These 
studies lead again to contradictory results, with some studies pointing to an increased sensitivity 
(188-191), and others not (190, 192). 
To assess the impact of a BRCA1 and BRCA2 mutation on radiosensitivity, we used mammary 
epithelial cells (MCF-10A) in which BRCA1 and BRCA2 were downregulated using RNA inter-
2  Radiosensitivity in relation to breast cancer treatm
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ference transduction (called respectively BRCA1i and BRCA2i) (article 2). The cell lines had a 
knockdown of the targeted proteins of approximately 50%, which is comparable with the BRCA1 
and BRCA2 levels in heterozygous mutation carriers and are as such very useful to assess the 
radiosensitivity of BRCA-mutation carriers. 
The BRCA1i cells showed a significant increase in cellular radiosensitivity compared to the con-
trol cells and this for high-LET as well as low-LET radiation (see discussion chapter 1.4). When 
the G1 synchronized cells were irradiated, the sensitivity was so high that no MN-results could 
be obtained, due to a dose-related cell killing. When the mixed cultures, containing cells from G1 
(37%), G2 (25%) and S (39%) were irradiated with neutrons, a 3.4-fold increase in sensitivity 
compared to the control cell line, irrespective of the dose was obtained. Irradiation with γ-rays 
resulted in a 3-fold increase in cellular radiosensitivity at a dose of 2Gy, rising to 5.5 at very low 
doses (193). 
The BRCA2i cells also showed an increased radiosensitivity. But unlike the BRCA1i cells they 
only show a clear increased radiosensitivity in mixed cell cultures. This can be explained by the 
role of BRCA2 in HR, which doesn’t play a role in the G1 phase of the cell cycle. After γ-irradia-
tion, approximately a 2-fold increase in MN-yield was obtained compared to the control cell line, 
this increase in MN yield raised to 2.4 after neutron irradiation (193). 
The increase in cellular radiosensitivity for both BRCA1 and BRCA2 we found in breast epitheli-
al cells might have an impact on the risk assessment for the use of mammography and radiother-
apy in BRCA1/2 mutation carriers. 
2.3.2 BRCA and mammography
Two-view mammography gives a dose of 4 mGy to the breast of 30 kV X-rays to the glandular tis-
sue of the breast. As previously discussed (see discussion chapter 1.2), the lower energy of mam-
mography X-rays might increase the risk of mammography by a factor 3 to 4 compared to γ-rays 
(article 3). However, risk models show that mammography screening programs in healthy women 
with a bi-annual mammogram starting at the age of 50 still have a favorable detection-over-in-
duction ratio. 
BRCA-mutation carriers need to be screened for breast cancer from a young age. Breast tissue in 
younger persons is more dense and a higher dose is needed to obtain a good image for scoring. 
Furthermore, the risk of radiation to induce breast cancer is higher at younger age. While mam-
mography screening comes with acceptable risks in the healthy population, it might not be optimal 
for BRCA1/2-mutation carriers. 
Recent research showed that mammography X-rays in the very low-dose region might induce more 
damage than extrapolation from the higher dose region with the LNT model would suggest (see 
discussion chapter 1.2). In article 3 and article 4 we detected DSB, by means of the γH2AX foci 
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assay, induced by doses less than 10mGy of 30kV X-rays in lymphocytes and breast epithelial cells 
and this was also reported by others (60, 76). This shows that 30kV X-rays induces DNA breaks 
at very low doses. Furthermore, in the very low dose region, we found a low dose hypersensitive 
response in mammary epithelial cells in breast tissue probably caused by the bystander effect. This 
hypersensitive response might further enhance the risks of mammography X-rays (article 4). 
Our experiments in article 2 were performed at doses between 0.2 and 4 Gy, which is much higher 
than the doses used in mammography screening. The results show that the increased radiosensi-
tivity for the BRCA1/2 knockdown cell lines is more pronounced in the low dose range compared 
to the high dose range (see figure 2.2) (193). Extrapolation to the very low-dose region, showed 
an increased radiosensitivity of BRCA1i and BRCA2i of respectively 5.5 and 2.2 fold after γ-ra-
diation in comparison with the control cell line, especially for BRCA1i (193). 
Some patient studies show no increased risk following exposures in BRCA1 and BRCA2 hete-
rozygote mutation carriers to diagnostic X-rays (194) and mammography X-rays (185, 195). In 
contrast, other retrospective studies did find an association between diagnostic imaging and the 
risk of developing breast cancer in BRCA mutation carriers and this risk seems correlated with the 
age of exposure and the total dose received (183, 184, 196, 197). Remarkably, in the patient-study 
of Pijpe et al a positive association was even found for individuals exposed to the lowest dose 
(<6.6 mGy) in the younger age group (<30y) (196). 
FIGURE 2.2
Overview of the fold increase of the cellular radiosensitivity of BRCA1i and BRCA2i .compared to control cell line following y-radiation of the 
mixed cultures.
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Results aren’t conclusive, but our study and other studies on BRCA1/2 related radiosensitivity 
provide evidence that BRCA1 and BRCA2 mutation carriers are likely to be more sensitive to low 
doses of radiation than individuals without a mutation. 
BRCA-tumors are generally aggressive and hard to detect and early detection by regular screening 
for breast cancer from a young age in BRCA-mutation carriers is necessary. The risks of mammog-
raphy for BRCA mutation carriers are not unambiguous, and national guidelines for breast cancer 
screening differ from country to country. 
Risk models which include radiation exposure risk, advice annual MRI from the age 25 followed 
by alternating mammography and MRI from the age of 30. Postponing mammography to the age 
of 30 decreases the total dose received and expected false positives (198). 
The United States National Comprehensive Cancer Network (NCCN) guidelines still advice to 
screen BRCA1 and BRCA2 mutation carriers with an annual mammogram and breast MRI start-
ing at the age of 25 and the ACS (American Cancer Society) advices a yearly mammogram and 
breast MRI from the age of 30 (199, 200). These guidelines might underestimate the risk from 
the possible increased radiosensitivity in mutation carriers, which might be further enhanced in 
young individuals. Other national guidelines take the risk of radiation exposure more into account. 
The Dutch guidelines advice to start screening with MRI from the age of 25 and to add annual 
mammography from the age of 30. The NICE (United Kingdom National Institute for Health and 
Care Excellence) guidelines advice to start screening with an annual MRI from the age of 30 and 
add annual mammography from the age of 40 (144). In Belgium, very high risk patients, amongst 
which are BRCA-mutation carriers, are advised to do a yearly MRI starting the age of 30 or 5 year 
before the age of diagnosis of the youngest family member. Additionally a single mammography 
is recommended at the age of 40 and between the ages of 50 and 69 a biannual mammography 
(201). 
2.3.3 BRCA and radiotherapy
In our study with BRCA knockdown cell lines (article 2), we also found an increased radiosensi-
tivity in the higher dose range (see figure 2.2). 
In literature, no clear evidence exists that BRCA mutation carriers are more sensitive to the toxic 
effects of normal tissue following radiotherapy. However, one should keep in mind that those 
studies are often unethical to set-up and it is difficult to find the appropriate study populations to 
investigate the correlation between increased risk for radiotherapy-induced breast cancer and the 
presence of a mutation in BRCA1 or BRCA2 (144) . So far, a number of patient studies have been 
conducted, which showed no or a very limited increased risk (202-204). The only study where an 
elevated relative risk was found, is a case-only study in patients with contralateral breast cancer. 
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More patients with mutations in DSB repair genes were found in the group receiving radiotherapy 
compared to the group not receiving radiotherapy. This suggests an increased risk to develop ra-
diation-induced contralateral breast cancer in patients with a mutation in a DSB repair gene. The 
relative risk was higher in younger patients(<40y) and when the time interval between radiother-
apy and the second primary was higher (>5y) (205). 
No conclusive evidence exists yet for an increased susceptibility to radiation carcinogenesis fol-
lowing radiotherapy in BRCA mutation carriers. However, the low doses of diagnostic irradiation, 
specifically mammography, seems to be carcinogenic in BRCA1 and BRCA2 mutation carriers, 
especially at young age. Hence, it is unlikely that the much higher doses received in radiotherapy 
don’t increase the risk for a second primary cancer in BRCA mutation carriers (144).
2  Radiosensitivity in relation to breast cancer treatm
ent and diagnostics
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3  Conclusion
Our results obtained with fast neutrons in human peripheral lymphocytes and MCF-10A cells 
are conform to literature reports regarding the effects of high-LET radiation. While a lower num-
ber of radiation-induced DNA DSB was observed for neutron radiation compared to γ-rays until 
about 4h post-IR, foci repair was slower and more residual foci were present at later time points. 
Furthermore, neutrons seem to be more effective in inducing micronuclei and inhibiting cell pro-
liferation. These results are important in the frame of high-LET radiotherapy and space radiation 
risk assessment. 
Irradiation of human lymphocytes with 30kV X-rays, which are low-LET radiation, resulted in a 
modest increase in the number of DNA DSB compared to γ-rays, but these DSB were more diffi-
cult to repair correctly by the cell and resulted in a more pronounced increase in micronuclei com-
pared to γ-rays. Furthermore, in the 0 to 20 mGy dose-range a low-dose hypersensitive response 
for DSB induction was observed in mammary glandular epithelial cells present in resected breast 
tissue, probably caused by the bystander effect. This hypersensitive response in the dose range 
representative for mammography screening, together with the findings obtained with chromosom-
al aberrations at higher doses might suggest that also in the 0-20mGy dose range more chromo-
somal aberrations than initially assumed by the LNT model will be induced. These findings may 
have important implications for risk assessment of mammography screening. 
Analysis of the relationship between cell cycle phase, LET and radiosensitivity using DSB repair 
deficient cell lines (MCF-10A cell lines with a knockdown in BRCA1, BRCA2 and Ku70) con-
firmed that NHEJ plays a role throughout the whole cell cycle, while HR only functions in late S 
and G2 phase of the cell cycle. Furthermore, the importance of HR in S or G2 phase rises as the 
complexity of the break increases. This results in RBE values for MN-induction which are much 
higher when cells are irradiated in G1 compared to the S and G2 phase of the cell cycle. 
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3  Conclusion
As BRCA1 and BRCA2 are important proteins in the DNA DSB repair pathways, mutations in 
the BRCA genes could lead to an increased susceptibility to radiation-induced carcinogenesis. The 
knockdown of BRCA1 and BRCA2 proteins in mammary epithelial cells of about 50%, a con-
dition which is representative for heterozygous mutation carriers, led to a significantly increased 
radiosensitivity based on MN formation and cell proliferation, which was most pronounced at low 
doses. The results imply that caution should be taken when administering ionizing radiation to 
heterozygous BRCA1 or BRCA2 mutation carriers.
We further attempted to identify breast-cancer patients who showed severe late toxic reactions to 
radiotherapy. In a matched case-control study using human lymphocytes, the in vitro clinical radi-
osensitivity of cases and controls was assessed with four different endpoints related to DNA repair 
and apoptosis. The results suggest that a patient’s intrinsic radiosensitivity is involved in the de-
velopment of late radiotoxic effects. As the biological mechanisms behind the different symptoms 
of late toxicity differ, it can be expected that not all clinical manifestations of late radiotoxicity are 
linked to the same degree to intrinsic radiosensitivity with respect to DNA repair and apoptosis. 
Of the four radiosensitivity tests applied, the apoptosis assay seems to be most promising in the 
framework of predicting radiotoxic effects in individual patients. 
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Philip Beukes, Emanuela Bortolin, Iwona Buraczewska, Christopher Burbidge, Andrea 
De Amicis, Cinzia De Angelis, Sara Della Monaca, Julie Depuydt, Stefania De Sanctis, 
Katalin Dobos, Mercedes Moreno Domene, Inmaculada Domínguez, Eva Facco, Paola 
Fattibene, Monika Frenzel, Octávia Monteiro Gil, Géraldine Gonon, Eric Gregoire, Gaëtan 
Gruel, Valeria Hadjidekova, Rositsa Hristova, Alicja Jaworska, Enikő Kis, Maria Kowalska, 
Ulrike Kulka, Florigio Lista, Katalin Lumniczky, Wilner Martinez-Lopez, Roberta Meschini, 
Simone Moertl, Mihaela Noditi, Ursula Oestreicher, Valentina Palma, Gabriel Pantelias, 
Alegria Montoro Pastor, Clarice Patrono, Laure Piqueret-Stephan, Maria Cristina Quattrini, 
Elisa Regalbuto, Michelle Ricoul, Sandrine Roch-Lefevre, Laurence Roy, Laure Sabatier, 
Lucia Sarchiapone, Natividad Sebastià, Sylwester Sommer, Yumiko Suto, Georgia Terzoudi, 
Francois Trompier, Vasiliki Hatzi, Anne Vral, Ruth Wilkins, Dimitros Zafiropoulos, Albrecht 
Wieser, Clemens Woda, Andrzej Wojcik, Reneb accident simulation exercise. International 
Journal of Radiation Biology, article submitted (TRAB-2016-IJRB-0098).
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10  Oestreicher, Ursula; Samaga, Daniel; Ainsbury, Elizabeth; Antunes, Ana Catarina; 
Baeyens, Ans; Barrios, Leonardo; Beinke, Christina; Beukes, Philip; Blakely, William 
F.; Cucu, Alexandra; DeAmicis, Andrea; Depuydt, Julie; DeSanctis, Stefania; DiGiorgio, 
Marina; Dobos, Katalin; Dominguez, Inmaculada; Duy, Pham Ngoc; Espinoza, Marco 
E.; Flegal, Farrah N; Figel, Markus; Garcia, O.; Monteiro Gil, Octavia; GREGOIRE, ERIC; 
Güçlü,  İnci; Hadjidekova, Valeria; Hande, M Prakash; Kulka, Ulrike Marianne; Lemon, 
Jennifer; Lindholm, Carita; Lista, Florigio; Lumniczky, Katalin; Martinez-Lopez, Wilner; 
Maznyk, Nataliya Alexandrovna; Meschini, Roberta; M´kacher, Radia; Montoro, Alegria; 
Moquet, Jayne; Moreno, Mercedes; Noditi, Mihaela; Pajic, Jelena; Ricoul, Michelle; Romm, 
Horst; Roy, L; Sabatier, L.; Sebastià, Natividad; Slabbert, Jacobus; Sommer, Sylwester; 
Suto, Yumiko; Tran, Que; Testa, Antonella; Terzoudi, Georgia; Vral, Anne; Wilkins, R. C.; 
Yanti, LusiYanti; Zafiropoulos, Demetre; Wojcik, Andrzej., RENEB intercomparisons 
applying the conventional Dicentric Chromosome Assay (DCA) International Journal of 
Radiation Biology, article submitted (TRAB-2016-IJRB-0087)
11  Baert A., Depuydt J., Van Maerken T., Poppe B., Malfait F., Storm K., van den Ende J., 
Van Damme T., De Nobele S., Perletti G., De Leeneer K., Claes K., Vral A., Increased 
chromosomal radiosensitivity in asymptomatic carriers of a heterzogous BRCA1 
mutation, breast cancer research, 2016, 18:52. 
12  Vral A., Decorte V., Depuydt J., Wambersie A., Thierens H., The semi-automated FISH-
based micronucleus-centromere assay for biomonitoring of hospital workers exposed 
to low doses of ionizing radiation, Molecular Medicine Reports, article accepted (MMR-
8070-155222). 
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Conferences
Closing meeting RENEB 
Lissabon, Portugal, 2-4/12/2015
Attendance
EPR biodose
Hanover, USA, 4-8/10/2015
Oral presentation: Lessons learned from the Inter-laboratory comparisons for the 
Micronucleus assay in the frame of the European Network of Biodosimetry – RENEB
RENEB at EPR biodose
Hanover, USA, 4/10/2015
Oral presentation: 2nd intercomparison on BCMN assay: results and lessons learned
15th International Conference of Radiation Research (ICRR)
Kyoto, 25-29/05/2015
Poster presentation: Inter-laboratory comparison for the Micronucleus assay in the frame 
of the European Network of Biodosimetry (RENEB)
Young investigators award
4th annual RENEB meeting
Rome, Italy, 4-6/03/2015
Attendance
41st Annual Meeting of the European Radiation Research Society (ERRS) 
Rhodes, Greece, 14-19/09/2014
Oral presentation: Micronucleus formation and cell proliferation in a BRCA1 and BRCA2 
knockdown breast epithelial cell line after exposure to gamma rays and neutrons
40th Annual Meeting of the European Radiation Research Society (ERRS) 
Dublin, Ireland, 1-5/09/2013
Poster presentation: The role of DNA double-strand break repair proteins after low- and 
high-LET radiation exposure
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International training and research
14/11/2012 – 03/12/2012
iThemba Labs, Cape Town, South Africa
VLIR own initiatives program between Belgium and South Africa.
Research into the role of DNA DSB break repair proteins in MCF-10A breast epithelial cells 
after irradiation with fast neutrons and γ-rays. 
20/05/2013 – 11/06/2013
iThemba Labs, Cape Town, South Africa
VLIR own initiatives program between Belgium and South Africa.
Continuation of research into the role of DNA DSB break repair proteins in MCF-10A breast 
epithelial cells after irradiation with fast neutrons and γ-rays. 
VLIR workshop
Cape town, South Africa, 12-13/08/2013
Oral presentation: The impact of BRCA1 and BRCA2 mutations on radiosensitivity
Science day UGENT
Ghent, Belgium, 07/03/2013
Poster presentation: RBE of mammography X-rays at the level of DNA dsb and 
chromosomal damage
PhD Day of the Department of Basic Medical Sciences
Ghent, Belgium, 08/05/2012
Oral presentation: The efficiency of mammography X-rays in inducing DNA double strand 
breaks and chromosomal damage
14th International Conference of Radiation Research (ICRR) (not attended)
Warsaw, Poland, 28/08-01/09/2011
Poster presented by Prof. dr. H. Thierens: RBE of mammography X-rays at the level of DNA 
dsb and chromosomal damage
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